So today, on Claudia’s wedding day, her grandfather Eduardo is there for the milestone event. Creating another special memory for the both of them.

For more than a century, Merck has been inventing medicines and vaccines for many of the world’s most challenging diseases. Today, we’re exploring entirely new approaches in our search to prevent Alzheimer’s. So people remain healthy and present, able to share every precious moment with the ones they love.

Learn more at Merck.com/InventingForLife
American College of Allergy, Asthma & Immunology

November 7 – 11, 2019
George R. Brown Convention Center
Houston, Texas

2018 – 2019 Officers and Board of Regents

<table>
<thead>
<tr>
<th>Position</th>
<th>Name</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Todd A. Mahr, MD, FACAAI</td>
<td>2019</td>
</tr>
<tr>
<td>Immediate Past President</td>
<td>Bradley E. Chipps, MD, FACAAI</td>
<td>2019</td>
</tr>
<tr>
<td>President-Elect</td>
<td>J. Allen Meadows, MD, FACAAI</td>
<td>2019</td>
</tr>
<tr>
<td>Vice President</td>
<td>Luz S. Fonacier, MD, FACAAI</td>
<td>2019</td>
</tr>
<tr>
<td>Treasurer</td>
<td>Kathleen R. May, MD, FACAAI</td>
<td>2019</td>
</tr>
<tr>
<td>Past Immediate Past President</td>
<td>Bryan L. Martin, DO, FACAAI</td>
<td>2018</td>
</tr>
<tr>
<td></td>
<td>Larry Borish, MD, FACAAI</td>
<td>2019</td>
</tr>
<tr>
<td></td>
<td>Mitchell R. Lester, MD, FACAAI</td>
<td>2019</td>
</tr>
<tr>
<td></td>
<td>Noel Rodriguez, MD, FACAAI</td>
<td>2019</td>
</tr>
<tr>
<td></td>
<td>Gailen D. Marshall, Jr., MD, PhD, FACAAI</td>
<td>2020</td>
</tr>
<tr>
<td></td>
<td>Mamta Reddy, MD, MBOE, FACAAI</td>
<td>2020</td>
</tr>
<tr>
<td></td>
<td>Gary C. Steven, MD, PhD, FACAAI</td>
<td>2020</td>
</tr>
<tr>
<td></td>
<td>Kelly M. Maples, MD, FACAAI</td>
<td>2021</td>
</tr>
<tr>
<td></td>
<td>Melinda M. Rathkopf, MD, FACAAI</td>
<td>2021</td>
</tr>
<tr>
<td></td>
<td>Michael R. Rupp, MD, FACAAI</td>
<td>2021</td>
</tr>
</tbody>
</table>

FIT Representatives: Christin L. Deal, MD (‘19), and Miriam Samstein, MD, PhD (‘20)

Speaker of the House of Delegates: Travis A. Miller, MD, FACAAI (‘19)

Executive Medical Director: Michael S. Blaiss, MD, FACAAI (‘19)

Annals Editor-in-Chief: Gailen D. Marshall, Jr., MD, PhD, FACAAI (‘21)

Alliance President: Patricia Wedner (‘19)
The American College of Allergy, Asthma and Immunology recognizes the indispensable role that health care companies play in furthering the mission of the College. ACAAI would like to thank the following companies for their generous support of this year’s Annual Meeting.

| Premier Partners | Diamond  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$500,000 and above</td>
</tr>
<tr>
<td></td>
<td>Aimmune Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.</td>
</tr>
</tbody>
</table>
|                  | Platinum  
|                  | $300,000 – $499,999                    |
|                  | AstraZeneca                             |
|                  | DBV Technologies                       |
|                  | GlaxoSmithKline                         |
|                  | Pfizer, Inc.                            |
|                  | Teva Pharmaceuticals                    |
|                  | Gold  
|                  | $100,000 – $299,999                    |
|                  | Abbvie                                 |
|                  | ALK Inc.                               |
|                  | CSL Behring                             |
|                  | Genentech                               |
|                  | Genentech and Novartis Pharmaceuticals Corporation |
|                  | Merck & Co., Inc.                      |
|                  | Novartis Pharmaceuticals Corporation   |
|                  | Takeda Pharmaceutical Company Limited   |
|                  | Silver  
|                  | $50,000 – $99,999                      |
|                  | Circassia                               |
|                  | kaléo                                  |
|                  | Optinose                               |
|                  | Pharming Group NV                      |
|                  | Stallergenes Greer                     |
|                  | Other Contributors                     |

HollisterStier Allergy • Micro Direct, Inc. • National Peanut Board
Optim LLC • RMS Medical Products • SmartPractice Dermatology | Allergy
# Table of Contents

ACAAI Premier Partners ............................................. 2  
Message From the Program Chair ............................... 5
2019 Program Committee .......................................... 6
2019 Award Winners .................................................. 7
Corporate Supporters ................................................ 9
Commercial Supporters ............................................. 10
Corporate Council Members ...................................... 11
Special Announcements ........................................... 13
Education Information ............................................. 17
Maintenance of Certification ...................................... 18
Evaluation and Credit Claiming ................................. 19
Daily Events ............................................................ 20
Committee Meetings ................................................ 28
Named Lectures ........................................................ 29
Workshops ............................................................... 30
Thursday International  
Food Allergy Symposium ........................................... 34
Friday Annual Literature Review ................................. 39
Friday General Sessions .......................................... 40
Saturday General Sessions ....................................... 48
Saturday Distinguished  
Industry Oral Abstracts ............................................. 61
FIT Bowl ................................................................. 62
Sunday ACAAI Allergen Extract  
Training Program .................................................... 63
Sunday General Sessions ......................................... 64
Sunday Oral Abstracts Sessions 1 ............................. 72
Sunday General Sessions ......................................... 75
Sunday Oral Abstracts Sessions 2 ............................. 77
Sunday Town Hall Meeting  
hosted by House of Delegates /  
ACAAI Annual Business Meeting ............................. 80
Monday General Sessions ....................................... 81
Fellows-in-Training Program ..................................... 85
Fellows-in-Training Awards  
and Scholarships .................................................. 86
Friday Office Administrators  
Practice Management Course ................................ 87
Friday Advanced Practice  
Health Care Providers Course ................................. 90
Saturday Allied Health  
Professionals Course ............................................. 92
Sunday Allied Health  
Professionals Course ............................................. 94
Non-CME Corporate Forums .................................... 95
E-posters – Meet the Authors ................................... 97
Faculty Index .......................................................... 98
Alliance of the ACAAI Program ............................... 100
Product Theaters ...................................................... 101
Exhibit Hall Passport Contest ................................ 104
Exhibits ................................................................. 105
Index of Exhibits ..................................................... 122
Index of Exhibitors ................................................ 124
Exhibit Hall Map ..................................................... 126
George R. Brown Convention Center Map .................. 127
Hilton Americas-Houston Hotel Maps ..................... 129
Marriott Marquis Houston Hotel Maps ..................... 131
Join us to learn more about the
EVOLVING UNDERSTANDING OF INFLAMMATORY MEDIATORS IN ASTHMA

Bradley Chipps, MD

Sunday, November 10
11:35 AM TO 1:00 PM
George R. Brown
Convention Center
The ACAAI 2019 Exhibit Halls A3 & B3, Product Theater 3

COME VISIT US AT
Novartis booth #1003
at the ACAAI 2019 Exhibit Hall

SUBMIT YOUR QUESTIONS
at the Novartis booth #1003 for the opportunity to have them answered personally by Dr Chipps during the presentation. Select questions will be used for discussion.

This presentation is sponsored by Novartis, and is open to all ACAAI 2019 Annual Meeting attendees.

The speaker is being compensated by Novartis Pharmaceuticals Corporation.

The Product Theater content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.
We’re Glad You’re Here!

On behalf of the Program Committee, welcome to Houston! We’ve got an exceptional experience planned for you at this year’s Annual Meeting.

The meeting promises to live up to its theme – New Frontiers: Advocating for Patients, Practices and Research. We’ll give you the tools you need to care for patients and advance your practice, no matter your career stage or clinical setting. You’ll return home from the meeting armed with practical information you can use in your practice right away.

What can you explore? Our sessions cover the most up-to-date information a practicing allergist needs. Here are some highlights:

- **Literature Review** – Join us Friday to keep abreast of the latest clinical developments in allergy and immunology with a review of the most important literature published in the last year.

- **Want your information concise and to the point?** Attend our brand new 7 for 11: Hot Topics in Pediatric Allergy session on Sunday! This exciting accelerated symposium format includes seven renowned experts who each have just 11 minutes to deliver dynamic, insightful presentations on current issues impacting your practice.

- **Ask the Expert Roundtables** – If you like an interactive learning experience, these sessions are for you. Select three topics, rotate through 15 to 20-minute discussions given by experts and receive personal attention to your questions. Sessions include phases of allergy practice, office operations and the changing practice environment.

- **Learn more about contact dermatitis and urticaria with our Interdisciplinary Panel Sessions**, during which you’ll receive a thorough review of these conditions from leading experts.

- **Continuous Assessment Program (CAP) review** – This popular Monday session will highlight and review many of the articles selected by the ABAI for the current six-month MOC cycle. Not sure which articles to select? Then stick around for this helpful guide.

If you’re looking for details on a specific allergy topic, our sessions are categorized into nine different tracks. Look for sessions divided into these tracks:

- Asthma and Respiratory/Sleep Disorders Track
- Clinical Immunology and Autoimmune and Biologicals Track
- Dermatology Track
- Environmental and Integrative Medicine Track
- Food & Drug Allergy and GI Disorders Track
- Immunotherapy and Diagnostics Track
- Population Health and Infectious Diseases/International Travel Track
- Practice Management/Professional Issues Track
- Rhinitis/Sinusitis/Ocular and Anaphylaxis Track

One of the best parts of our annual meeting is networking and forging personal connections with friends and colleagues. Make sure to include the College’s social events in your schedule. All attendees are invited to the **President’s Welcome Reception** on Friday at Minute Maid Park – home of the Houston Astros. Join the crowd for the annual **FIT Bowl** on Saturday as FIT teams endure serious (and not so serious) questions from experts while the audience cheers them on and enjoys complimentary drinks and snacks.

I hope you enjoy your experience at this year’s Annual Meeting. Please feel free to give us feedback during and after the meeting. I assure you that your comments are extremely important to us as we plan future meetings – after all, this meeting is for your benefit.
2019 Program Committees

2019 Annual Meeting Program Committee

David R. Stukus, MD, Chair
Lisa J. Kobrynski, MD, MPH, Vice-chair

Michael Blaiss, MD • Anne K. Ellis, MD, MSc • Luz S. Fonacier, MD • Sandra M. Gawchik, DO
Alan B. Goldsobel, MD • Matthew Greenhawt, MD, MBA, MSc • Brian T. Kelly, MD, MA • Todd A. Mahr, MD
Gailen D. Marshall, Jr., MD, PhD • Kevin P. McGrath, MD • J. Allen Meadows, MD • John J. Oppenheimer, MD
James M. Tracy, DO • Janna M. Tuck, MD • Christin L. Deal, MD, FIT Representative

Literature Review Liaison: David Khan, MD

2019 Allied Health Committee

Jodi A. Shroba, MSN, APRN, CPNP, Chair
Abby L. Allen, RN, NP, Vice-chair

Cheryl K. Bernstein, RN, BSN • Kimberly G. Clay, RN, MSN, APRN, FNP-BC • Tara Doran, RN, BSN, MHA
Raquel Z. Durban, MS RD CSP LDN • Megan Ott Lewis, NP • Amanda L. Michaud, PA-C
Helen M. Murphy, RRT, AE-C • Iris Torres, RMA • Maureen George, PhD, RN, AE-C
The College is proud to honor the following individuals for their service to the College and the specialty of allergy/immunology. The Gold-Headed Cane Award will be presented during the Opening Ceremony at 7:30 am, Saturday. All other awards will be presented during the ACAAI Business Meeting 5:30 pm, Sunday. Both sessions will be held in the Grand Ballroom (Level 3) of the George R. Brown Convention Center.

### Distinguished Fellow Awards

- **James Tracy, DO, FACAAI**  
  *Omaha, Nebraska*  
  Private practice, Allergy, Asthma and Immunology Associates, P.C., Omaha, Nebraska.

- **John Oppenheimer, MD, FACAAI**  
  *Morristown, New Jersey*  
  Private practice, Pulmonary and Allergy Associates, New Jersey; clinical professor, UMDNJ/Rutgers.

### International Distinguished Fellow Award

- **Stephen Holgate, MD, FACAAI**  
  *Southampton, United Kingdom*  
  Medical Research Council Clinical Professor, University of Southampton, United Kingdom.

### Distinguished Service Awards

- **Paul Dowling, MD, FACAAI**  
  *Kansas City, Missouri*  
  Director, Allergy/Immunology Training Program, University of Missouri – Kansas City; co-director, Eosinophilic Esophagitis Multi-disciplinary Clinic, Children’s Mercy Hospitals and Clinics.

- **Renata Engler, MD, FACAAI**  
  *Bethesda, Maryland*  
  Professor of medicine and pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.

### Woman in Allergy Award

- **Anna Nowak-Wegrzyn, MD**  
  *New York City, New York*  
  Professor of pediatrics, New York University School of Medicine, Department of Pediatrics, New York, NY.

### Gold Headed Cane Award

- **Dana V. Wallace, MD, FACAAI**  
  *Hollywood, Florida*  
  Dr. Wallace is an associate professor at Nova Southeastern Allopathic Medical School in Fort Lauderdale, Florida. She has been a College member for 41 years and was College President in 2010-2011. She has chaired and been a member of many College committees over the years. Dr. Wallace was the recipient of the Distinguished Fellow Award in 2018.
The College is proud to honor the following individuals for their service to the College and the specialty of allergy/immunology. The Gold-Headed Cane Award will be presented during the Opening Ceremony at 7:30 am, Saturday. All other awards will be presented during the ACAAI Business Meeting 5:30 pm, Sunday. Both sessions will be held in the Grand Ballroom (Level 3) of the George R. Brown Convention Center.

**Special Recognition Awards**

N. Franklin Adkinson, Jr., MD  
*Baltimore, Maryland*

Louis Mendelson, MD, FACAAI  
*West Hartford, Connecticut*

James Wolfe, MD, FACAAI  
*San Jose, California*

**Clemens von Pirquet Awards**

*First Place – Alliance Memorial Award*  
Michelle Maciag, MD  
*Boston Children’s Hospital, Boston, MA*

*Second Place*  
Peter Capucilli, MD  
*The Children’s Hospital of Philadelphia, Philadelphia, PA*

*Third Place*  
Brittanie Neaves, MD  
*Wilford Hall Ambulatory Surgical Center, San Antonio, TX*

**Young Faculty Support Award**

David A. Hill, MD, PhD  
*The Children’s Hospital of Philadelphia, Philadelphia, PA*
ACAAI appreciates the following promotional contributions from its corporate supporters.

AbbVie
Supporter of the ACAAI Corporate Council.

Aimmune Therapeutics
Supporter of the ACAAI Corporate Council...a Non-CME Corporate Forum...hotel restaurant and lounge promotion...Allied Health Professionals Networking Reception...Allied Health Professionals Luncheon...President’s Welcome Reception...hotel tent card...banner in the convention center...Advanced Registrants Brochure...prior authorization letter...non-CME webinars on Peanut Oral Immunotherapy Billing and Coding and Setting up Your Practice for Peanut Oral Immunotherapy...and the Peanut Oral Immunotherapy Bootcamp Toolkit.

ALK Inc.
Supporter of the ACAAI Corporate Council...a Non-CME Corporate Forum...FIT and Program Directors’ Breakfast...”Find an Allergist” widget...and the USP 797 Toolkit.

AstraZeneca
Supporter of the ACAAI Corporate Council...three Product Theaters...hotel elevator clings...convention center window clings...micro fiber cleaning cloth...signage in the convention center...ACAAI Media Wall...convention center lightboxes...banner in the convention center...and the Leadership Summit.

Circassia
Supporter of the ACAAI Corporate Council...FITs General Meeting...and a non-CME webinar on Beyond E&M Coding: Procedures and More.

CSL Behring
Supporter of a Product Theater...daily schedule display...and hotel room door hangers.

DBV Technologies
Supporter of the ACAAI Corporate Council...badge lanyards...wall clings...signage in the convention center...Board of Regents Dinner...and the FIT Bowl.

Genentech
Supporter of the ACAAI Corporate Council...and FIT Travel Scholarships.

Genentech and Novartis Pharmaceuticals Corporation
Supporter of the Women in Allergy Luncheon...a Non-CME Corporate Forum...two banners in the convention center...and the Foundation Honor Display.

GlaxoSmithKline
Supporter of the ACAAI Corporate Council...a Non-CME Corporate Forum...a Product Theater...signage in the convention center...and five sets of park benches.

HollisterStier Allergy
Supporter of the FIT Travel Scholarships.

kaléo
Supporter of the ACAAI Corporate Council.

Merck & Co., Inc.
Supporter of advertisements in College Advantage...and the final program guide.

National Peanut Board
Supporter of the Early Introduction Size 4 – 6 Program...and the Early Peanut Introduction Campaign.

Novartis Pharmaceuticals Corporation
Supporter of the ACAAI Corporate Council...two advertisements in the final program guide...signage in the convention center...digital signage at the convention center...mobile projection...and two Product Theaters.

Optinose
Supporter of the ACAAI Corporate Council...a Product Theater...and XHANCE prior authorization letter.

Pfizer, Inc.
Supporter of the Translating the Atopic Dermatitis Yardstick into Practice RFP...and a Product Theater.

Pharming Group NV
Supporter of the ACAAI Corporate Council...and FIT Travel Scholarships.

Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Supporter of the ACAAI Corporate Council...three Product Theaters...three Non-CME Corporate Forums...Annual Business Meeting...Annual Meeting daily e-newsletter...branded floor clings in the convention center...escalator clings in the convention center and hotel...signage in the convention center...four convention center banners...refreshment breaks...e-posters...an advertisement in the final program guide...FIT Travel Scholarships...Eczema page on ACAAI website...Biologics Toolkit...Severe Asthma Allergist and Patient Success Video...Atopic Dermatitis Allergist and Patient Success Video...Severe Asthma Allergist and Patient Education Campaign...Atopic Dermatitis Patient Guide...
This activity is supported by independent educational grants from the following commercial supporters:

**Abbvie**
Supporter of the Saturday Symposium on Difficult-to-control Atopic Dermatitis.

**Aimmune Therapeutics**
Supporter of the Allied Health Professionals Course…the Friday luncheon symposium on Implementing Food Allergy Therapy in Clinical Practice…and enduring on-demand video webcast of the symposium.

**ALK Inc.**
Supporter of Friday Breakfast Symposium AACA 2019: Subcutaneous Versus Sublingual Allergen Immunotherapy – Where Do We Stand in 2019?

**CSL Behring**
Supporter of the Sunday symposium on Primary Immune Deficiency: Optimal Care for Optimal Outcomes.

**DBV Technologies**
Supporter of Thursday’s International Food Allergy Symposium.

**GlaxoSmithKline**
Supporter of the Sunday breakfast symposium on Pediatric Asthma: Where Are We Going?…and the Sunday PBL session on An Older Adult Patient With Difficult to Control Asthma: Learning to Care for the Older Adult Patient Using SDM.

**Merck & Co., Inc.**
Supporter of the Saturday symposium on Cough Across the Ages…and an enduring on-demand video webcast of the symposium.

**Micro Direct, Inc.**
In-kind support consisting of loaned durable equipment for the Allied Health Professionals Hands-on Workshop on Strategies for Getting the Most From Spirometry.

**Optim LLC**
In-kind support consisting of loaned durable equipment for the Sunday workshops Hands-on Session: in Rhinolaryngoscopy: Introductory and Intermediate/Advanced.

**Pfizer, Inc.**
Supporter of the 2019 Annual Scientific Meeting.

**RMS Medical Products**
In-kind support consisting of loaned durable equipment and disposable supplies for the Saturday workshop Hands-on: Facilitated SQ Immunoglobulin Infusion.

**SmartPractice**
In-kind support consisting of disposable supplies for the Sunday workshop on The Nuts and Bolts of Wraps, Biopsy, Patch Testing and Metal Hypersensitivity.

**Stallergenes Greer**
Supporter of the Sunday ACAAi Allergen Extract Mixer Training Program.

**Teva Pharmaceuticals**
Supporter of the Saturday symposium on Practical Use and Effectiveness of New Digital Health Technologies in Effective Treatment of Asthma.
Thank you to the 2019 ACAAI Corporate Council Members

BENEFACTOR MEMBERSHIP

ALK  Genentech  Pharming

SANOFI  GENZYME  REGENERON

PATRON MEMBERSHIP

abbvie  aimmune  AstraZeneca

CIRCASSIA  dbv  gsk

kaléo  NOVARTIS  optinose

STALLERGENES  GREER  teva
Immune Response Pathways: Characteristics of Asthma and Comorbidities

Allergic asthma is a specific phenotype of a common disease with wide heterogeneity. Associated comorbidities often go hand-in-hand with the condition. Such comorbidities may share common immunopathological mechanisms with asthma that can influence its control. *Immune Response Pathways: Characteristics of Asthma and Comorbidities* will focus on the immune response of allergic asthma, accurate recognition of these characteristics, and proper management of comorbidities.
Admission by Badge Only
Admission to all meeting rooms and the exhibit area will be by badge only. This rule will be strictly enforced by security guards at all entrances. Note: Children under 12 are not admitted to the scientific sessions or the exhibit area.

Alliance Hospitality Suite
The Alliance Hospitality Suite – located in the Lanier Grand Ballroom Salons J-K (Level 4) of the Hilton Americas-Houston Hotel – will be open to registered spouses and guests only from 8:00 – 10:30 am, Friday through Sunday.

Annual Meeting Website
Maximize your time at the meeting! Find schedules, download handouts and access all the information you need at annualmeeting.acaai.org.

Audience Response System
Sessions indicated with this icon will feature interactive audience response.

Badge Designations
Blue: Member/Fellow Physicians  
Purple: Non-member Physicians  
Green: Nurses/Allied Health  
Lime: Fellows-in-Training/Residents  
Orange: Non-Physicians  
Red: Technical Exhibitors  
Teal: Spouses/Guests  
Lt Orange: Press  
Fuschia: Staff  
Gray: Meeting Technicians

Replacement badges – $10.00 each

Capturing of NPI Numbers
As part of the health care reform legislation signed into law in March 2010, the Physician Payment Sunshine Act requires medical device, biologic and drug companies to publicly disclose gifts and payments made to physicians.

To help our ACAAI Annual Scientific Meeting exhibitors and industry partners in fulfilling the mandatory reporting provisions of the Sunshine Act, the College is requesting U.S. health care provider attendees supply their 10-digit NPI (National Provider Identifier) number when registering for the Annual Scientific Meeting. The NPI will be embedded in the bar code data on the attendee’s badge – it will NOT be printed on the badge. Exhibitors can download the NPI information by scanning the badge through a lead retrieval system so that they can record and track any reportable transactions.

Child Care Services
Please contact the concierge at the hotel at which you are staying for a list of bonded independent babysitters and babysitting agencies. Note: Children under 12 are not admitted to the scientific sessions or the exhibit area.

Coat/Luggage Check
A coat/luggage check is located on Level 3 near Room 370 of the George R. Brown Convention Center and will be available:

Hours:
- 7:00 am – 6:30 pm, Thursday
- 6:00 am – 6:30 pm, Friday
- 6:30 am – 6:00 pm, Saturday
- 6:30 am – 7:00 pm, Sunday
- 7:00 am – 1:00 pm, Monday

Cost:
- $3 for coat/umbrella
- $5 for luggage

College Resource Center
Stop by the College Resource Center, located at Booth #613 in the exhibit hall – Halls A3 & B3 (Level 3) – of the George R. Brown Convention Center, to get connected and learn about ongoing College programs, Vision 2020 and more. Learn what’s available online in the College Learning Connection and Practice Management Center.

Hours:
- 2:00 – 6:00 pm, Friday
- 9:00 am – 4:30 pm, Saturday
- 9:00 am – 1:30 pm, Sunday
Credit Claiming
For your convenience, the College will be using an online evaluation and credit claiming system for the 2019 Annual Scientific Meeting. This system will allow you to complete evaluations and claim credit for sessions attended. After completing an annual meeting evaluation, you will be able to save and/or print your certificate. Complete details can be found on page 19.

Disclaimer
The primary purpose of the ACAAI Annual Scientific Meeting is educational. Information, as well as technologies, products and/or services discussed, is intended to inform participants about the knowledge, techniques and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty and the views of the College disclaim any and all liability for damages to any individual attending this conference and for all claims which may result from the use of information, technologies, products and/or services discussed at the conference.

Doctors’ Job Fair
Looking for new opportunities, an associate for your group or a buyer for your practice? The Doctors’ Job Fair brings together all interested parties seeking or offering professional opportunities.

This unique program is scheduled from 11:30 am – 3:00 pm, Saturday, in Halls A3 & B3 (Level 3) of the George R. Brown Convention Center. Representatives of clinics, groups and physicians’ offices looking for associates will be among those conducting interviews, which will be held in private draped booths.

E-posters – Meet the Authors
E-posters provide an engaging and interactive visual presentation of abstracts and allow for online access with full search capabilities. Each presenting author has a 10 – 15 minute presentation slot. E-posters are also accessible at college.acaai.org/eposters and through the meeting app. The e-posters will be on display in Halls A3 & B3 (Level 3) of the George R. Brown Convention Center and will be assigned to monitors by category. When e-posters are not being presented, the monitors are self-service for searching and viewing e-posters.

Exhibit Hall
More than 80 technical and scientific exhibitors in over 250 booths are displaying their latest products in Halls A3 & B3 (Level 3) of the George R. Brown Convention Center during the convention. The College appreciates the support of its exhibitors and urges all registrants to visit the displays. Plus, participate in our new Passport Contest for a chance to win great prizes! See game card and page 104 for details.

Hours: 2:00 – 6:00 pm, Friday
9:00 am – 4:30 pm, Saturday
9:00 am – 1:30 pm, Sunday

Exhibit Hall Passport Contest
NEW THIS YEAR! Get your passport stamped by visiting each company listed on your game card (included in your registration bag), and drop your completed card at the College Resource Center, Booth #613. You could win one of two Apple iPads, $500 Amazon gift cards or complimentary registrations for the 2020 Annual Meeting! See page 104 for complete details.

First Aid
A First Aid station is located in Hall B3 (Level 3) of the George R. Brown Convention Center during the following hours:

Hours: 6:30 am – 7:00 pm, Thursday
5:30 am – 7:00 pm, Friday
6:00 am – 6:30 pm, Saturday
6:00 am – 10:00 pm, Sunday
6:30 am – 5:00 pm, Monday

Foundation Display
The Foundation of the ACAAI is proud to recognize those individuals who have generously contributed to the Foundation. A list of donors can be found on the Foundation Honor Display located on Level 3 of the George R. Brown Convention Center.

Supported by Genentech and Novartis Pharmaceuticals Corporation

Handouts
Session handouts are available for download online at annualmeeting.acaai.org or through the meeting app.
Special Announcements

Meeting App
Maximize your time at the meeting with the free ACAAI Annual Scientific Meeting app. To download, visit acaai.org/apps or search for ACAAI in your app store.

Supported by Teva Pharmaceuticals

Meeting on Demand
The recorded educational sessions from the 2019 Annual Meeting will be hosted on the College Learning Connection website. We provide a variety of online packages designed to meet your particular needs, from the entire set of recordings to topical collections. Go to education.acaai.org/ondemand.

MOC Designated Sessions MOC/CME
Nine sessions have been designated for MOC this year. For details please see the Education Information on page 18.

Networking Goes Viral: #ACAAI
Be a part of the Annual Meeting conversation! Use #ACAAI19 in your meeting-related tweets and follow the College @ACAAI. Also, share Facebook posts from facebook.com/TheACAAI.

Non-CME Corporate Forums NOT FOR CREDIT
Following the close of Thursday, Friday, Saturday and Sunday’s scientific sessions, all registrants are invited to attend the special Corporate Forums at the Hilton Americas-Houston Hotel and the Marriott Marquis Houston Hotel. Corporate Forums are non-CME promotional symposia organized by industry and designed to enhance your educational experience. Please see pages 95-96 for additional info.

Photography/Video Recordings
By registering for this meeting, attendees acknowledge and agree that ACAAI or its agents may take photographs during events and may freely use those photographs in any media for College purposes, including, but not limited to, news and promotional purposes.

The presentations, slides and materials provided in this program are the property of the College or are used with permission of the owner. You may not photograph, videotape, audiotape or otherwise record or reproduce any of the presentations without express written permission from the College. Any attendee believed to be violating this restriction will be removed from the session and may be prohibited from participating in future College meetings.

President’s Welcome Reception
All registered attendees are encouraged to attend the President’s Welcome Reception on Friday, held at Minute Maid Park (home of the Houston Astros) from 6:00 – 7:30 pm. It’s the perfect place to catch up with old friends and make new acquaintances. View the World Series trophy on the warning track by home plate from 6:00 – 7:00 pm.

Minute Maid Park is walking distance from the hotels. Transportation will not be provided. Enter ballpark at the Atrium Entrance off of Texas Street. Name badges must be worn for admittance to ballpark.

Supported by Aimmune Therapeutics

Registration Desk Hours
The Registration Desk is located in the Grand Ballroom Foyer (Level 3) of the George R. Brown Convention Center and will be open:

Hours: 3:30 – 6:30 pm, Wednesday
7:00 am – 5:00 pm, Thursday
6:00 am – 6:00 pm, Friday
7:00 am – 4:00 pm, Saturday
7:00 am – 4:00 pm, Sunday
7:00 am – noon, Monday

Speaker Ready Room
The Speaker Ready Room is located in Room 310C of the George R. Brown Convention Center and will be open:

Hours: 3:00 – 7:00 pm, Wednesday
7:00 am – 7:00 pm, Thursday
6:00 am – 6:30 pm, Friday
6:30 am – 6:00 pm, Saturday
6:00 am – 6:00 pm, Sunday
7:00 am – 12:30 pm, Monday

All presenters must check into the Speaker Ready Room at least six hours before the start of their presentation.
**Special Needs**

In compliance with the Americans with Disabilities Act, ACAAI requests that participants in need of special accommodation submit a written request to the College well in advance.

**Virtual Meeting**

Select sessions from Saturday and Sunday’s program will be webcast live. Meeting registrants will have free access to this content after the meeting. Details will be available on the College Learning Connection at education.acaai.org/virtualarchive.

**Wireless Internet**

Free Wi-Fi is provided to all meeting attendees at the George R. Brown Convention Center and the Hilton Americas-Houston Hotel.

**George R. Brown Convention Center**
- Open your wireless network connections
- Connect to the “ACAAI” wireless network
- Enter password: acaai2019

**Hilton Americas-Houston Hotel (Meeting Space)**
- Open your wireless network connections
- Connect to the “ACAAI” wireless network
- Enter password: acaai2019

*Supported by Takeda Pharmaceutical Company Limited*

---

### SPARK Program

The ACAAI SPARK program was developed to help “spark” an interest in residents who might be considering a career in allergy-immunology. The SPARK program provides $1,500 to help cover the expenses for residents (Pediatric, Internal Medicine, or Med-Peds) to spend three days at the ACAAI Annual Meeting. Residents are encouraged to attend a wide variety of sessions covering all aspects of allergy-immunology. With the leadership of the Program Director’s Committee and FIT Representatives, Christin Deal, MD, and Miriam Samstein, MD, PhD, each SPARK recipient will have a FIT mentor while they are in Houston and beyond. You might recognize them by their yellow SPARK ribbon, so please say hello and welcome our 2019 SPARK recipients:

- Tonia Afshan, MD • Spectrum Health/MSU/Helen DeVos Children’s Hospital
- Kristian Cantrell, MD • OU Health Science Center Pediatrics Residency
- Patricia J. Choi, MD • Spectrum Health/Michigan State University
- Sofia Edwards-Salmon, MD • Emory Pediatrics
- Stanislaw Gabryszewski, MD • Residency in General Pediatrics/Children’s Hospital of Philadelphia
- Nina Hein, MD • University of Miami/Jackson Memorial Hospital
- Kamran Hussain Imam, MD • White Memorial Medical Center
- Jennifer Li, MD • University of Wisconsin Internal Medicine Residency
- Giulia Martone, MD • University at Buffalo – UBMD Pediatrics
- Priya Patel, MD • University of Mississippi Medical Center
- Mara Shapero, MD • Northwell Health General Pediatrics at Cohen Children’s Medical Center
- Shannon Sullivan, MD • University of South Florida Pediatrics Residency
- Andrea Tham, MD • University of California, Irvine
- Stephanie Nicole Vazquez, MD • Memorial Healthcare System Joe DiMaggio Children’s Hospital
- Sehrish Viqar, MD • Johns Hopkins All Children’s Hospital
This activity is supported by independent educational grants from:

- Abbvie
- Aimmune Therapeutics
- ALK – Abello Inc
- CSL Behring
- DBV Technologies
- GlaxoSmithKline
- Merck & Co., Inc.
- Pfizer, Inc.
- Stallergenes Greer
- Teva Pharmaceuticals

This activity is also supported by independent educational grants consisting of loaned durable equipment and disposable supplies from:

- Micro Direct, Inc.
- Optim LLC
- RMS Medical Products
- SmartPractice

Target Audience
Medical professionals who treat patients with allergic and/or immunological conditions:

- Practicing allergist/immunologists
- Allergy/immunology Fellows-in-Training
- Physician assistants
- Advanced practice nurses
- Allied health professionals
- Primary care physicians
- Other medical professionals

Overall Educational Objectives
At the conclusion of this activity, participants should be able to:

- Identify major advances in key areas of cutting-edge research in immunologic mechanisms and allergic responses, including anaphylaxis and pathophysiology of the upper airways, lungs, eyes, skin and gastrointestinal tract.
- Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency.
- Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases.
- Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases.
- Explain the impact of environmental exposures and external influences on patients with allergic disorders.
- Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health.
- Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes.
- Discuss processes, tools and technologies for the efficient allergy and immunology practice.

Disclosure Statement
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, and/or evaluation relevant to a CME activity. Disclosed information is reviewed in advance in order to manage and resolve any potential conflicts of interest. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.

Specific disclosure information for the 2019 Annual Meeting is conveniently located on the Annual Meeting website at college.acaai.org/disclosures. There is a link to this web page in the meeting app.

Accreditation Statements
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 34 contact hours.

Credit Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 34 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The continuing medical education activity has been reviewed by the American Academy of Pediatrics (AAP) and is acceptable for a maximum of 34 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the AAP.

Advanced Practice Health Care Providers
1-Day Course:
This activity has been designated for up to 6 Continuing Education contact hours.

Advanced Practice Health Care Providers 1.5-Day Course:
This activity has been designated for up to 9.0 Continuing Education contact hours.
The American Board of Allergy and Immunology's (ABAI) Maintenance of Certification (MOC) program offers evidence of highly qualified physicians who use best practices and evidence-based standards for care. Linking the educational content of the ACAAI Annual Scientific Meetings to the MOC program is one way the College helps its members provide ABAI with evidence of their commitment to lifelong learning.

**IMPORTANT:** ABAI's MOC program requires diplomates to obtain a minimum of **25 CME credits in allergy and immunology each year**. CME credits for the Annual Meeting can be used to satisfy this requirement.

Additionally, the ABAI recommends that **6 of the 25 credits be designated as self-assessment (MOC Part II) credit.** With the approval of ABAI, the College has designated nine sessions at the meeting for MOC self-assessment credit.

In order to earn MOC self-assessment credit at designated sessions:

- You must be currently enrolled in the ABAI's MOC program.
- You must attend the entire designated session. (Be in the session room no later than 5 minutes after the start.)

- You must fully complete a paper form, including answering all pre- and post-test questions, providing a full name and ACAAI badge ID number.

**Forms must be legible in order to receive credit.** ACAAI will submit the required reports that include MOC self-assessment credits to the ABAI. ABAI will enter the MOC self-assessment credits onto the ABAI web portal page (portal.abai.org/session/new). The amount of MOC self-assessment credit earned is always equal to the amount of AMA PRA Category 1 Credit™ claimed for the session. (Partial self-assessment credit is not available.) Faculty cannot earn CME or MOC self-assessment credit for their own presentations.

Ultimately, CME activities for which MOC self-assessment credit is awarded may be cross-referenced to the ABAI examination content outline, available on the ABAI website (abai.org/Overview.asp). Details of the six Core Competencies are also located on the ABAI website. The six Core Competencies are: **Patient Care and Procedural Skills; Medical Knowledge; Practice-based Learning and Improvement; Interpersonal and Communication Skills; Professionalism; and System-based Practice.**

### MOC/CME Sessions:

**Friday**
- 3:00 – 4:30 pm
  - Room 370
  - Symposium
  - Physician Health and Wellness: Advocating for Ourselves

**Saturday**
- 10:00 – 11:30 am
  - Grand Ballroom (Level 3)
  - Clinical Conundrum
  - When Drugs Go Wild!
- 1:00 – 2:30 pm
  - Grand Ballroom (Level 3)
  - Symposium
  - Evolution of Food Allergy Therapies

**Sunday**
- 8:00 – 9:30 am
  - Grand Ballroom (Level 3)
  - Plenary Session
  - Modifying Our Approach
- 10:00 – 11:30 am
  - Grand Ballroom (Level 3)
  - Symposium
  - USP 797, The Final Word – What Does It Say? What Does It Mean? What Do I Have to Do?
- 1:00 – 2:30 pm
  - Room 360
  - Symposium
  - Recurrent Infections with Normal or Near-normal Immunoglobulins: Now What?
- 3:00 – 4:30 pm
  - Grand Ballroom (Level 3)
  - Symposium
  - Telemedicine for the Allergist

**Monday**
- 9:45 – 11:00 am
  - Room 370
  - Symposium
  - Climate Change and Natural Disasters: The Central Role of Allergists
- 11:15 am – 12:30 pm
  - Room 370
  - Symposium
  - New Horizons in Chronic Rhinosinusitis
For your convenience, the College will be using an online evaluation and credit claiming system for the 2019 Annual Scientific Meeting. This system will allow you to complete evaluations and claim credit for sessions attended. After completing an overall meeting evaluation, you will be able to save and/or print your certificate.

**Where to access the evaluation and credit claiming system:**

**At the meeting:**
- CME Kiosks located on Level 3 of the George R. Brown Convention Center.
- Personal laptops, tablets and other mobile devices (recommended) at annualmeeting.acaai.org.

**After the meeting:**
- Office or home computers at annualmeeting.acaai.org.

**How to log into the evaluation and credit claiming system:**
1) Go to annualmeeting.acaai.org.
2) Click the “Claim Credit” button.
3) Log in using your last name and badge ID number.
4) Complete the evaluations and claim your credit for the sessions you attended.
5) Complete the overall meeting evaluation.
6) Save and/or print your certificate.

Please complete the evaluation and credit claiming by December 31, 2019.

**Certificates:**
- CME Certificates will be awarded to physicians only, per the American Medical Association (AMA PRA Handbook, p. 8).
- Certificates of Attendance will be awarded to any non-physician participants that complete the evaluation and credit claiming.

Visit annualmeeting.acaai.org for additional information.

**Replacement Certificates:**
Once you have claimed credit for the 2019 Annual Meeting, your certificate will always be available on the College Learning Connection (education.acaai.org). Log in using your College username/password, and click “My Account,” then “My Learning” to find your learning transcript.
### Daily Events

All programs held at the George R. Brown Convention Center unless otherwise noted.

<table>
<thead>
<tr>
<th>HOURS</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wednesday, November 6th</strong></td>
<td></td>
</tr>
<tr>
<td>3:00 – 7:00 pm</td>
<td>Speaker Ready Room ............................................... 310C</td>
</tr>
<tr>
<td>3:30 – 6:30 pm</td>
<td>Registration ................................................... Grand Ballroom Foyer (Level 3)</td>
</tr>
<tr>
<td><strong>Thursday, November 7th</strong></td>
<td></td>
</tr>
<tr>
<td>7:00 am – 5:00 pm</td>
<td>Registration ................................................... Grand Ballroom Foyer (Level 3)</td>
</tr>
<tr>
<td>7:00 am – 6:30 pm</td>
<td>Coat / Luggage Check ........................................... Level 3</td>
</tr>
<tr>
<td>7:00 am – 7:00 pm</td>
<td>Speaker Ready Room ............................................ 310C</td>
</tr>
<tr>
<td>7:45 am – 4:30 pm</td>
<td>Board of Regents Meeting ................................. 335AB (Level 3 / Hilton)</td>
</tr>
<tr>
<td>8:00 – 11:45 am</td>
<td>International Food Allergy Symposium ................. Grand Ballroom Salon A (Level 3)</td>
</tr>
<tr>
<td>9:45 – 10:00 am</td>
<td>Refreshment Break .............................................. Grand Ballroom Foyer (Level 3)</td>
</tr>
<tr>
<td>11:45 am – 12:50 pm</td>
<td>International Food Allergy Symposium Luncheon .......... Ballroom of the Americas Salons DEF (Level 2 / Hilton)</td>
</tr>
<tr>
<td>1:00 – 6:00 pm</td>
<td>International Food Allergy Symposium ................. Grand Ballroom Salon A (Level 3)</td>
</tr>
<tr>
<td>2:45 – 3:00 pm</td>
<td>Refreshment Break .............................................. Grand Ballroom Foyer (Level 3)</td>
</tr>
<tr>
<td>6:30 – 8:30 pm</td>
<td>Non-CME Corporate Forum: Aimmune Therapeutics .......... Ballroom of the Americas Salons DE (Level 2 / Hilton)</td>
</tr>
<tr>
<td>6:30 – 8:30 pm</td>
<td>Non-CME Corporate Forum: Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. .......... Houston Ballroom Salons I-II (Level 2 / Marriott)</td>
</tr>
<tr>
<td><strong>Friday, November 8th</strong></td>
<td></td>
</tr>
<tr>
<td>6:00 am – 6:00 pm</td>
<td>Registration ................................................... Grand Ballroom Foyer (Level 3)</td>
</tr>
<tr>
<td>6:00 am – 6:30 pm</td>
<td>Speaker Ready Room ............................................ 310C</td>
</tr>
<tr>
<td>6:00 am – 6:30 pm</td>
<td>Coat / Luggage Check ........................................... Level 3</td>
</tr>
<tr>
<td>6:45 – 7:30 am</td>
<td>SPARK Welcome Program ......................................... 340 (Level 3 / Hilton)</td>
</tr>
<tr>
<td>7:30 – 11:30 am</td>
<td>Annual Literature Review ........................................ Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>8:00 – 9:30 am</td>
<td>Symposium: Idiopathic Anaphylaxis – Knowledge Gaps and Patient Needs ........................................ 360</td>
</tr>
<tr>
<td>8:00 – 9:30 am</td>
<td>Ask the Expert Roundtables: Phases of Allergy Practice ................. 361ABC</td>
</tr>
<tr>
<td>8:00 – 9:30 am</td>
<td>Office Administrators Practice Management Course ................. 371ABDE</td>
</tr>
<tr>
<td>8:00 – 10:30 am</td>
<td>Alliance Hospitality Suite ...................................... Lanier Grand Ballroom Salons J-K (Level 4 / Hilton)</td>
</tr>
<tr>
<td>8:00 – 11:30 am</td>
<td>Advanced Practice Health Care Providers Course ................. 362ABDE</td>
</tr>
<tr>
<td>9:30 – 10:00 am</td>
<td>Refreshment Break .............................................. Grand Ballroom Foyer (Level 3) &amp; 350-370 Pre-Function</td>
</tr>
</tbody>
</table>
### Daily Events

**Friday, November 8th (continued)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 10:45 am</td>
<td><strong>Office Administrators Breakout Sessions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biologics: A Look at the Risks, Rewards and Service</td>
<td>371C</td>
</tr>
<tr>
<td></td>
<td>Use of Technology in Revenue Cycle Management</td>
<td>371F</td>
</tr>
<tr>
<td></td>
<td>USP 797: What the New Rule Means for Your Practice</td>
<td>371ABDE</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td><strong>Symposium: Across the Spectrum of Immunotherapy</strong></td>
<td>370</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td><strong>Symposium: Biologics for the Young and the Restless</strong></td>
<td>360</td>
</tr>
<tr>
<td>10:30 – 11:30 am</td>
<td>Publications Committee</td>
<td>350A</td>
</tr>
<tr>
<td>10:45 – 11:30 am</td>
<td><strong>Office Administrators Breakout Sessions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biologics: A Look at the Risks, Rewards and Service</td>
<td>371C</td>
</tr>
<tr>
<td></td>
<td>Use of Technology in Revenue Cycle Management</td>
<td>371F</td>
</tr>
<tr>
<td></td>
<td>USP 797: What the New Rule Means for Your Practice</td>
<td>371ABDE</td>
</tr>
<tr>
<td>11:30 am – 12:30 pm</td>
<td>Accreditation and Certification Committee</td>
<td>320A</td>
</tr>
<tr>
<td>11:30 am – 12:55 pm</td>
<td>Luncheon Symposium: Implementing Food Allergy Therapy in Clinical Practice</td>
<td>Lanier Grand Ballroom Salons A-F (Level 4 / Hilton)</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Advanced Practice Health Care Providers Course Lunch Break</td>
<td>On Own</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Literature Review Lunch Break</td>
<td>On Own</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Office Administrators Practice Management Course Lunch Break</td>
<td>On Own</td>
</tr>
<tr>
<td>11:30 am – 1:30 pm</td>
<td>Corporate Council Meeting</td>
<td>340</td>
</tr>
<tr>
<td>Noon – 2:00 pm</td>
<td>FIT Bowl Subcommittee</td>
<td>310A</td>
</tr>
<tr>
<td>1:00 – 1:45 pm</td>
<td><strong>Office Administrators Practice Management Course</strong></td>
<td>371ABDE</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td><strong>Interdisciplinary Panel Session: Don't Be Rash!</strong></td>
<td>360</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Assessing Contact Dermatitis</td>
<td>360</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td><strong>Ask the Expert Roundtables: Pearls to Improve Your Practice Operations</strong></td>
<td>361ABC</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td><strong>Advanced Practice Health Care Providers Breakout Sessions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shared Decision-making and Improved Adherence and Compliance</td>
<td>362ABDE</td>
</tr>
<tr>
<td></td>
<td>A Tough Nut to Crack: The Complexity of Tree Nut Allergy Management</td>
<td>362CF</td>
</tr>
<tr>
<td>1:00 – 4:30 pm</td>
<td>Annual Literature Review</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>1:45 – 2:30 pm</td>
<td><strong>Office Administrators Breakout Sessions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>But This Is How We’ve Always Done It!</td>
<td>371ABDE</td>
</tr>
<tr>
<td></td>
<td>HR: Investing in the Happy Factor</td>
<td>371C</td>
</tr>
<tr>
<td></td>
<td>Why Patient Experience and Patient Engagement Is Crucial to the Success of Your Practice</td>
<td>371F</td>
</tr>
<tr>
<td>2:00 – 6:00 pm</td>
<td>College Resource Center</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>2:00 – 6:00 pm</td>
<td>Exhibit Hours</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>2:30 – 3:00 pm</td>
<td>Refreshment Break / Visit Exhibits</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
</tbody>
</table>

*All programs held at the George R. Brown Convention Center unless otherwise noted.*
Daily Events

**Friday, November 8th (continued)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 – 3:45 pm</td>
<td><strong>Office Administrators Breakout Sessions</strong></td>
<td>371ABDE</td>
</tr>
<tr>
<td></td>
<td>But This Is How We’ve Always Done It!</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HR: Investing in the Happy Factor</td>
<td>371C</td>
</tr>
<tr>
<td></td>
<td>Why Patient Experience and Patient Engagement Is Crucial to the Success of Your Practice</td>
<td>371F</td>
</tr>
<tr>
<td>3:00 – 4:30 pm</td>
<td><strong>Advanced Practice Health Care Providers Breakout Sessions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Management of the Coughing and Wheezing Infant and Toddler</td>
<td>362CF</td>
</tr>
<tr>
<td></td>
<td>PBL – Review of Common Immunodeficiency Diagnosis</td>
<td>362ABDE</td>
</tr>
<tr>
<td>3:00 – 4:30 pm</td>
<td><strong>Clinical Conundrum:</strong> Evidence-based Diagnosis of Food Allergy</td>
<td>360</td>
</tr>
<tr>
<td>3:00 – 5:00 pm</td>
<td><strong>Symposium:</strong> Physician Health and Wellness: Advocating for Ourselves</td>
<td>370</td>
</tr>
<tr>
<td>3:00 – 5:00 pm</td>
<td>Alliance Pre-board Meeting</td>
<td>340 (Level 3 / Hilton)</td>
</tr>
<tr>
<td>3:00 – 6:00 pm</td>
<td>E-posters – Meet the Authors: Session 1</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>3:45 – 4:30 pm</td>
<td><strong>Office Administrators Practice Management Course</strong></td>
<td>371ABDE</td>
</tr>
<tr>
<td>4:30 – 5:30 pm</td>
<td>Leadership Summit Reception</td>
<td>339 (Level 3 / Hilton)</td>
</tr>
<tr>
<td>4:30 – 6:00 pm</td>
<td>American Association of Allergists and Immunologists of Indian Origin (AAAII) Annual Meeting and Symposium</td>
<td>Houston Ballroom Salon IV (Level 2 / Marriott)</td>
</tr>
<tr>
<td>4:30 – 6:00 pm</td>
<td>FIT Integrated Educational Program &amp; Business Meeting</td>
<td>350DEF</td>
</tr>
<tr>
<td>4:45 – 6:00 pm</td>
<td>Advanced Practice, Allied Health and Office Administrators Networking Reception</td>
<td>335AB (Level 3 / Hilton)</td>
</tr>
<tr>
<td>6:00 – 7:30 pm</td>
<td>President’s Welcome Reception</td>
<td>Off-Site (Minute Maid Park)</td>
</tr>
<tr>
<td>8:00 – 10:00 pm</td>
<td>Non-CME Corporate Forum: ALK Inc.</td>
<td>Houston Ballroom Salons I-III (Level 2 / Marriott)</td>
</tr>
<tr>
<td>8:00 – 10:00 pm</td>
<td>Non-CME Corporate Forum: Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.</td>
<td>Ballroom of the Americas Salons DE (Level 2 / Hilton)</td>
</tr>
</tbody>
</table>

**Saturday, November 9th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:15 – 7:15 am</td>
<td>Fellows-in-Training / Allergy/Immunology Program Directors’ Breakfast</td>
<td>Ballroom of the Americas Salons AB (Level 2 / Hilton)</td>
</tr>
<tr>
<td>6:30 – 7:30 am</td>
<td>Committee Chair and Vice Chair Breakfast</td>
<td>340</td>
</tr>
<tr>
<td>6:30 am – 6:00 pm</td>
<td>Speaker Ready Room</td>
<td>310C</td>
</tr>
<tr>
<td>6:30 am – 6:00 pm</td>
<td>Coat / Luggage Check</td>
<td>Level 3</td>
</tr>
<tr>
<td>7:00 – 8:30 am</td>
<td>Annals Editors Meeting</td>
<td>310B</td>
</tr>
<tr>
<td>7:00 am – 4:00 pm</td>
<td>Registration</td>
<td>Grand Ballroom Foyer (Level 3)</td>
</tr>
<tr>
<td>7:30 – 8:00 am</td>
<td>Opening Ceremony and Welcome Announcements</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>8:00 – 9:30 am</td>
<td><strong>Presidential Plenary Session:</strong> Adapting to New Evidence</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
</tbody>
</table>

All programs held at the George R. Brown Convention Center unless otherwise noted.
### Saturday, November 9th (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 – 10:30 am</td>
<td>Alliance Hospitality Suite</td>
<td>Lanier Grand Ballroom Salons J-K</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Level 4 / Hilton)</td>
</tr>
<tr>
<td>8:30 – 9:30 am</td>
<td>Alliance: Fine Jewelry with Vincent Peach</td>
<td>Lanier Grand Ballroom Salons J-K</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Level 4 / Hilton)</td>
</tr>
<tr>
<td>9:00 am – 4:30 pm</td>
<td>College Resource Center</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>9:00 am – 4:30 pm</td>
<td>Exhibit Hours</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>9:30 – 10:00 am</td>
<td>Refreshment Break / Visit Exhibits</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>9:35 – 10:00 am</td>
<td>Product Theater 1: AstraZeneca</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>9:35 – 10:00 am</td>
<td>Product Theater 2: Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>10:00 – 11:00 am</td>
<td>Anaphylaxis Committee</td>
<td>310A</td>
</tr>
<tr>
<td>10:00 – 11:00 am</td>
<td>Asthma Committee</td>
<td>320C</td>
</tr>
<tr>
<td>10:00 – 11:00 am</td>
<td>Biologics and Pharmacology Committee</td>
<td>350A</td>
</tr>
<tr>
<td>10:00 – 11:00 am</td>
<td>Government Relations Committee</td>
<td>350C</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td>Allied Health Professionals Course</td>
<td>371</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td>Symposium: The Challenges of Infant Food Allergy and Anaphylaxis</td>
<td>360</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td>Panel Discussion: Ensuring the Success of Academic Allergy (Invitation Only)</td>
<td>335 (Level 3 / Hilton)</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td>Practical Applications at Work Seminar: Practical Use and Effectiveness of New Digital Health Technologies in Effective Treatment of Asthma</td>
<td>370</td>
</tr>
<tr>
<td>11:00 am – noon</td>
<td>Payer and Managed Care Committee</td>
<td>350B</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>2020 Annual Meeting Program Committee</td>
<td>310B</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Allied Health Professionals Luncheon</td>
<td>Ballroom of the Americas Salon B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Level 2 / Hilton)</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Lunch Concessions / Visit Exhibits</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>E-posters – Meet the Authors: Session 2</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>GME Program Directors’ Luncheon</td>
<td>340</td>
</tr>
<tr>
<td>11:30 am – 3:00 pm</td>
<td>Doctors’ Job Fair</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>11:35 am – 1:00 pm</td>
<td>Product Theater 1: AstraZeneca</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>11:35 am – 1:00 pm</td>
<td>Product Theater 2: CSL Behring</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>11:35 am – 1:00 pm</td>
<td>Product Theater 3: Novartis Pharmaceuticals Corporation</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>11:45 am – 12:45 pm</td>
<td>Building ABAI Continuing Certification Together</td>
<td>371</td>
</tr>
</tbody>
</table>
### Daily Events

#### Saturday, November 9th (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 – 2:00 pm</td>
<td>Billing and Coding Committee</td>
<td>350B</td>
</tr>
<tr>
<td>1:00 – 2:00 pm</td>
<td>Environmental Allergy Committee</td>
<td>350C</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Symposium: Advances in the Care of Patients With Common Variable Immune Deficiency (CVID)</td>
<td>360</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Symposium: Evolution of Food Allergy Therapies</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Practical Applications at Work Seminar: Integrative Approaches to Office Health: Improving Patient Outcomes</td>
<td>382</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Symposium: New Frontiers: COPD, ACO and Adults With Wheezing</td>
<td>351</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Symposium: Racial, Ethnic and Socioeconomic Disparities in Food Allergy</td>
<td>370</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Ask the Expert Roundtables: The Changing Face of an Allergy Practice</td>
<td>361ABC</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td><strong>Allied Health Professionals Breakout Sessions</strong></td>
<td></td>
</tr>
<tr>
<td>1:30 – 3:00 pm</td>
<td>Managing the Whole Person, Not Just the Food Allergy</td>
<td>371</td>
</tr>
<tr>
<td>2:30 – 3:00 pm</td>
<td>Cookies &amp; Refreshment Break / Visit Exhibits</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>2:30 – 3:00 pm</td>
<td>E-posters – Meet the Authors: Session 3</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>2:35 – 3:00 pm</td>
<td>Product Theater 1: Optinose</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>2:35 – 3:00 pm</td>
<td>Product Theater 2: Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>3:00 – 4:30 pm</td>
<td>Clinical Conundrum: Cannabis in 2019: Navigating Our Patients Through Facts and Misconceptions</td>
<td>360</td>
</tr>
<tr>
<td>3:00 – 4:30 pm</td>
<td>Symposium: Coding and Governmental Regulations Update</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>3:00 – 4:30 pm</td>
<td>Symposium: Cough Across the Ages</td>
<td>382</td>
</tr>
<tr>
<td>3:00 – 4:30 pm</td>
<td>Symposium: The Difficult-to-control Atopic Dermatitis: Cutting Edge Science, Practical Pearls and Targeted Therapy</td>
<td>370</td>
</tr>
<tr>
<td>3:00 – 4:30 pm</td>
<td>Practical Applications at Work Seminar: The Updated EoE Guidelines – Whose Disease Is It Anyway?</td>
<td>351</td>
</tr>
<tr>
<td>3:00 – 4:30 pm</td>
<td>Hands-on Workshop: The Use of Case Simulation for the Education of Allergy Emergencies – Spotlight on Anaphylaxis</td>
<td>350DEF</td>
</tr>
<tr>
<td>3:00 – 4:30 pm</td>
<td><strong>Allied Health Professionals Breakout Sessions</strong></td>
<td></td>
</tr>
<tr>
<td>3:00 – 5:00 pm</td>
<td>In-office Challenges: The Good, The Bad and Anaphylaxis: Is Your Office Ready?</td>
<td>371</td>
</tr>
<tr>
<td>3:00 – 5:00 pm</td>
<td>Strategies for Getting the Most From Spirometry</td>
<td>362ABDE</td>
</tr>
<tr>
<td>3:00 – 5:00 pm</td>
<td>Annals Editorial Board Meeting</td>
<td>310B</td>
</tr>
<tr>
<td>4:30 – 5:30 pm</td>
<td>Distinguished Industry Oral Abstracts: Session A</td>
<td>360</td>
</tr>
</tbody>
</table>
### Saturday, November 9th (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 – 5:30 pm</td>
<td>Distinguished Industry Oral Abstracts: Session B</td>
<td>370</td>
</tr>
<tr>
<td>5:30 – 7:30 pm</td>
<td>28th Annual FIT Bowl Competition</td>
<td>Houston Ballroom (Level 2 / Marriott)</td>
</tr>
<tr>
<td>8:00 – 10:00 pm</td>
<td>Non-CME Corporate Forum: Genentech and Novartis Pharmaceuticals Corporation</td>
<td>Ballroom of the Americas Salon A (Level 2 / Hilton)</td>
</tr>
<tr>
<td>8:00 – 10:00 pm</td>
<td>Non-CME Corporate Forum: GlaxoSmithKline</td>
<td>Ballroom of the Americas Salon F (Level 2 / Hilton)</td>
</tr>
<tr>
<td>8:00 – 10:00 pm</td>
<td>Non-CME Corporate Forum: Teva Pharmaceuticals</td>
<td>Ballroom of the Americas Salon D (Level 2 / Hilton)</td>
</tr>
</tbody>
</table>

### Sunday, November 10th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 am – 6:00 pm</td>
<td>Speaker Ready Room</td>
<td>310C</td>
</tr>
<tr>
<td>6:30 – 8:15 am</td>
<td>Advocacy Council Meeting</td>
<td>340</td>
</tr>
<tr>
<td>6:30 am – 7:00 pm</td>
<td>Coat / Luggage Check</td>
<td>Level 3</td>
</tr>
<tr>
<td>6:45 – 7:45 am</td>
<td>Committee Meetings</td>
<td>335 (Level 3 / Hilton)</td>
</tr>
<tr>
<td></td>
<td>Allied Health Professionals</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dermatology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Immunotherapy and Diagnostics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Population Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rhinitis / Sinusitis / Ocular</td>
<td></td>
</tr>
<tr>
<td>7:00 am – 4:00 pm</td>
<td>Registration</td>
<td>Grand Ballroom Foyer (Level 3)</td>
</tr>
<tr>
<td>8:00 – 9:00 am</td>
<td>Exhibitors Advisory Meeting</td>
<td>320C</td>
</tr>
<tr>
<td>8:00 – 9:30 am</td>
<td>Plenary Session: Modifying Our Approach</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>8:00 – 10:30 am</td>
<td>Alliance Hospitality Suite</td>
<td>Lanier Grand Ballroom Salons J-K (Level 4 / Hilton)</td>
</tr>
<tr>
<td>8:00 am – 2:00 pm</td>
<td>ACAAI Allergen Extract Mixer Training Program</td>
<td>382</td>
</tr>
<tr>
<td>8:30 – 9:30 am</td>
<td>Alliance: Gentle Morning Workout</td>
<td>Lanier Grand Ballroom Salons J-K (Level 4 / Hilton)</td>
</tr>
<tr>
<td>9:00 am – 1:30 pm</td>
<td>College Resource Center</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>9:00 am – 1:30 pm</td>
<td>Exhibit Hours</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>9:30 – 10:00 am</td>
<td>E-posters: Meet the Authors: Session 4</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>9:30 – 10:00 am</td>
<td>Refreshment Break / Visit Exhibits</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>9:35 – 10:00 am</td>
<td>Product Theater 1: Pfizer, Inc.</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>10:00 – 11:00 am</td>
<td>Education Services, Data and Technology Committee</td>
<td>350B</td>
</tr>
<tr>
<td>10:00 – 11:00 am</td>
<td>Practice Management Committee</td>
<td>350A</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td>Allied Health Professionals Course</td>
<td>371</td>
</tr>
</tbody>
</table>
### Daily Events

**Sunday, November 10th (continued)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 11:30 am</td>
<td>Symposium: 7 for 11: Hot Topics in Pediatric A/I.</td>
<td>360</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td>Symposium: Primary Immune Deficiency: Optimal Care for Optimal Outcomes</td>
<td>370</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td>Symposium: USP 797: The Final Word – What Does It Say?</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td>Didactic Workshop: Introductory Course in Rhinolaryngoscopy</td>
<td>361ABC</td>
</tr>
<tr>
<td>10:00 – 11:30 am</td>
<td>Hands-on Workshop: The Nuts and Bolts of Wraps, Biopsy, Patch Testing and Metal Hypersensitivity</td>
<td>361DEF</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Lunch Concessions / Visit Exhibits</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Fellows-in-Training / Allergy/Immunology Program Directors’ Luncheon</td>
<td>Ballroom of the Americas Salon E (Level 2 / Hilton)</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Women in Allergy Luncheon</td>
<td>Ballroom of the Americas Salons AB (Level 2 / Hilton)</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>E-posters: Meet the Authors: Session 5</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>Past Presidents’ Committee</td>
<td>310A</td>
</tr>
<tr>
<td>11:35 am – 1:00 pm</td>
<td>Product Theater 1: AstraZeneca</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>11:35 am – 1:00 pm</td>
<td>Product Theater 2: Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.</td>
<td>Halls A3 &amp; B3 (Level 3)</td>
</tr>
<tr>
<td>Noon – 3:00 pm</td>
<td>Alliance Brunch</td>
<td>Off-Site (The Grove Houston)</td>
</tr>
<tr>
<td>1:00 – 2:00 pm</td>
<td>Food Allergy Committee</td>
<td>320C</td>
</tr>
<tr>
<td>1:00 – 2:00 pm</td>
<td>Respiratory and Sleep-related Breathing Disorders Committee</td>
<td>350B</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Allied Health Professionals Course</td>
<td>371</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Practical Applications at Work Seminar: Filling the Gaps:</td>
<td>370</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Problem-based Learning: PBL – An Older Adult Patient</td>
<td>320AB</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Clinical Conundrum: Recurrent Infections With Normal or Near-normal Immunglobulins: Now What?</td>
<td>360</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Symposium: WAO World Allergy Forum: New Frontiers in Atopic Dermatitis</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Hands-on Workshop: Hands-on Session in Rhinolaryngoscopy: Introductory</td>
<td>350DEF</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Oral Abstracts Session 1A: Adverse Drug Reactions, Insect Reactions, Anaphylaxis</td>
<td>351ABC</td>
</tr>
<tr>
<td>1:00 – 2:30 pm</td>
<td>Oral Abstracts Session 1B: Allergy Diagnostics and Immunotherapy and Clinical Immunology, Immunodeficiency, Food Allergy</td>
<td>351DEF</td>
</tr>
<tr>
<td>1:00 – 2:15 pm</td>
<td>Oral Abstracts Session 1C: Adverse Drug Reactions, Insect Reactions, Anaphylaxis, Asthma, Other Lower Airway Disorders, Other</td>
<td>361ABC</td>
</tr>
</tbody>
</table>

*All programs held at the George R. Brown Convention Center unless otherwise noted.*
**Sunday, November 10th (continued)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30–2:30 pm</td>
<td>Women in Allergy Committee</td>
<td>350A</td>
</tr>
<tr>
<td>2:00–4:30 pm</td>
<td>ACAAI Allergen Extract Mixer Training Program – Hands-on Workshop</td>
<td>372</td>
</tr>
<tr>
<td>2:30–3:00 pm</td>
<td>Refreshment Break</td>
<td>Level 3 Lobby</td>
</tr>
<tr>
<td>3:00–4:00 pm</td>
<td>International Committee</td>
<td>310A</td>
</tr>
<tr>
<td>3:00–4:30 pm</td>
<td>Allied Health Professionals Course</td>
<td>371</td>
</tr>
<tr>
<td>3:00–4:30 pm</td>
<td>Problem-based Learning: PBL – A Child With Asthma and Food Allergy That Needs Proper Coding: Codeman and Doctor Document Strike Again</td>
<td>320AB</td>
</tr>
<tr>
<td>3:00–4:30 pm</td>
<td>Symposium: Telemedicine for the Allergist</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>3:00–4:30 pm</td>
<td>Symposium: How to Implement a Penicillin Allergy Program in Your Community</td>
<td>360</td>
</tr>
<tr>
<td>3:00–4:30 pm</td>
<td>Hands-on Workshop: Hands-on Session in Rhinolaryngoscopy: Intermediate / Advanced</td>
<td>350DEF</td>
</tr>
<tr>
<td>3:00–4:30 pm</td>
<td>Oral Abstracts Session 2A: Food Allergy</td>
<td>351ABC</td>
</tr>
<tr>
<td>3:00–4:30 pm</td>
<td>Oral Abstracts Session 2B: Asthma, Other Lower Airway Disorders</td>
<td>351DEF</td>
</tr>
<tr>
<td>3:00–4:30 pm</td>
<td>Oral Abstracts Session 2C: Other, Rhinitis, Other Upper Airway Disorders, Skin Disorders</td>
<td>361ABC</td>
</tr>
<tr>
<td>3:30–4:30 pm</td>
<td>Alliance Post-board Meeting</td>
<td>320C</td>
</tr>
<tr>
<td>4:45–5:30 pm</td>
<td>Town Hall Meeting Hosted by ACAAI House of Delegates</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>5:30–6:30 pm</td>
<td>ACAAI Annual Business Meeting</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>7:00–9:00 pm</td>
<td>Non-CME Corporate Forum: Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.</td>
<td>Ballroom of the Americas Salon D (Level 2 / Hilton)</td>
</tr>
</tbody>
</table>

**Monday, November 11th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – noon</td>
<td>Registration</td>
<td>Grand Ballroom Foyer (Level 3)</td>
</tr>
<tr>
<td>7:00 am – 12:30 pm</td>
<td>Speaker Ready Room</td>
<td>310C</td>
</tr>
<tr>
<td>7:00 am – 1:00 pm</td>
<td>Coat / Luggage Check</td>
<td>Level 3</td>
</tr>
<tr>
<td>8:00 – 9:30 am</td>
<td>Plenary Session: Allergists Can Offer More Than Just Skin Testing</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>9:30 – 9:45 am</td>
<td>Refreshment Break</td>
<td>Grand Ballroom Foyer (Level 3)</td>
</tr>
<tr>
<td>9:45 – 11:00 am</td>
<td>Symposium: Climate Change and Natural Disasters: The Central Role of Allergists</td>
<td>370</td>
</tr>
<tr>
<td>9:45 – 11:00 am</td>
<td>Interdisciplinary Panel Session: Urticaria: Are You Itching to Learn More?</td>
<td>360</td>
</tr>
<tr>
<td>9:45 am – 12:30 pm</td>
<td>CAP (Continuous Assessment Program) Review</td>
<td>Grand Ballroom (Level 3)</td>
</tr>
<tr>
<td>11:00 – 11:15 am</td>
<td>Refreshment Break</td>
<td>Level 3 Lobby</td>
</tr>
<tr>
<td>11:15 am – 12:30 pm</td>
<td>Clinical Conundrum: Managing the Patient With Recurrent Infections</td>
<td>360</td>
</tr>
<tr>
<td>11:15 am – 12:30 pm</td>
<td>Symposium: New Horizons in Chronic Rhinosinusitis</td>
<td>370</td>
</tr>
</tbody>
</table>
Committee Meetings

All programs held at the George R. Brown Convention Center unless otherwise noted.

<table>
<thead>
<tr>
<th>HOURS</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 11:30 am</td>
<td></td>
</tr>
<tr>
<td>Publications Committee</td>
<td>350A</td>
</tr>
<tr>
<td>11:30 am – 12:30 pm</td>
<td></td>
</tr>
<tr>
<td>Accreditation and Certification Committee</td>
<td>320A</td>
</tr>
<tr>
<td>Noon – 2:00 pm</td>
<td></td>
</tr>
<tr>
<td>FIT Bowl Subcommittee</td>
<td>310A</td>
</tr>
</tbody>
</table>

Friday, November 8th

<table>
<thead>
<tr>
<th>HOURS</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 – 7:30 am</td>
<td></td>
</tr>
<tr>
<td>Committee Chair and Vice Chair Breakfast*</td>
<td>340</td>
</tr>
<tr>
<td>10:00 – 11:00 am</td>
<td></td>
</tr>
<tr>
<td>Anaphylaxis Committee</td>
<td>310A</td>
</tr>
<tr>
<td>Asthma Committee</td>
<td>320C</td>
</tr>
<tr>
<td>Biologics and Pharmacology Committee</td>
<td>350A</td>
</tr>
<tr>
<td>Government Relations Committee</td>
<td>350C</td>
</tr>
<tr>
<td>11:00 am – noon</td>
<td></td>
</tr>
<tr>
<td>Payer and Managed Care Committee</td>
<td>350B</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td></td>
</tr>
<tr>
<td>GME Program Directors’ Committee</td>
<td>340</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td></td>
</tr>
<tr>
<td>2020 Annual Meeting Program Committee**</td>
<td>310B</td>
</tr>
<tr>
<td>1:00 – 2:00 pm</td>
<td></td>
</tr>
<tr>
<td>Billing and Coding Committee</td>
<td>350B</td>
</tr>
<tr>
<td>1:00 – 2:00 pm</td>
<td></td>
</tr>
<tr>
<td>Environmental Allergy Committee</td>
<td>350C</td>
</tr>
<tr>
<td>1:30 – 3:00 pm</td>
<td></td>
</tr>
<tr>
<td>ACAAI Foundation Board of Trustees</td>
<td>320C</td>
</tr>
<tr>
<td>3:00 – 5:00 pm</td>
<td></td>
</tr>
<tr>
<td>Annals Editorial Board</td>
<td>310B</td>
</tr>
</tbody>
</table>

Saturday, November 9th

<table>
<thead>
<tr>
<th>HOURS</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 – 7:45 am</td>
<td></td>
</tr>
<tr>
<td>Allied Health Professionals Committee*</td>
<td>335 (Hilton)</td>
</tr>
<tr>
<td>Dermatology Committee*</td>
<td></td>
</tr>
<tr>
<td>Immunotherapy and Diagnostics Committee*</td>
<td></td>
</tr>
<tr>
<td>Population Health Committee*</td>
<td></td>
</tr>
<tr>
<td>Rhinitis / Sinusitis / Ocular Committee*</td>
<td></td>
</tr>
<tr>
<td>10:00 – 11:00 am</td>
<td></td>
</tr>
<tr>
<td>Education Services, Data and Technology Committee</td>
<td>350B</td>
</tr>
<tr>
<td>10:00 – 11:00 am</td>
<td></td>
</tr>
<tr>
<td>Practice Management Committee</td>
<td>350A</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td></td>
</tr>
<tr>
<td>Past Presidents’ Committee**</td>
<td>310A</td>
</tr>
<tr>
<td>1:00 – 2:00 pm</td>
<td></td>
</tr>
<tr>
<td>Food Allergy Committee</td>
<td>320C</td>
</tr>
<tr>
<td>1:00 – 2:00 pm</td>
<td></td>
</tr>
<tr>
<td>Respiratory and Sleep-related Breathing Disorders Committee</td>
<td>350B</td>
</tr>
<tr>
<td>1:30 – 2:30 pm</td>
<td></td>
</tr>
<tr>
<td>Women in Allergy Committee</td>
<td>350A</td>
</tr>
<tr>
<td>3:00 – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>International Committee</td>
<td>310A</td>
</tr>
</tbody>
</table>

Sunday, November 10th

* A complimentary breakfast will be served at these meetings.

**A complimentary lunch will be served at this meeting.
Each year, the American College of Allergy, Asthma & Immunology presents several named lectures during the Annual Scientific Meeting. The Bela Schick, John P. McGovern, Bernard Berman and Edward J. O’Connell lectures are presented annually. The Luisa Businco Lecture is presented during the International Food Allergy Symposium.

The allergists selected to present named lectures embody the high standards and achievements of the physicians for whom the lectures are named. The College is proud to present the following named lectures at its 2019 Annual Scientific Meeting. All lectures will be held at the George R. Brown Convention Center.

### Luisa Businco Memorial Lecture

**Harmonization, Differences in Guidelines, Unmet Needs and Implementation Barriers**

*International Food Allergy Symposium*

Thursday, Nov. 7, 8:05 – 8:35 am  
Jonathan Hourihane, MD

The Businco Lecture is named in honor of Professor Luisa Businco of Rome, Italy. Her hard work in providing excellent patient care, effective teaching and quality research led to significant advances in understanding several aspects of pediatric food allergy. Her clinical and laboratory research was focused on the development, prediction and prevention of allergy in children. Dr. Businco worked with dedication to promote the specialty of pediatric allergy, and her work continues in the careers of the many physicians taught and trained by her. This lecture is presented during the International Food Allergy Symposium.

### Edward J. O’Connell Memorial Lecture

**GRADEing Eosinophilic Esophagitis: What Is the Role of the Allergist?**

Saturday, Nov. 9, 8:05 – 8:30 am  
Matthew Rank, MD, FACAAI

This annual lectureship was established to honor the legacy of Dr. O’Connell, a past president of the College and past editor-in-chief of *Annals*, who was a caring, compassionate physician with a life-long passion for serving children. He was an adept educator and authored nearly 100 original articles, along with many book chapters related to allergy and immunology.

### Bernard Berman Memorial Lecture

**Hot Topics: FDA**

Monday, Nov. 11, 8:05 – 8:25 am  
Bryan L. Martin, DO, FACAAI

The annual Bernard Berman Memorial Lecture recognizes a kind, caring clinician-allergist with interests in the various aspects of allergy and a passion for teaching. The Memorial Lecture is a testament to Dr. Berman’s caring nature, unique skills as a gifted teacher and unselfish compassion for his patients. He was a past president of the College and one of the founders of the American Board of Allergy and Immunology.

### Bela Schick Lecture

**Something Special, Is It the Specialty or the Practitioner?**

Monday, Nov. 11, 8:45 – 9:05 am  
Michael R. Nelson, MD, PhD, FACAAI

The annual Bela Schick Lecture is named in honor of one of medicine’s most respected scientists. Bela Schick was born in Hungary and attended medical school in Austria. After serving as Extraordinary Professor of Children’s Diseases at the University of Vienna, he immigrated to the United States in 1923. He was a pediatrician at Mt. Sinai in New York for many years, loved by his patients and respected by his fellows. Dr. Schick is best known for his work with Clemens von Pirquet on anaphylaxis and for the test he developed to assess immunity in diphtheria.
Hands-on: Facilitated SQ Immunoglobulin Infusion


Supported by RMS Medical Products through an independent educational grant consisting of loaned durable equipment and disposable supplies.

Clinicians frequently prescribe gamma globulins for antibody deficiencies but are not very familiar with the administration of immunoglobulins. However, their oversight of these infusions is important. This workshop will provide instruction on administration of IV SQ in order to facilitate SQ and assist clinicians in determining the best product for each patient.

Track: Clinical Immunology and Autoimmune and Biologicals

Faculty:
Nikita Raje, MD, FACAAI
Richard L. Wasserman, MD, PhD, FACAAI
Nicholas Rider, DO
Lisa R. Forbes, MD

Learning Objectives
Upon completion of this session, participants should be able to:
• Understand the different modalities of immune globulin administration.
• Manage side effects of immune globulin administration.

Hands-on: The Use of Case Simulation for the Education of Allergy Emergencies – Spotlight on Anaphylaxis

Moderators: Anne K. Ellis, MD, MSc, FACAAI, and Sara Barmettler, MD

Studies have demonstrated that hands-on practice, offered by case simulations, is more effective than standard classroom instruction for emergency situational training. Simulations allow health care professionals to practice crisis management and teamwork skills to increase confidence in life-threatening emergencies such as anaphylaxis.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

Faculty:
Marcella R. Aquino, MD, FACAAI
Kimberly G. Blumenthal, MD, MSc
Aleena Banerji, MD

Learning Objectives
Upon completion of this session, participants should be able to:
• Recognize and manage anaphylaxis via hands-on practice with a wireless patient simulator.
• Demonstrate cohesive work by a group (leadership roles, task delegation, etc.) to manage and treat a patient.
Saturday, November 9 (continued)

3:00 – 4:30 pm • Room 350DEF • George R. Brown Convention Center
Fee: $150 (FITs/AHPs: $50). Limit 25.

Hands-on: The Use of Case Simulation for the Education of Allergy Emergencies – Spotlight on Anaphylaxis

Moderators: Anne K. Ellis, MD, MSc, FACAAI, and Sara Barmettler, MD

Studies have demonstrated that hands-on practice, offered by case simulations, is more effective than standard classroom instruction for emergency situational training. Simulations allow health care professionals to practice crisis management and teamwork skills to increase confidence in life-threatening emergencies such as anaphylaxis.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

Faculty:
Marcella R. Aquino, MD, FACAAI
Aleena Banerji, MD
Kimberly G. Blumenthal, MD, MSc

Learning Objectives
Upon completion of this session, participants should be able to:
• Recognize and manage anaphylaxis via hands-on practice with a wireless patient simulator.
• Demonstrate cohesive work by a group (leadership roles, task delegation, etc.) to manage and treat a patient.

Sunday, November 10

10:00 – 11:30 am • Room 361ABC • George R. Brown Convention Center
Fee: $80 (FITs: $35). Limit 50.

Didactic: Introductory Course in Rhinolaryngoscopy

This workshop will provide attendees with the ability to discuss the surgical anatomy of the upper airway, including the nasal cavity, pharynx and larynx; identify normal and abnormal anatomy, as well as disease presentations and postoperative changes found with endoscopic examination of the upper airway; and identify the indications for, and the use of, the fiber-optic rhinoscope in the allergist’s office.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

Faculty:
Jerald W. Koepke, MD, FACAAI
Seong H. Cho, MD, FACAAI

Learning Objectives
Upon completion of this session, participants should be able to:
• Describe the major anatomical findings in the upper airway.
• Identify normal and abnormal anatomy, disease presentations and post-op findings.
• Identify indications for use of the rhinoscope in the allergist’s office.
Workshops

Sunday, November 10 (continued)

10:00 – 11:30 am • Room 361DEF • George R. Brown Convention Center
Fee: $150 (FITs/AHPs: $50). Limit 45.

Hands-on: The Nuts and Bolts of Wraps, Biopsy, Patch Testing and Metal Hypersensitivity

Moderator: Kelly M. Maples, MD, FACAAI

Supported by SmartPractice through an independent educational grant consisting of disposable supplies.

This will be a hands-on workshop demonstrating techniques in dermatology: patch testing, skin biopsy, physical urticaria challenges and wet wraps. Some case studies may be used to set the stage, but the focus will be hands-on stations. Attendees may select the stations of their choice.

Track: Dermatology

Faculty:
Luz S. Fonacier, MD, FACAAI
Sharon E. Jacob, MD
Karin Pacheco, MD, MSPH
David R. Weldon, MD, FACAAI
Anil Nanda, MD, FACAAI
Sandra M. Gawchik, DO, FACAAI

Learning Objectives

Upon completion of this session, participants should be able to:
• Perform a biopsy in an allergy practice.
• Apply and interpret a patch test.
• Apply wet and dry wraps and use biologics to treat atopic dermatitis.

1:00 – 2:30 pm • Room 350DEF • George R. Brown Convention Center

Hands-on: Session in Rhinolaryngoscopy: Introductory

Moderator: Jerald W. Koepke, MD, FACAAI

Supported by Optim LLC through an independent educational grant consisting of loaned durable equipment and disposable supplies.

This workshop will provide attendees with the ability to describe the major anatomical structures of the nasal, pharyngeal and glottic areas as visualized during examination with the fiber-optic rhinolaryngoscope; describe variations of normal seen when participants examine one another in this hands-on session; and demonstrate the proper handling and initial skills needed to perform a comprehensive upper airway examination with a fiber-optic endoscope.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

Faculty:
Jerald W. Koepke, MD, FACAAI
Seong H. Cho, MD, FACAAI
Kevin R. Murphy, MD, FACAAI
Grant C. Olson, MD, FACAAI
Donald W. Pulver, MD, FACAAI
David Elkayam, MD

Learning Objectives

Upon completion of this session, participants should be able to:
• Describe the major anatomical structures of the nasal, pharyngeal and glottic areas as visualized during examination with the fiber-optic rhinolaryngoscope.
• Describe variations of normal seen when participants examine one another in this hands-on session.
• Demonstrate the proper handling and initial skills needed to perform a comprehensive upper airway examination with a fiber-optic endoscope.
Hands-on: Session in Rhinolaryngoscopy: Intermediate/Advanced

Moderator: Jerald W. Koepke, MD, FACAAI

Supported by Optim LLC through an independent educational grant consisting of loaned durable equipment and disposable supplies.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

The following criteria must be met to qualify for participation in this workshop:

- Have taken the Introductory Rhinolaryngoscopy Course at a prior meeting or have received similar training.
- Have a basic working knowledge of the nasal and laryngeal anatomy.
- Be familiar with the use of and have performed examinations with a flexible fiber-optic rhinoscope.
- Be willing to be examined by course participants.

Faculty:
Jerald W. Koepke, MD, FACAAI
Seong H. Cho, MD, FACAAI
Grant C. Olson, MD, FACAAI
Kevin R. Murphy, MD, FACAAI
Donald W. Pulver, MD, FACAAI
David Elkayam, MD

Learning Objectives

Upon completion of this session, participants should be able to:

- Better navigate the recesses of the nasal airway and larynx with the rhinolaryngoscope by acquiring more advanced skills using a fiber-optic endoscope.
- More confidently identify the major structures of the nasal, pharyngeal and glottic areas as visualized during a rhinoscopic examination and describe variations from normal, if seen, when participants examine one another.
- Discuss challenging cases or problems they have encountered when performing this procedure.
Multiple countries now have recommendations for early allergenic solid food introduction to help prevent food allergy. However, these guidelines differ on what, when and how to introduce, providing conflicting information. Moreover, there are other emerging factors, beyond solid food introduction, which are not incorporated in the present guidelines but may be relevant to the prevention of food allergy. This session will review the evidence to date, discuss guideline discrepancies and present data on the horizon that goes beyond the present guidelines toward where the next breakthroughs may be, to educate attendees about where we stand in our ability to comprehensively help prevent food allergy development.

**Learning Objectives**
Upon completion of this session, participants should be able to:

- Detail the discrepancies between different international food allergy prevention guidelines and highlight where better harmonization could be promoted.
- Discuss the current understanding of how the microbiome and exposome may contribute to the development and prevention of food allergies.
- Describe the concept of diet diversity and highlight the importance of diet diversity as a tool in food allergy prevention.
Thursday International Food Allergy Symposium

Thursday, Nov. 7 • 8:00 am – 6:00 pm
Separate Registration Fee • Admission by Ticket Only

Supported by an independent educational grant from DBV Technologies

10:00 – 11:45 am • Grand Ballroom Salon A (Level 3) • George R. Brown Convention Center

Assessing Prevalence

Moderators: David R. Stukus, MD, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

Methodologies in how to measure food allergy prevalence differ tremendously among westernized countries. Birth, infant and population-level cohorts are invaluable tools for the study of food allergy across a nationally-representative population, in particular to assess the prevalence of food allergy through the use of oral food challenges. However, the U.S. continues to lack such an approach. This session will detail how food allergy prevalence has been assessed using food challenge in three large international cohorts.

Track: Food & Drug Allergy and GI Disorders

10:00 am Introductions
David R. Stukus, MD, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

10:05 am Rectifying Direct and Indirect Methods of Assessing Prevalence: Where We Are, Why Rates Differ and the Importance of Population-level Studies
Rachel Peters, MD, MPH, PhD

10:35 am Birth and Infant Cohorts: Why These Are Needed – the International Perspective
Syed Hasan Arshad, MBBS, DM

10:45 am Break

11:05 am Food Allergy in Africa: the SAFAR Cohort
Michael Levin, MBChB, FCPaed, MMed, PhD, FACAAI

Learning Objectives
Upon completion of this session, participants should be able to:
- Understand how the effects of methodology differences in measuring food allergy can affect food allergy prevalence estimates.
- Identify the value of the longitudinal birth cohort in tracking the trajectory of food allergy and other allergic diseases as a child develops from infancy to youth.
- Describe the differences in a rural versus urban population cohort in terms of the development of food allergy.

11:45 am – 12:50 pm • Ballroom of the Americas Salons DEF (Level 2) • Hilton Americas-Houston Hotel

Luncheon

From the Horse’s Mouth – The FDA Perspective on Treatment and Unmet Needs

Moderator: Warner W. Carr, MD, FACAAI

This lunchtime discussion will address regulatory aspects of food allergy that impact our patients on a daily basis.

Track: Food & Drug Allergy and GI Disorders

Noon An Update on Thresholds and Labeling
Stefano Luccioli, MD, FDA Center for Food Safety and Applied Nutrition, Office of Compliance

Learning Objectives
Upon completion of this session, participants should be able to:
- Assist patients in understanding food allergen precautionary labeling requirements and limitations
Thursday International Food Allergy Symposium

Thursday, Nov. 7 • 8:00 am – 6:00 pm
Separate Registration Fee • Admission by Ticket Only

Supported by an independent educational grant from DBV Technologies

1:00 – 2:45 pm • Grand Ballroom Salon A (Level 3) • George R. Brown Convention Center

Treatment

Moderators: David R. Stukus, MD, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

There is a bright horizon for food allergy treatment, with commercial options for peanut allergy anticipated in the next year. Moreover, new approaches are under investigation in the clinical pipeline to help foster evolution in the treatment approach. It is important for parents and providers to understand what treatment options exist and how to communicate them and foster shared decision-making among patients regarding these options.

Track: Food & Drug Allergy and GI Disorders

1:00 pm Welcome and Introductions
David R. Stukus, MD, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

1:05 pm Treatment Updates: What Are Our Present Options?
Edwin H. Kim, MD, MS, FACAAI

1:35 pm New Horizons: Anticipating the Next Evolution in Treatments
Rima A. Rachid, MD

2:05 pm Shared Decision-making and Understanding Parental Preference in Choice of Food Allergy Treatment
Matthew Greenhawt, MD, MSc, MBA, FACAAI

2:45 pm Refreshment Break

Learning Objectives
Upon completion of this session, participants should be able to:

• Discuss currently-available treatment options for food immunotherapy.
• Detail the robust clinical pipeline and next generation of research regarding future potential treatment options.
• Understand how to utilize shared decision-making when discussing treatment options with parents and patients.
Bigger Success Begets Bigger Problems: Issues on the Horizon

Moderators: David R. Stukus, MD, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

With the development of new treatment options, there have been similar innovations made regarding new diagnostic testing to complement older, more established methods. Understanding the relative value, utility and costs associated with these approaches is imperative. Equally important is shaping the conversations with parents and patients, so that providers can anticipate and understand the information that patients are receiving outside of our scope of practice. This session will address these issues that are impacting current and future approaches to management.

**Track:** Food & Drug Allergy and GI Disorders

- **3:00 pm**
  - **Introductions**
    - David R. Stukus, MD, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

- **3:05 pm**
  - **Cost-effective Practices in Food Allergy and Anaphylaxis**
    - Marcus Shaker, MD, FACAAI

- **3:35 pm**
  - **Something Borrowed, Something Blue, Something Old, Something New: Making Sense of Older Versus New Diagnostic and Lab Technologies for Treatment Monitoring**
    - Wayne G. Shreffler, MD, PhD

- **4:05 pm**
  - **Social Media, Advocacy and the Rise of Myths and Alternative Facts in Food Allergy**
    - David R. Stukus, MD, FACAAI

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Detail the cost-effectiveness of diagnostic and management strategies within food allergy.
- Understand the current limitations of diagnostic testing for food allergy and describe potential future options under development.
- Address misinformation regarding food allergy found online and through non-reputable resources and describe how to handle being presented with this by parents and patients during clinical encounters.
Thursday International Food Allergy Symposium

Thursday, Nov. 7 • 8:00 am – 6:00 pm
Separate Registration Fee • Admission by Ticket Only
Supported by an independent educational grant from DBV Technologies

5:00 – 6:00 pm • Grand Ballroom Salon A (Level 3) • George R. Brown Convention Center

Texas Pro/Con Thunderdome

Moderators: David R. Stukus, MD, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

Refreshments will be provided.

Two allergists enter...one leaves. See leading experts in the field debate some of the hottest topics facing the field at present, Texas-style. This session will include three pro/con debates surrounding interesting and controversial topics related to food allergy immunotherapy. With beer! (This session is non-CME.)

Track: Food & Drug Allergy and GI Disorders

5:00 pm  Welcome and Introductions
David R. Stukus, MD, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

5:05 pm  We Need Further Development of FDA-approved OIT Approaches
Anna Nowak-Wegrzyn, MD, FACAAI, and Richard L. Wasserman, MD, PhD, FACAAI

5:25 pm  EPIT Versus OIT for Treating Peanut Allergy
David M. Fleischer, MD, FACAAI, and Brian P. Vickery, MD

5:45 pm  OFC’s Are Necessary for Starting Food Allergy Treatment
Aikaterini (Katherine) Anagnostou, MD, MSc, PhD, FACAAI, and Douglas Mack, MD, MSc

6:00 pm  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:

• Describe the relative arguments regarding the future commercialization of food immunotherapy.
• Identify key differences between epicutaneous and oral immunotherapy as options for treating peanut allergy.
• Detail key arguments regarding the necessity of a diagnostic food challenge prior to starting food immunotherapy.

6:30 – 8:30 pm
Non-CME Corporate Forums
(See page 95 for details.)
Friday Annual Literature Review

7:30 am – 4:30 pm • Grand Ballroom (Level 3) • George R. Brown Convention Center

Separate Registration Fee • Admission by Ticket Only
(Attendees must be registered for the Annual Scientific Meeting to enroll in the Annual Literature Review.)

Everything You Should Have Read Last Year, but Didn’t!

To help you keep abreast of the latest clinical developments in allergy and immunology, the College will continue its highly successful Literature Review program. It’s a review of the most important, clinically focused literature of our specialty published between November 2017 and October 2018, with emphasis on clinical relevance. Faculty includes allergy-immunology training program directors and specialists in practice.

**Moderator:** James T. Li, MD, PhD, FACAAI

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td><strong>Basic Immunology</strong>&lt;br&gt;Mitchell H. Grayson, MD, FACAAI</td>
</tr>
<tr>
<td>8:00 am</td>
<td><strong>Rhinitis and Sinusitis</strong>&lt;br&gt;Anju T. Peters, MD</td>
</tr>
<tr>
<td>8:30 am</td>
<td><strong>Update in Clinical Immunology</strong>&lt;br&gt;John M. Routes, MD, FACAAI</td>
</tr>
<tr>
<td>9:00 am</td>
<td><strong>Asthma and Lower Respiratory Diseases</strong>&lt;br&gt;James T. Li, MD, PhD, FACAAI</td>
</tr>
<tr>
<td>9:30 am</td>
<td><strong>Refreshment Break</strong></td>
</tr>
<tr>
<td>10:00 am</td>
<td><strong>Update on Skin Diseases, Urticaria, Angioedema and Other Skin Disorders</strong>&lt;br&gt;Marc A. Riedl, MD, MS</td>
</tr>
<tr>
<td>10:30 am</td>
<td><strong>Update in Pediatric Allergy</strong>&lt;br&gt;John M. Kelso, MD, FACAAI</td>
</tr>
<tr>
<td>11:00 am</td>
<td><strong>Anaphylaxis and Stinging Insect Hypersensitivity</strong>&lt;br&gt;Anne K. Ellis, MD, MSc, FACAAI</td>
</tr>
<tr>
<td>11:30 am</td>
<td><strong>Lunch Break</strong> (on own)</td>
</tr>
</tbody>
</table>

**Moderator:** David A. Khan, MD, FACAAI

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 pm</td>
<td><strong>Immunotherapy</strong>&lt;br&gt;Harold S. Nelson, MD, FACAAI</td>
</tr>
<tr>
<td>1:30 pm</td>
<td><strong>Food Allergy</strong>&lt;br&gt;Matthew Greenhawt, MD, MSc, MBA, FACAAI</td>
</tr>
<tr>
<td>2:00 pm</td>
<td><strong>Occupational and Environmental Allergy</strong>&lt;br&gt;Mark S. Dykewicz, MD, FACAAI</td>
</tr>
<tr>
<td>2:30 pm</td>
<td><strong>Refreshment Break</strong></td>
</tr>
<tr>
<td>3:00 pm</td>
<td><strong>Drug Allergy</strong>&lt;br&gt;Aleena Banerji, MD</td>
</tr>
<tr>
<td>3:30 pm</td>
<td><strong>The Year’s Best Articles</strong>&lt;br&gt;David A. Khan, MD, FACAAI</td>
</tr>
<tr>
<td>4:00 pm</td>
<td><strong>Questions and Discussion</strong></td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

**Learning Objectives**
Upon completion of this session, participants should be able to:

- Discuss recent advances in basic science that are relevant to allergy and immunology.
- Describe recent developments in rhinitis and sinusitis.
- Recognize the clinical presentation of activated phosphoinositide 3-kinase delta syndrome and distinguish it from common variable immunodeficiency.
- Better diagnose and manage asthma and COPD.
- Discuss important scientific and clinical advances in the pathophysiology and treatment of urticaria, angioedema and other skin disorders.
- Summarize the role of the microbiome in human atopic diseases.
- Identify new concepts in anaphylaxis, drug allergy and stinging insect hypersensitivity, as well as utilize clinically relevant findings in these areas.

**Learning Objectives**
Upon completion of this session, participants should be able to:

- Describe recent developments in immunotherapy.
- Discuss recent developments in food allergy.
- Better counsel patients on environmental factors that may impact respiratory and allergic disease; and better recognize, diagnose and manage occupational allergic diseases.
- Apply practical lessons learned from recent literature in allergy, asthma and immunology.
6:15 am • Room 370 • George R. Brown Convention Center

Breakfast Symposium

AACA 2019: Subcutaneous Versus Sublingual Allergen Immunotherapy – Where Do We Stand in 2019?

Moderator: Warner W. Carr, MD, FACAAI

Supported by an independent educational grant from ALK – Abello Inc

This program will provide an up-to-date review of recent studies supporting the use of allergen immunotherapy for allergic rhinitis and allergic asthma, allowing the attendee to be fully versed on recent studies related to the mechanism, efficacy and safety of both subcutaneous and sublingual immunotherapy. Issues impacting clinical practice will be reviewed, including patient adherence, patient selection and mitigating factors in favor of particular immunotherapy formats, based on both U.S. and international published data.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:15 am</td>
<td>Welcome and Introductions</td>
<td>Warner W. Carr, MD, FACAAI</td>
</tr>
<tr>
<td>6:40 am</td>
<td>Efficacy of SLIT Tablets in Pollen Allergy and Dust Allergy: A Review of the Literature Related to Allergic Rhinitis and Asthma Which Has Led to FDA and International Regulatory Approvals</td>
<td>Lawrence M. DuBuske, MD, FACAAI</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Comparative Safety of SLIT Versus SCIT: A Recent Appraisal of Adverse Events and Fatalities</td>
<td>Russell Settipane, MD, FACAAI</td>
</tr>
<tr>
<td>7:20 am</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>7:30 am</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Compare the usage of SCIT versus SLIT in the U.S. and internationally.
- Examine the long- and short-term efficacy of SLIT for grass pollen seasonal allergy. Identify the efficacy of SLIT for grass and ragweed pollen in children.
- Identify the efficacy of SLIT for ragweed pollen seasonal allergy. Recognize the efficacy of SLIT for dust mite allergy.
- Differentiate the efficacy of SLIT in patients with allergic rhinitis and concomitant asthma.
- Recognize the comparative efficacy of SLIT versus SCIT in pollen allergy and dust mite allergy.
- Differentiate the safety of SLIT versus SCIT including recent U.S. data. Identify the appropriate patient to select for SCIT versus SLIT. Summarize the mechanisms underlying SLIT versus SCIT.
Friday General Sessions

8:00 – 9:30 am • Room 360 • George R. Brown Convention Center

Symposium

Idiopathic Anaphylaxis – Knowledge Gaps and Patient Needs

Moderators: Anne K. Ellis, MD, MSc, FACAAI, and Nicole M. Chase, MD, FACAAI

This symposium will help the learner know what to investigate when referred a patient for anaphylaxis and no obvious trigger can be identified. The attendee will leave with a good approach to the differential diagnosis of recurrent idiopathic anaphylaxis and be able to initiate the appropriate management strategy for the same.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

8:00 am Welcome and Introductions
Anne K. Ellis, MD, MSc, FACAAI, and Nicole M. Chase, MD, FACAAI

8:05 am Idiopathic Anaphylaxis – Prevalence and Presentation
Jay A. Lieberman, MD, FACAAI

8:30 am The Genetics, Biomarkers and Phenotypes of Idiopathic Anaphylaxis
Paul A. Greenberger, MD, FACAAI

8:55 am Overlap Between Mast Cell Disorders and Anaphylaxis
Phillip L. Lieberman, MD, FACAAI

9:20 am Questions and Discussion

9:30 am Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Describe the incidence and prevalence of anaphylaxis NYD.
• Initiate an appropriate work up for mast cell disorders in the idiopathic anaphylaxis setting.
• Describe the differential diagnosis of recurrent idiopathic anaphylaxis.

8:00 – 9:30 am • Room 361ABC • George R. Brown Convention Center

Seats Available on First-come, First-served Basis • Limit 54

Ask the Expert Roundtables

Phases of Allergy Practice

Moderator: Kevin P. McGrath, MD, FACAAI

Whether you are just getting started or a seasoned veteran, this exciting interactive learning opportunity has something for you. Choose three of the six topics and spend 25 minutes with each expert addressing a phase of allergy practice. The expert will give a five-minute overview of the topic and will then answer questions and facilitate discussion with the table participants for 20 minutes.

Track: Practice Management/Professional Issues

8:00 am Welcome and Introductions
Kevin P. McGrath, MD, FACAAI

Table Rotations
8:05 am, 8:35 am, 9:05 am

Table 1 Academic Practice Versus Private Practice
Kathleen May, MD, FACAAI

Table 2 Joining a Practice or Starting Your Own Practice
William E. Berger, MD, MBA, FACAAI

Table 3 Expanding a Practice
James L. Sublett, MD, FACAAI

Table 4 Working With Nurse Practitioners and/or Physician Assistants
Melinda M. Rathkopf, MD, FACAAI

Table 5 Retirement Planning
Stanley M. Fineman, MD, MBA, FACAAI

Table 6 Selling a Practice/Transitioning Out of a Practice
Dana V. Wallace, MD, FACAAI

9:30 am Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Discuss topics relevant to the early phase of the practice of allergy.
• Discuss topics relevant to the middle phase of the practice of allergy.
• Discuss topics related to the late phase of the practice of allergy and transitioning out of practice.
Friday General Sessions

10:00 – 11:30 am • Room 370 • George R. Brown Convention Center
Symposium

Across the Spectrum of Immunotherapy
Moderators: Ira Finegold, MD, FACAAI, and Joseph P. Forester, DO, FACAAI

For some patients, use of rush or cluster immunotherapy can result in greater adherence and ultimate success. Identifying this patient population and preparing for potential side effects and practical impediments to their use of immunotherapy is essential in comprehensive allergy care.

Track: Immunotherapy and Diagnostics

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Welcome and Introductions</td>
<td>Ira Finegold, MD, FACAAI and Joseph P. Forester, DO, FACAAI</td>
</tr>
<tr>
<td>10:05</td>
<td>Cluster and Rush: How Does It Differ From Standard IT?</td>
<td>Jay M. Portnoy, MD, FACAAI</td>
</tr>
<tr>
<td>10:25</td>
<td>Identifying Appropriate Patients for Different Types of AIT</td>
<td>John J. Oppenheimer, MD, FACAAI</td>
</tr>
<tr>
<td>10:45</td>
<td>Practical Issues That May Impede Success of AIT</td>
<td>Michael Tankersley, MD, MBA, FACAAI</td>
</tr>
<tr>
<td>11:05</td>
<td>Evidence-based Use of SLIT</td>
<td>Moises Calderon-Zapata, MD, PhD</td>
</tr>
<tr>
<td>11:20</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

Learning Objectives
Upon completion of this session, participants should be able to:
- Understand mechanism(s) for rush and cluster IT.
- Identify appropriate patients for rush and cluster IT.
- Identify potential risks with these therapies.

10:00 – 11:30 am • Room 360 • George R. Brown Convention Center
Symposium

Biologics for the Young and the Restless
Moderators: Jay A. Lieberman, MD, FACAAI, and William C. Anderson, MD, FACAAI

Biologic therapy is increasingly important in the armamentarium of the allergist/immunologist. New biologics have been approved for treatment of severe asthma, atopic dermatitis and CRS, and new indications are being investigated, including food allergy.

Track: Asthma and Respiratory/Sleep Disorders

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Welcome and Introductions</td>
<td>Jay A. Lieberman, MD, FACAAI and William C. Anderson, MD, FACAAI</td>
</tr>
<tr>
<td>10:05</td>
<td>Biologics: How to Choose the Right One for Asthma</td>
<td>Jonathan Corren, MD, FACAAI</td>
</tr>
<tr>
<td>10:30</td>
<td>Beyond Asthma: Biologics in Adults</td>
<td>Thomas B. Casale, MD, FACAAI</td>
</tr>
<tr>
<td>10:55</td>
<td>Biologics in Pediatrics</td>
<td>Carla M. Davis, MD, FACAAI</td>
</tr>
<tr>
<td>11:20</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

Learning Objectives
Upon completion of this session, participants should be able to:
- Differentiate the biologic agents used for severe asthma.
- Describe the indications for biologic therapy for CRS.
- Understand emerging development of biologic therapy for food allergy.
Friday General Sessions

11:30 am – 12:55 pm • Lanier Grand Ballroom Salons A-F (Level 4) • Hilton Americas-Houston Hotel

Luncheon Symposium
Implementing Food Allergy Therapy in Clinical Practice

Moderators: Edwin Kim, MD, FACAAI, and Douglas Jones, MD, FACAAI

Supported by an independent educational grant from Aimmune Therapeutics

This symposium has been designed to aid attendees in their efforts to align their practice with current guidelines and expert recommendations and ensure they are aware of the full complement of therapeutic options for helping patients manage their food allergies. In doing so, session participants will be better positioned to help patients who have (or are at risk for) food allergies avoid a lifetime of managing the substantial burden associated with avoiding the allergen and coping with the consequences of accidental exposures.

**Track:** Food & Drug Allergy and GI Disorders

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 am</td>
<td>Welcome and Introductions</td>
<td>Edwin H. Kim, MD, MS, FACAAI</td>
</tr>
<tr>
<td>11:35 am</td>
<td>Understanding the Safety of Food Allergy Therapy</td>
<td>Jonathan Hourihane, MD</td>
</tr>
<tr>
<td>11:50 am</td>
<td>Outcomes and Documentation: Choosing Wisely</td>
<td>Aikaterini (Katherine) Anagnostou, MD, PhD, FACAAI</td>
</tr>
<tr>
<td>12:05 pm</td>
<td>Implementation of Food Allergy Therapy in a Clinical Practice Setting</td>
<td>Douglas P. Mack, MSc, MD</td>
</tr>
<tr>
<td>12:20 pm</td>
<td>Choosing the Optimal Candidate: Considerations for Conversations With Families</td>
<td>Warner W. Carr, MD, FACAAI</td>
</tr>
<tr>
<td>12:35 pm</td>
<td>Questions and Discussion</td>
<td>Douglas Jones, MD, FACAAI</td>
</tr>
<tr>
<td>12:55 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:
- Summarize clinical trial data on the efficacy and safety of novel immunologic treatments for peanut allergy.
- Adopt practical strategies for implementing food allergy immunotherapy in a clinical practice setting.
- Select appropriate candidates for food allergy immunotherapy.
- Provide patients and families/caregivers with appropriate guidance on the use of novel immunologic treatments for food allergy.

A recording of this session will be available after the Annual Meeting at education.acaai.org/ondemand.
Friday General Sessions

1:00 – 2:30 pm • Room 360 • George R. Brown Convention Center

Interdisciplinary Panel Session

Don’t Be Rash! Assessing Contact Dermatitis

Moderators: Sandra M. Gawchik, DO, FACAAI, and Stephanie Mawhirt, DO

From basic science to the clinical conundrums, this session will cover how to evaluate and manage patients with contact dermatitis.

Track: Dermatology

1:00 pm Welcome and Introductions Sandra M. Gawchik, DO, FACAAI, and Stephanie Mawhirt, DO

1:05 pm Histopathology of Allergic and Irritant Contact Dermatitis Whitney A. High, MD, MEng

1:30 pm Clinical Pearls and Pitfalls in Evaluating Patients With Contact Dermatitis Sharon E. Jacob, MD

1:55 pm Beyond Soap: How to Help Patients With Contact Dermatitis Sandy Skotnicki, MD

2:20 pm Questions and Discussion

2:30 pm Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

• Describe the immunology and the pathophysiology of contact dermatitis and irritant dermatitis and the differences between them.
• Recognize the various patterns of contact dermatitis and gain knowledge on how to correlate location of the rash with causative agents.
• Diagnose, treat and educate patients on pertinent allergen avoidance and location of reference materials.

1:00 – 2:30 pm • Room 361ABC • George R. Brown Convention Center

Seats Available on First-come, First-served Basis • Limit 45

Ask the Expert Roundtables

Pearls to Improve Your Practice Operations

Moderator: Stanley M. Fineman, MD, MBA, FACAAI

Every allergy practice can benefit from these pearls to help improve how your practice operates. Choose three of the five topics and spend 25 minutes with each expert addressing an aspect of allergy practice. The expert will give a five-minute overview of the topic and will then answer questions and facilitate discussion with the table participants for 20 minutes.

Track: Practice Management/Professional Issues

1:00 pm Welcome and Introductions Stanley M. Fineman, MD, MBA, FACAAI

Table Rotations
1:05 pm, 1:30 pm, 2:00 pm

Table 1 How Can Cash Flow/Revenue Cycle Management Help Our Bottom Line? Scott McCutcheon, MHA

Table 2 Coding and Billing Gary N. Gross, MD, FACAAI

Table 3 How Can You Add Additional Revenue Services in A/I Practice? Jean Owen, MBA

Table 4 Should I Buy and Bill for Biologics? James M. Tracy, DO, FACAAI

Table 5 A Novel Use of a CRNP as a Team With a Doctor (As Opposed to Working Independently) J. Wesley Sublett, MD, MPH, FACAAI

2:30 pm Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

• Understand the importance of revenue cycle management and brand development.
• Utilize additional revenue sources in allergy practice.
• Explain how practice mergers and venture capital could impact your practice.
Friday General Sessions

2:00 – 6:00 pm
Exhibit Hall Open
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
Bring your passport game card for a chance to win!

2:00 – 6:00 pm
College Resource Center Open in Exhibit Hall
Booth #613 • Halls A3 & B3 (Level 3)
George R. Brown Convention Center

2:30 – 3:00 pm
Refreshment Break in Exhibit Hall
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

3:00 – 4:30 pm • Room 360 • George R. Brown Convention Center
Clinical Conundrum
Evidence-based Diagnosis of Food Allergy
Moderators: Jay M. Portnoy, MD, FACAAI, and David B.K. Golden, MD, FACAAI
With the advent of commercial peanut allergy therapy, making a basic diagnosis of peanut allergy is essential. However, new and emerging diagnostic tests may complicate this process, and clinicians must be up-to-date on the indications for testing, what test to choose and how to interpret these tests. This session will review the current state of peanut allergy diagnostic testing, including potential applications of component testing and whether diagnostic testing can be used to infer future risk.

Track: Food & Drug Allergy and GI Disorders

3:00 pm  Welcome and Introductions
Jay M. Portnoy, MD, FACAAI, and David B. K. Golden, MD, FACAAI

3:05 pm  The Role of Skin Prick and Serum IgE Testing
Julie Wang, MD, FACAAI

3:35 pm  The Role of Component Testing
Matthew Greenhawt, MD, MBA, MSc, FACAAI

4:05 pm  Can We Predict the Likelihood or Severity of Allergic Reactions?
Marcus Shaker, MD, FACAAI

4:30 pm  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Detail the indications for when to test for peanut allergy and what test to run.
• Understand the potential role for peanut allergy component testing.
• Describe the evidence surrounding whether diagnostic testing for peanut allergy can be used to infer future reaction severity.
Physician Health and Wellness: Advocating for Ourselves

Moderators: Travis A. Miller, MD, FACAAI, and Andrew Nickels, MD, FACAAI

Provider health and wellness involves multiple issues, including provider stress, burnout and depression, which can lead to medical errors, early retirement, addiction, divorce and suicide. It has been shown that burnout issues start in medical school and progress through residency, fellowship and throughout a provider's career. Many medical schools, residencies and allergy/immunology fellowships do not spend a lot of time on this issue during training, and, given the modern health care climate, physician/provider health and wellness is likely to continue becoming a more significant issue. This symposium will review the scientific literature about provider health and wellness and discuss the major causes of provider burnout and stress, along with potential solutions to alleviate this burden. Specific data regarding this topic among allergists/immunologists will be reviewed. This session can help allergy/immunology providers throughout their careers.

Track: Environmental and Integrative Medicine

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 pm</td>
<td>Welcome and Introductions</td>
<td>Travis A. Miller, MD, FACAAI, and Andrew Nickels, MD, FACAAI</td>
</tr>
<tr>
<td>3:05 pm</td>
<td>Compare and Contrast Potential Solutions to Provider Stress and Burnout, Specifically With Regards to Allergy and Immunology Providers</td>
<td>Maeve O’Connor, MD, FACAAI</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Health and Wellness Among Allergists and Immunologists: What Does the Data Show?</td>
<td>Gailen D. Marshall Jr., MD, PhD, FACAAI</td>
</tr>
<tr>
<td>3:55 pm</td>
<td>Ways to Reduce Burnout and Stress in the Practice Setting</td>
<td>Anil Nanda, MD, FACAAI</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

Learning Objectives

Upon completion of this session, participants should be able to:

- Formulate and categorize the multiple causes of provider burnout and stress.
- Demonstrate the ability to summarize the current scientific literature involving provider health and wellness, including allergy/immunology data.
- Compare and contrast potential solutions to provider stress and burnout, specifically with regards to allergy and immunology providers.

E-posters – Meet the Authors: Session 1

Halls A3 & B3 (Level 3)
George R. Brown Convention Center
(See page 97 for details.)

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Friday General Sessions

4:30 – 6:00 pm
American Association of Allergists and Immunologists of Indian Origin (AAAI)
Annual Meeting and Symposium
Houston Ballroom Salon IV (Level 2)
Marriott Marquis Houston Hotel

4:45 – 6:00 pm
Advanced Practice, Allied Health and Office Administrators Networking Reception
Room 335AB • Hilton Americas-Houston Hotel
Supported by Aimmune Therapeutics

6:00 – 7:30 pm
President’s Welcome Reception
Minute Maid Park
All registered attendees are invited to the ACAAI President’s Welcome Reception. Join us at Minute Maid Park, home of the Houston Astros! The main event will be in the park’s Union Station lobby, the grand entrance to Minute Maid Park, with an open bar and great food. You’ll get a great view of the field by stepping into areas of the covered concourse level and will have access to the infield warning track and dugouts. View the World Series trophy on the warning track by home plate from 6:00 – 7:00 pm. It all adds up to a home-run event!

Minute Maid Park is walking distance from the hotels. Transportation will not be provided. Enter ballpark at the Atrium Entrance off of Texas Street. Name badges must be worn for admittance to ballpark.
Supported by Aimmune Therapeutics

8:00 – 10:00 pm
Non-CME Corporate Forums
(See page 95 for details.)
Saturday General Sessions

Opening Ceremony and Welcome Announcements
7:30 – 8:00 am • Grand Ballroom (Level 3) • George R. Brown Convention Center

Todd A. Mahr, MD, FACAAI
President

David R. Stukus, MD, FACAAI
Program Chair

Mrs. Patricia Wedner
Alliance President

The 2019 Gold Headed Cane Award will be presented at this time to Dana V. Wallace, MD, FACAAI.

Dana V. Wallace, MD, FACAAI
2019 Gold Headed Cane Recipient

President Program Chair Alliance President

8:00 – 9:30 am • Grand Ballroom (Level 3) • George R. Brown Convention Center
Presidential Plenary Session
Adapting to New Evidence
Moderator: Todd A. Mahr, MD, FACAAI

This session will address the evolution of evidence pertaining to conditions for which allergists play a central role in management. Attendees will hear discussion surrounding new guidelines, new conditions and new approaches to long-standing beliefs.

8:00 am Welcome and Introductions
Todd A. Mahr, MD, FACAAI

8:02 am Edward J. O’Connell Tribute
Susan Rudd Bailey, MD, FACAAI

8:05 am Edward J. O’Connell Memorial Lecture
GRADEing Eosinophilic Esophagitis: What Is the Role of the Allergist?
Matthew Rank, MD, FACAAI

8:30 am Alpha-gal: A Fascinating and Evolving Story
Michael Levin, MD, PhD, FACAAI

9:00 am Asthma: Inflammation Is the Symptom, Not the Cause
Stephen Holgate, MD, FACAAI

9:30 am Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Apply evidence surrounding medical treatment and elimination diets in the management of patients with eosinophilic esophagitis.
• Identify patients at risk for having red meat allergy.
• Appreciate the role of epithelial dysfunction in the pathophysiology of asthma.
Saturday General Sessions

9:00 am – 4:30 pm
Exhibit Hall Open
Halls A3 & B3 (Level 3)
George R. Brown Convention Center

Bring your passport game card for a chance to win!

9:30 – 10:00 am
Product Theaters
Halls A3 & B3 (Level 3)
George R. Brown Convention Center

(See page 101 for details.)

10:00 – 11:30 am • Room 360 • George R. Brown Convention Center

Symposium

The Challenges of Infant Food Allergy and Anaphylaxis

Moderators: Anne K. Ellis, MD, MSc, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

Oral food challenges are the gold standard to diagnose food allergy. However, oral food challenges are underutilized in clinical practice. This session will address the challenges of implementing oral food challenges into clinical practice, with particular focus on performing food challenges in infants, as well as a review of anaphylaxis management in infants.

Tracks: Food & Drug Allergy and GI Disorders and Rhinitis/Sinusitis/Ocular and Anaphylaxis

10:00 am Welcome and Introductions
Anne K. Ellis, MD, MSc, FACAAI, and Matthew Greenhawt, MD, MSc, MBA, FACAAI

10:05 am Best Practice for Oral Food Challenges – Which Patients Need a Challenge and When?
Justin C. Greiwe, MD, FACAAI

10:30 am Practical Aspects of Infant Oral Food Challenges Suggested
Benjamin Prince, MD, MSc

10:55 am Prevention and Management of Infant Anaphylaxis
Jay A. Lieberman, MD, FACAAI

11:20 am Questions and Discussion

11:30 am Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

- Determine which patients referred to them for diagnosis of food allergy require an oral challenge to confirm or refute the same.
- Perform an oral challenge in their office with confidence and supported by best evidence.
- Diagnose and manage infant anaphylaxis.
Saturday General Sessions

10:00 – 11:30 am • Room 335 • Hilton Americas-Houston Hotel

Panel Discussion

Ensuring the Success of Academic Allergy

(Invitation only)

Moderators: Bryan L. Martin, DO, FACAAI, and Aidan A. Long, MD

This panel discussion is a program of the Joint Task Force on Academic Allergy/Immunology, which was created to evaluate needs and develop tools and strategies to support the success of academic allergy/immunology divisions. The interactive session will discuss challenges and opportunities facing A/I divisions within academic medical centers. There will be opportunity for significant audience involvement to discuss challenges, successes and opportunities at your center with other academic leaders.

10:00 am  Welcome and Introductions
Bryan L. Martin, DO, FACAAI, and Aidan A. Long, MD

10:05 am  Task Force Update
Bryan L. Martin, DO, FACAAI, and Aidan A. Long, MD

10:30 am  Financing within the Academic Allergy Division
Kevin J. Kelly, MD, FACAAI

11:00 am  Mentorship in Academic Allergy/Immunology
James T. Li, MD, PhD, FACAAI

11:25 am  Questions and Discussion

11:30 am  Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

• Be aware of the work being done by the Joint Task Force for Academic Allergy. Increase their effectiveness by better understanding the challenges and opportunities for academic allergy at the national level, and how they affect individual allergists in academic programs.

• Better understand common financial challenges to academic allergy/immunology programs and the strategies used by other programs to overcome these challenges.

• Understand current opportunities for mentoring and being mentored and future strategies to increase the opportunities and variety of available mentoring.
Despite advances in pharmaceutical management of asthma, patients continue to have high frequency of health care utilization due to poor control of asthma symptoms and frequent exacerbations. Many factors are thought to contribute to this, with poor adherence to medical treatment felt to be a major factor. Adherence to asthma medications has historically been very poor, particularly with inhaled medications. Also, poor recognition of symptoms has frequently been found in a subset of patients with chronic asthma, leading to poor outcomes. Digital technology has the opportunity to address many of these issues. Mobile apps are being developed specifically for patients with asthma, including both educational and self- and remote-monitoring functions. New inhalers are being developed that contain chips to provide real-time feedback at the time of use. Digital technology has the opportunity to reduce health and social inequities incurred by the disease.

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Explain how the use of new digital technologies help risk-assess the poorly controlled asthma patient.
- Assess in a patient with uncontrolled asthma the potential use of new digital technology aids in improving outcomes.
- Review the use of new technological aids in monitoring patients with severe uncontrolled asthma.

**Track:** Asthma and Respiratory/Sleep Disorders

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Welcome and Introductions</td>
<td>Jared Darveau, MD, and Mark C. Stahl, DO, FACAAI</td>
</tr>
<tr>
<td>10:05</td>
<td>The Spectrum of Digital Health Offerings for Asthma</td>
<td>Bruce Bender, PhD</td>
</tr>
<tr>
<td>10:35</td>
<td>What Does the Evidence Show?</td>
<td>William C. Anderson, MD, FACAAI</td>
</tr>
<tr>
<td>11:05</td>
<td>Ready for Prime Time?</td>
<td>Nabeel Farooqui, MD, FACAAI</td>
</tr>
<tr>
<td>11:30</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Prevention of Allergic Conditions: What Conversations to Have With Expecting Parents

Moderators: Angela D. Hogan, MD, FACAAI, and Bruce J. Lanser, MD, FACAAI

Multiple new studies have been published that show the potential benefit of specific interventions in preventing the development of atopic dermatitis and food allergies. Allergists need to remain at the forefront of this research and understand how to implement evolving data into clinical practice. This session will utilize case-based discussions to review the most up-to-date evidence and provide practical talking points to help educate parents and primary care providers.

Track: Population Health and Infectious Diseases/International Travel

10:00 am Welcome and Introductions
   Angela D. Hogan, MD, FACAAI, and Bruce J. Lanser, MD, FACAAI

10:05 am What the Latest Evidence Supports Regarding Early Life Interventions and the Prevention of Allergic Conditions
   David M. Fleischer, MD, FACAAI

10:35 am Let the Babies Eat: How to Discuss Introduction of Foods With Parents
   Edmond S. Chan, MD

11:05 am Probiotics, Prebiotics, Vitamin D and Fish Oil Supplements: How to Combat Misinformation Surrounding Allergy Prevention
   Carina Venter, PhD, RD

11:30 am Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:
• Understand the evidence surrounding interventions in expectant mothers and newborns that attenuate the development of allergic conditions.
• Implement active conversations and anticipatory guidance with expecting parents.
• Appreciate the various forms of misinformation parents receive from online resources, friends and family members.
Saturday General Sessions

11:30 am – 1:00 pm
**Allied Health Professionals Luncheon**
Ballroom of the Americas Salon B (Level 2)
Hilton Americas-Houston Hotel
Supported by Aimmune Therapeutics

11:30 am – 1:00 pm
**Visit Exhibits** (Lunch on Own)

11:30 am – 3:00 pm
**Doctors’ Job Fair**
Halls A3 & B3 (Level 3)
George R. Brown Convention Center

11:30 am – 1:00 pm
**Product Theaters**
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
(See page 101 for details.)

11:30 am – 1:00 pm
**E-posters – Meet the Authors: Session 2**
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
(See page 97 for details.)
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

11:35 am – 1:00 pm
**Building ABAI Continuing Certification Together**
Room 371 • George R. Brown Convention Center
ACAAI, ABAI and diplomates are key stakeholders in the current transformation of allergy/immunology continuing certification. This session will provide attendees an overview of the current landscape of continuing board certification, an update on the continuous assessment program (CAP) and personal progress meter. An interactive town hall will be held during this session, as part of ABAI’s commitment to co-development of specialty-continuing certification.
Symposium
Advances in the Care of Patients With Common Variable Immune Deficiency (CVID)

Moderators: Nikita Raje, MD, FACAAI, and Benjamin Prince, MD, MSci

We have an expanding supply of tools for managing the noninfectious complications of CVID. Understanding the availability and utility of these tools will help practitioners in the diagnosis and treatment of the noninfectious complications of CVID.

Track: Clinical Immunology and Autoimmune and Biologicals

1:00 pm  Welcome and Introductions
Nikita Raje, MD, FACAAI and Benjamin Prince, MD, MSci

1:05 pm  Medical Knowledge – Lung Disease in CVID
John M. Routes, MD, FACAAI

1:30 pm  Genetic Testing and Treatment
Lisa R. Forbes, MD

1:55 pm  Best Practices in Patient Care
Elena E. Perez, MD

2:20 pm  Questions and Discussion

2:30 pm  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Understand how to assess lung function in CVID patients.
• Identify the role of genetic diagnosis in the care and treatment of patients with CVID.
• Recognize the role of biologics for treating complications of CVID.
Saturday General Sessions

1:00 – 2:30 pm • Grand Ballroom (Level 3) • George R. Brown Convention Center

Symposium • MOC/CME

Evolution of Food Allergy Therapies

Moderators: John J. Oppenheimer, MD, FACAAI, and Marcus Shaker, MD, MSc, FACAAI

Several new interventions are likely to be approved by the FDA in the upcoming year. These therapies have different levels of efficacy and side effects and will likely greatly impact office flow. Thus, it is imperative that allergists become more facile with their knowledge regarding these therapies.

Track: Immunotherapy and Diagnostics

1:00 pm Welcome and Introductions
John J. Oppenheimer, MD, FACAAI, and Marcus Shaker, MD, MSc, FACAAI

1:05 pm Efficacy and Safety of OIT and EPIT
J. Andrew Bird, MD, FACAAI

1:30 pm Practical Impediments to These New Therapies
Julie Wang, MD, FACAAI

1:55 pm Food Immunotherapy 2.0: What the Future May Hold
Brian P. Vickery, MD

2:20 pm Questions and Discussion

2:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Differentiate OIT from EPIT in terms of efficacy and safety.
• Understand impediments for implementation of these therapies.
• Identify frequently asked questions regarding these therapies.

1:00 – 2:30 pm • Room 382 • George R. Brown Convention Center

Practical Applications at Work Seminar

Integrative Approaches to Office Health: Improving Patient Outcomes

Moderators: Janna M. Tuck, MD, FACAAI, and Meagan W. Shepherd, MD, FACAAI

The healthy allergy and immunology clinic involves more than just keeping the schedule full. An unhealthy clinic can contribute to the allergist's stress level, burnout and depression, as well as poor patient satisfaction, compliance and outcomes. In this session, find out what constitutes an unhealthy work environment in the clinic and learn how to use the principles of integrative medicine to improve the health of the clinic and, consequently, of our patients and ourselves as providers.

Track: Environmental and Integrative Medicine

1:00 pm Welcome and Introductions
Janna M. Tuck, MD, FACAAI, and Meagan W. Shepherd, MD, FACAAI

1:05 pm Define and Outline the Unhealthy A/I Clinic and Its Impact on the Provider, Office Staff and Patient
Maeve E. O’Connor, MD, FACAAI

1:30 pm Application of Integrative Medicine Principles in A/I Practice That Improve Office Health and Bring Better Patient Outcomes
Randy J. Horwitz, MD, PhD

1:55 pm MBSR and Breath Work Applications for You and Your Patient
James Carmody, PhD

2:20 pm Questions and Discussion

2:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Outline the unhealthy habits in their A/I clinics that lead to physician and clinical team burnout and poor patient outcomes.
• Identify tools to help navigate the chaotic daily life of an allergy clinic with proven integrative medicine techniques to benefit the entire office team.
• Understand how a healthy provider and office improves patient outcomes through evidence-based literature review.
COPD is the third leading cause of death in the United States, and our specialty is encountering both diagnosed and undiagnosed COPD patients at an increased rate. Allergy/immunology specialists are in a unique position to be at the forefront of COPD care, including evaluating potential immune deficiencies in this patient population. In addition, many patients may have asthma-COPD overlap (ACO), and there is still considerable debate in the medical community regarding the exact diagnosis and treatment of this condition.

Track: Asthma and Respiratory/Sleep Disorders

1:00 pm Welcome and Introductions
Anil Nanda, MD, FACAAI, and Michael B. Foggs, MD, FACAAI

1:05 pm COPD GOLD Guidelines for the Allergist/Immunologist
William J. Calhoun, MD, FACAAI

1:30 pm Diagnosis and Treatment of ACO: What Is Known and What Is New
Nicola A. Hanania, MD, MS

1:55 pm What’s Left: Other Causes of Wheezing in Adults
Mario Castro, MD, MPH

2:20 pm Questions and Discussion
2:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Categorize the treatment of COPD patients in an allergy/immunology practice setting, utilizing GOLD Guidelines.
• Identify and treat patients with asthma-COPD overlap (ACO).
• Identify COPD patients who may benefit from immunodeficiency workup and treatment.

1:00 – 2:30 pm • Room 370 • George R. Brown Convention Center
Symposium
Racial, Ethnic and Socioeconomic Disparities in Food Allergy
Moderators: Cherie Y. Zachary, MD, FACAAI, and Princess Ogbogu, MD, FACAAI

This session will provide the allergist/immunologist a perspective on the diversity of food allergy along racial, ethnic and socioeconomic lines. There will be particular focus on associations with morbidity and mortality, what diverse families may value regarding food allergy, how they may choose to spend their health care dollars and how this may differ from the primarily white, middle class families typically described in food allergy.

Track: Food & Drug Allergy and GI Disorders

1:00 pm Welcome and Introductions
Cherie Y. Zachary, MD, FACAAI, and Princess Ogbogu, MD, FACAAI

1:05 pm Does Food Allergy Disproportionately Affect Particular Races or Ethnicities?
Ruchi Gupta, MD, MPH

1:30 pm What Is the Socioeconomic Burden of Food Allergy Among Racially and Ethnically Diverse Populations?
Rachel Peters, MD, MPH, PhD

1:55 pm Is There Racial and Ethnic Disparity in What Families Value Regarding Food Allergy?
Michael Levin, MD, PhD, FACAAI

2:20 pm Questions and Discussion
2:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Identify racial and ethnic disparities in food allergy prevalence.
• Describe socioeconomic disparities in food allergy.
• Understand potential differences in values clarification among racially and ethnically diverse food-allergic populations.
Saturday General Sessions

1:00 – 2:30 pm • Room 361ABC • George R. Brown Convention Center
Seats Available on First-come, First-served Basis • Limit 45

Ask the Expert Roundtables
The Changing Face of an Allergy Practice
Moderator: Warner W. Carr, MD, FACAAI

These expert round table discussions will address some of the threats and potential pitfalls of allergy practice today. Choose three of the five topics and spend 25 minutes with each expert addressing a phase of allergy practice. The expert will give a five-minute overview of the topic and will then answer questions and facilitate discussion with the table participants for 20 minutes.

Track: Practice Management/Professional Issues

1:00 pm Welcome and Introductions
Warner W. Carr, MD, FACAAI

Table Rotations
1:05 pm, 1:30 pm, 2:00 pm

Table 1 Safeguarding Your Patient Data
James M. Tracy, DO, FACAAI

Table 2 Safeguarding Your Online Reputation
Melinda M. Rathkopf, MD, FACAAI

Table 3 Branding and Marketing
Stanley M. Fineman, MD, MBA, FACAAI

Table 4 USP
James L. Sublett, MD, FACAAI

Table 5 Financial Benchmarking
Kevin P. McGrath, MD, FACAAI

2:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Protect their patient data and online reputation.
• Brand and market their allergy practice.
• Describe the new rules for preparing allergy extracts.

2:30 – 3:00 pm E-posters – Meet the Authors: Session 3
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
(See page 97 for details.)

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

2:30 – 3:00 pm Cookies and Refreshment Break in Exhibit Hall
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

2:35 – 3:00 pm Product Theaters
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
(See page 101 for details.)
This session will address cannabis legalization and patient perceptions and patterns of use. We will discuss how cannabis is commonly used, review the importance of asking our patients about cannabis use, the effects of cannabis on the lungs (also versus tobacco) and review allergic sensitization to cannabis. Common misconceptions will be discussed, including the ideas that cannabis is “good” for asthma, that it is safer than tobacco, that it is not addictive and that cannabis allergy does not exist. Attendees will gain a greater understanding of cannabis and its effects, so they can instantly bring this knowledge to their clinical practice in order to empower their patients and advocate for their well-being.

**Track:** Environmental and Integrative Medicine

**3:00 pm** Welcome and Introductions  
William S. Silvers, MD, FACAIAI, and Michael R. Rupp, MD, FACAIAI

**3:05 pm** Introduction to Cannabis; Its Legalization, Patient Perceptions, Patterns of Use and Common Misconceptions  
David R. Naimi, DO

**3:35 pm** The Effects of Cannabis on the Lungs  
Rohit K. Katial, MD, FACAIAI

**4:05 pm** Allergic Sensitization to Cannabis  
Hannelore A. Brucker, MD, FACAIAI

**4:30 pm** Adjourn

**Learning Objectives**  
Upon completion of this session, participants should be able to:  
- Recognize how cannabis legalization impacts patient perceptions and use of the drug.  
- Identify the effects of cannabis on the lungs.  
- Recognize the potential symptoms and nuances of allergic sensitization to cannabis.

This session will address relevant changes, modifications and implementation of CPT and ICD-10 coding for 2019 and the AMA’s outlook for medicine. This will be accomplished by practical case-based scenarios focused on how the change may affect the practice of allergy and clinical immunology. In addition, we’ll review the state of politics and the national perspective of medicine as seen through the eyes of the AMA. Finally, we’ll offer an update on the changing landscape on Capitol Hill as it relates to the current state of government.

**Track:** Practice Management/Professional Issues

**3:00 pm** Welcome and Introductions  
James M. Tracy, DO, FACAIAI, and Stephen A. Imbeau, MD, FACAIAI

**3:05 pm** Coding Update  
Gary N. Gross, MD, FACAIAI

**3:30 pm** The National Landscape of Medicine as Seen Through the Eyes of the AMA  
Susan Rudd Bailey, MD, FACAIAI

**3:55 pm** The Political World With a Changing US Congress  
Bill Finerfrock

**4:20 pm** Questions and Discussion

**4:30 pm** Adjourn

**Learning Objectives**  
Upon completion of this session, participants should be able to:  
- Describe coding changes and updates relevant to allergy practice.  
- Describe governmental and legislative updates relevant to allergists.
Cough is one of the most common symptoms of patients seen by allergist/immunologists. Understanding the mechanisms that lead to cough is paramount. A new paradigm has emerged of patients with cough (neural) hypersensitivity that does not respond to asthma, rhinitis and/or GERD therapy. Allergists need to understand the different therapeutic agents and their mechanisms of action in all stages of cough.

**Track: Asthma and Respiratory/Sleep Disorders**

3:00 pm  **Welcome and Introductions**
Jeremy S. Katcher, MD, FACAAI, and J. Wesley Sublett, MD, MPH, FACAAI

3:05 pm  **Evaluation of a Child With Cough**
Kevin R. Murphy, MD, FACAAI

3:30 pm  **Not All That Coughs Is Asthma: Considerations for Adults**
Alan B. Goldsobel, MD, FACAAI

3:55 pm  **Treatment Options in Cough**
Mandel R. Sher, MD, FACAAI

4:20 pm  **Questions and Discussion**

4:30 pm  **Adjourn**

**Learning Objectives**
Upon completion of this session, participants should be able to:
- Understand the role of the varied cough receptors in the pathogenesis of cough.
- Evaluate a patient with cough.
- Explain the mechanisms of action of therapeutic agents in the treatment of cough.

**Symposium**

**Difficult-to-control Atopic Dermatitis: Cutting Edge Science, Practical Pearls and Targeted Therapy**

**Moderators: Myron J. Zitt, MD, FACAAI, and Allison C. Ramsey, MD, FACAAI**

**Supported by an independent educational grant from Abbvie**

This session will consider treatment of the itch in persons with atopic dermatitis. Should allergists prescribe monoclonal antibodies or drugs that block neurotransmitters?

**Track: Dermatology**

3:00 pm  **Welcome and Introductions**
Myron J. Zitt, MD, FACAAI, and Allison C. Ramsey, MD, FACAAI

3:05 pm  **The Microbiome of the Skin and Atopic Dermatitis**
Donald Y. Leung, MD, PhD, FACAAI

3:30 pm  **Atopic Dermatitis in Patients of Color**
Andrew Alexis, MD, MPH

3:55 pm  **The Treatment Options to Control Atopic Dermatitis**
Mark Boguniewicz, MD, FACAAI

4:20 pm  **Questions and Discussion**

4:30 pm  **Adjourn**

**Learning Objectives**
Upon completion of this session, participants should be able to:
- Describe and understand the complex nature of the pathophysiology of atopic dermatitis and the role of the microbiome.
- Recognize the systemic nature of atopic dermatitis.
- Identify components of the step-wise approach to the management of AD following both national and international guidelines.
Saturday General Sessions

3:00 – 4:30 pm • Room 351 • George R. Brown Convention Center

Practical Applications at Work Seminar

The Updated EoE Guidelines – Whose Disease Is It Anyway?

Moderators: John J. Oppenheimer, MD, FACAAI, and Dana V. Wallace, MD, FACAAI

This session will review the newly published jointly developed AGA/AAAAI/AACAI GRADE-based EoE guidelines discussing the new clinical recommendations and areas of emerging evidence. There will be particular emphasis on how the allergist and gastroenterologist can co-manage this illness.

Track: Food & Drug Allergy and GI Disorders

3:00 pm  Welcome and Introductions
          John J. Oppenheimer MD, FACAAI, and Dana V. Wallace, MD, FACAAI

3:05 pm  Out With the Old, In With the New – Key Guideline Updates to Managing the Patient With EoE
          Matthew Greenhawt, MD, MSc, MBA, FACAAI

3:30 pm  Diet Versus Steroid – Choosing the Right Therapy
          Matthew Rank, MD, FACAAI

3:55 pm  One Ring to Rule Them All – Approaches for How the Allergist and Gastroenterologist can Co-manage EoE
          Edmond S. Chan, MD

4:20 pm  Questions and Discussion

4:30 pm  Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

• Identify best-practice strategies for steroid, PPI and dietary management in EoE.
• Identify best-practice strategies for biologics and emerging potential therapies management in EoE.
• Identify best-practice strategies for shared management between GI and allergy in the care of patients with EoE.
Saturday General Sessions

**Distinguished Industry Oral Abstracts: Session A**

Moderators: Brian T. Kelly, MD, MA, and David R. Stukus, MD, FACAAI

- **4:30 pm** Welcome and Introductions
  - Brian T. Kelly, MD, MA, and David R. Stukus, MD, FACAAI

- **4:35 pm** D200 – Relationship Between Systemic Corticosteroid Use, Associated Complications, and Health Care Costs in Patients with Persistent Asthma
  - James L. Kreindler, MD

- **4:45 pm** D201 – Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-severe Asthma and Serologic Evidence of Allergic Bronchopulmonary Aspergillosis
  - Jonathan Corren, MD, FACAAI

- **4:55 pm** D202 – Rescue Medication Use and Inhalation Patterns During Asthma Exacerbations Recorded by Digihaler
  - Roy Pleasants, PharmD

- **5:05 pm** D450 – Omalizumab Efficacy and Safety in Nasal Polyposis: Results From Two Parallel, Double-blind, Placebo-controlled trials
  - Philippe Gevaert, MD, PhD

- **5:15 pm** D451 – Clinical Activity of AK002, an Anti-Siglec-8 Antibody, in Severe Allergic Conjunctivitis and Comorbid Atopic Diseases
  - Terry Levine, MD

**Distinguished Industry Oral Abstracts: Session B**

Moderators: Lisa R. Kobrynski, MD, MPH, FACAAI, and Janna Tuck, MD, FACAAI

- **4:30 pm** Welcome and Introductions
  - Lisa R. Kobrynski, MD, MPH, FACAAI, and Janna Tuck, MD, FACAAI

- **4:35 pm** D100 – CDX-0159, An Anti-KIT Monoclonal Antibody, As a Modulator of Mast Cell-related Diseases
  - Richard Gedrich, PhD

- **4:45 pm** D301 – Etokimab Monotherapy in Peanut-allergic Participants: A Proof of Concept Study
  - Sharon Chinthrajah, MD

- **4:55 pm** D302 – Perceptions Among Peanut-allergic Children: A Survey
  - Matthew Greenhawt, MD, MBA, MSc, FACAAI

- **5:05 pm** D303 – Improvements in Quality of Life Following Epicutaneous Peanut Immunotherapy: PEPITES and PEOPLE Studies
  - Audrey Dunn Galvin, PhD

- **5:15 pm** Adjourn
5:30 – 7:30 pm

28th Annual FIT Bowl Competition

Houston Ballroom (Level 2) • Marriott Marquis Houston Hotel

Test your knowledge, sharpen your wits and join in the fun at the dynamic, fast-paced FIT Bowl! Participating teams from training programs around the country will compete to answer a variety of serious (and not so serious) questions posed by an expert panel. Approximately 30 teams from the US and Mexico will participate in this popular game show.

Supported by DBV Technologies

8:00 – 10:00 pm

Non-CME Corporate Forums
(See page 96 for details.)
This inaugural program will offer didactic presentations, developed specifically to detail the expectations of the revised USP 797, followed by a hands-on workshop, where attendees will accurately garb to meet 797 standards, participate in area sterilization techniques and perform individualized media fill and glove tip testing. The session will conclude with a brief exam, and certificates of completion will be awarded to those who successfully complete the training program.

8:00 am – 2:00 pm • Room 382 • George R. Brown Convention Center

ACAAI Allergen Extract Mixer Training Program

Moderator: Bryan L. Martin, DO, FACAAI

Supported by an independent educational grant from Stallergenes Greer

Learning Objectives
Upon completion of this session, participants should be able to:
- Understand the requirements for a USP 797-compliant mixing station.
- Provide sterile, safe immunotherapy kits for patients.
- Ensure allergy kits contain appropriate allergen extracts in the appropriate quantities for safe immunotherapy administration, mixed according to a patient’s individualized prescription.
Pediatric asthma is one of the most common chronic diseases in children. There is a continued need to understand best practices to improve the care of these children. Understanding how the environment plays a role in pediatric asthma is key in providing better control for our patients. How does climate change affect pediatric asthma? How can we improve the indoor environment to decrease flare-ups of pediatric asthma? Biologics are playing a major role in severe asthma in adults, but where do they play a role in children with asthma? What are the benefits and risks for the pediatric population? What are the new biologics we may see in children? With the Asthma Controller Step Down Yardstick in Pediatric Asthma, how does an allergist decrease medications in asthma in the pediatric population? When is it safe to decrease controller treatments, and how do you monitor the child after you decrease it?

Track: Asthma and Respiratory/Sleep Disorders

6:30 am  Welcome and Introductions
William C. Anderson, MD, FACAAI, and Alan Goldsobel, MD, FACAAI

6:35 am  The Environment and Pediatric Asthma
Jonathan Corren, MD, FACAAI

7:00 am  Current and Future Biologics in Pediatric Asthma
Leonard Bacharier, MD, FACAAI

7:25 am  How to Apply Asthma Controller Step Down Yardstick in Pediatric Asthma
Matthew Rank, MD, FACAAI

7:45 am  Questions and Discussion

7:55 am  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Use data on how changes in the indoor and outdoor environment can improve pediatric asthma control.
• Know when to use biologics and which biologics can benefit the child with moderate-to-severe asthma.
• Have a plan to implement step-down treatment in the child with stable asthma.
Sunday General Sessions

8:00 – 9:30 am • Grand Ballroom (Level 3) • George R. Brown Convention Center

Plenary Session MOC/CME

Modifying Our Approach
Moderator: Mark L. Corbett, MD, FACAAI

The advent of targeted therapies and further understanding of the microbiome offer exciting opportunities for new approaches to patients with asthma and allergic conditions. However, knowledge gaps continue to exist. This session will review what we’ve learned, what we have yet to learn and, most importantly, what can be implemented now.

Track: Asthma and Respiratory/Sleep Disorders

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td></td>
<td>Mark L. Corbett, MD, FACAAI</td>
</tr>
<tr>
<td>8:05</td>
<td>Making Sense of New Approaches to Asthma Therapy</td>
</tr>
<tr>
<td></td>
<td>Paul O’Byrne, MD</td>
</tr>
<tr>
<td>8:25</td>
<td>Risk Factors for Developing Allergic Disease: Lessons From the Isle of Wright</td>
</tr>
<tr>
<td></td>
<td>Syed H. Arshad, MBBS, DM</td>
</tr>
<tr>
<td>8:45</td>
<td>John P. McGovern Lecture</td>
</tr>
<tr>
<td></td>
<td>Rewilding the Microbiome: The Importance of Ecological Approaches to Immune Health</td>
</tr>
<tr>
<td></td>
<td>Susan Prescott, MD, MBBS, PhD</td>
</tr>
<tr>
<td>9:05</td>
<td>Manipulating the Microbiome to Prevent or Treat Allergic Conditions</td>
</tr>
<tr>
<td></td>
<td>Carina Venter, PhD, RD</td>
</tr>
<tr>
<td>9:30</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

Learning Objectives
Upon completion of this session, participants should be able to:
- Utilize evidence-based treatment options for patient’s refractory-to-standard asthma management.
- Identify risk factors associated with the development of allergic conditions.
- Identify current knowledge gaps regarding how the microbiome is associated with the development of allergic conditions.
- Discuss current evidence regarding treatment options surrounding the microbiome with patients who have allergic conditions.

9:00 am – 1:30 pm

Exhibit Hall Open
Halls A3 & B3 (Level 3)
George R. Brown Convention Center

*Bring your passport game card for a chance to win!*

9:00 am – 1:30 pm

College Resource Center Open
Booth #613 • Halls A3 & B3 (Level 3)
George R. Brown Convention Center

9:30 – 10:00 am

Refreshment Break in Exhibit Hall
Halls A3 & B3 (Level 3)
George R. Brown Convention Center

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

9:35 – 10:00 am

Product Theaters
Halls A3 & B3 (Level 3)
George R. Brown Convention Center

(See page 102 for details.)
### Sunday General Sessions

**10:00 – 11:30 am • Room 360 • George R. Brown Convention Center**

**Symposium**

**7 for 11: Hot Topics in Pediatric A/I**

*Moderator: Todd A. Mahr, MD, FACAAI*

*A joint presentation from AAP-SOAI and ACAAI.*

Each of the 7 presenters will have only 11 minutes to deliver insightful, targeted and dynamic information on their assigned topics.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 am</td>
<td>Welcome and Introductions</td>
<td>Todd A. Mahr, MD, FACAAI</td>
</tr>
<tr>
<td>10:05 am</td>
<td>Asthma</td>
<td>Angela D. Hogan, MD, FACAAI</td>
</tr>
<tr>
<td>10:16 am</td>
<td>Food Allergy – Non-Treatment</td>
<td>J. Wesley Sublett, MD, MPH, FACAAI</td>
</tr>
<tr>
<td>10:27 am</td>
<td>Food Allergy – Treatment</td>
<td>J. Andrew Bird, MD, FACAAI</td>
</tr>
<tr>
<td>10:38 am</td>
<td>Biologics</td>
<td>Carla M. Davis, MD, FACAAI</td>
</tr>
<tr>
<td>10:49 am</td>
<td>Anaphylaxis</td>
<td>Julie Wang, MD, FACAAI</td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:
- Review current recommendations for treatment of food allergy in children.
- Describe recent advances in pediatric asthma management.
- Understand novel changes in management of atopic dermatitis in children.

---

**10:00 – 11:30 am • Room 370 • George R. Brown Convention Center**

**Symposium**

**Primary Immune Deficiency: Optimal Care for Optimal Outcomes**

*Moderators: Purvi S. Parikh, MD, and Kenneth Paris, MD, MPH*

*Supported by an independent educational grant from CSL Behring*

This session will help participants recognize the key features that impact the disease burden and outcomes for patients with primary immune deficiencies. Early recognition of these issues can help to reduce their impact on patient’s well-being and, by reducing disease related morbidity, improve patient outcomes.

**Track:** Clinical Immunology and Autoimmune and Biologicals

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 am</td>
<td>Welcome and Introductions</td>
<td>Purvi S. Parikh, MD, and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kenneth Paris, MD, MPH</td>
</tr>
<tr>
<td>10:05 am</td>
<td>Patient-centered Outcomes</td>
<td>Mark M. Ballow, MD, FACAAI</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Medical Knowledge of Complications of Primary Immune Deficiencies</td>
<td>Alexandra Freeman, MD</td>
</tr>
<tr>
<td>10:55 am</td>
<td>Communication With Patients</td>
<td>Richard L. Wasserman, MD, PhD, FACAAI</td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:
- Identify long-term prognosis markers for primary immune deficiencies and maximize life expectancy.
- Identify new infectious threats to patients with primary immune deficiencies.
- Recognize the burden of care for patients with primary immune deficiencies.
Any allergist that mixes allergy vaccines should be following the guidance of USP 797. Recent issues, unrelated to allergy vaccine preparation, have caused the USP to alter its requirements for drug compounding. Though initially allergy mixing seemed as though it might be consumed by the “compounding” controversy, the ACAAI and others worked to demonstrate the differences between mixing allergy vaccines in an allergist’s office and the compounding of pharmaceuticals by commercial compounding companies. Although the efforts of the ACAAI Advocacy Council and others were largely successful, changes to the USP 797 requirements for the mixing of allergy vaccines did occur. This symposium will review the history of the issue, address the changes and suggest operational recommendations for implementation of these changes.

Learning Objectives
Upon completion of this session, participants should be able to:
• Describe the new USP 797 standards.
• Explain the implications of the new standards.
• Describe how to make their mixing lab compliant.
Transition is challenging for anyone, and different ages present different needs. This session will review unique aspects affecting children, adolescents and elderly patients who have asthma, food allergies and other allergic conditions. From discussion with caregivers to practical tips to help prepare for self-management, this session will provide an overview and a blueprint that attendees can immediately apply to patient care.

**Track:** Population Health and Infectious Diseases/International Travel

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 pm</td>
<td>Welcome and Introductions</td>
<td>Dana V. Wallace, MD, FACAAI, and Kelly M. Maples, MD, FACAAI</td>
</tr>
<tr>
<td>1:05 pm</td>
<td>The Parent Is the Teacher: How to Help Parents Prepare for Transitioning Their Child to School</td>
<td>Ruchi Gupta, MD, MPH</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>You’re on Your Own: How to Help Adolescents Prepare for Self-management and Independent Living</td>
<td>William C. Anderson, MD, FACAAI</td>
</tr>
<tr>
<td>1:55 pm</td>
<td>Helping Our Elderly Patients: Unique Aspects of Their Care</td>
<td>Mervat Nassef, MD, FACAAI</td>
</tr>
<tr>
<td>2:20 pm</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:
- Assist care transition from adolescence to adulthood.
- Develop a plan to facilitate wellness assessments.
- Be aware of wellness concerns for aging.
Problem-based Learning

PBL – An Older Adult Patient With Difficult-to-control Asthma: Learning to Care for the Older Adult Patient Using SDM

Moderator: Ray S. Davis, MD, FACAAI

Supported by an independent educational grant from GlaxoSmithKline

An interactive PBL presentation of an older asthmatic patient with poor adherence to asthma medication and inadequate communication will be presented. These are critical problems in asthma care in the older patient because they contribute to morbidity and mortality through poor control, frequent asthma exacerbations, acute care visits and oral corticosteroid usage. The elderly asthmatic is particularly vulnerable and needs a shared decision-making to improve adherence. To improve patient adherence in the older asthmatic, clinicians need to consider a variety of factors and implement strategies directly targeting underlying issues that may be specific to the older patient. Strategies will be discussed, including customizing and simplifying learning and intervention regimes, identifying barriers to adherence and addressing them, ensuring patient support structures are in place and improving self-efficacy and health literacy through shared decision-making.

Track: Asthma and Respiratory/Sleep Disorders

1:00 pm
Welcome and Introductions
Ray S. Davis, MD, FACAAI

Post-PBL Interactive Discussion:
Better Adherence through Shared Decision Making
Allan T. Luskin, MD, FACAAI
Andrew Weinstein, MD, FACAAI

2:30 pm
Adjourn

Learning Objectives

Upon completion of this session, participants should be able to:

• Engage interactively with peers about their approach to treating the difficult-to-control older adult patient.
• Discuss how to offer and interpret the care options in context of what is important to the patient and their family.
• Investigate ideas on how to encourage patients to collaborate with existing community resources to improve adherence in older adult patients.
Recurrent Infections With Normal or Near-normal Immunoglobulins: Now What?

Moderators: Sami L. Bahna, MD, DrPH, FACAAI, and Erinn Gardner, MD

Clinicians are often presented with patients complaining of recurrent infections; however, basic workup including serum immunoglobulins and specific antibodies may fail to demonstrate evidence of any immune deficiency. This clinical conundrum will review the presentation of these causes and the diagnostic workup. Treatment may include supportive therapies, and this clinical conundrum will review treatment options.

Track: Clinical Immunology and Autoimmune and Biologicals

1:00 pm  Welcome and Introductions  Sami L. Bahna, MD, DrPH, FACAAI, and Erinn Gardner, MD

1:05 pm  When Does the Infection History Support the Diagnosis of an Immune Deficiency?  Elena E. Perez, MD

1:30 pm  Beyond Hypogammaglobulinemia: Additional Workup  Lisa R. Forbes, MD

1:55 pm  Evidence-based Management Strategies  Ivan Chinn, MD

2:20 pm  Questions and Discussion

2:30 pm  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:

• Determine when infections are due to immune deficiency or other conditions.
• Describe approach and evaluation for patients with recurrent infections, including what diagnostic testing is indicated.
• Describe management strategies and evidence-based care.
New discoveries in atopic dermatitis are advancing our understanding of the underlying causes of this complex disease, as well as its role in allergic disease. New therapies give clinicians a wider range of treatment options to target specific manifestations of the disease and implement possible prevention strategies. This symposium will report on what we are learning from the new frontier of atopic dermatitis toward optimal care of the patient.

**Track:** Dermatology

1:00 pm  **Welcome and Introductions**  
Todd A. Mahr, MD, FACAAI, and Ignacio J. Ansotegui, MD, PhD

1:05 pm  **The Many Faces of Atopic Dermatitis**  
Motohiro Ebisawa, MD, PhD

1:30 pm  **Novel Treatments in Atopic Dermatitis: Biologicals and Small Molecules**  
Mario A. Sánchez-Borges, MD

1:55 pm  **International Classification of Diseases (ICD-11) and Evaluation of Quality of Life in Skin Conditions**  
Luciana K. Tanno, MD, PhD

2:00 pm  **Questions and Discussion**

2:30 pm  **Adjourn**

**Learning Objectives**
Upon completion of this session, participants should be able to:

- Identify phenotypes of atopic dermatitis and discuss its role as a cause of allergic diseases.
- Report recent advances on the pathophysiology of atopic dermatitis and review current and future potential therapies based on new research.
- List advances of ICD-11 for skin conditions and explain how the ICD-11 can impact epidemiological data and the burden of skin conditions.
Sunday Oral Abstracts Session 1

1:00 – 2:30 pm • Room 351ABC • George R. Brown Convention Center

Session 1A
Adverse Drug Reactions, Insect Reactions, Anaphylaxis

Moderators: Kevin Kelly, MD, FACAAI, and Stephanie Mawhirt, DO

1:00 pm Welcome and Introductions
Kevin Kelly, MD, FACAAI, and Stephanie Mawhirt, DO

1:00 pm A001 – A Retrospective Analysis of Penicillin Allergy Relabeling During Readmission After Negative Inpatient Penicillin Allergy Testing
Matthew R. Norris, MD

1:15 pm A002 – Impact of Educational Lecture on Physician Barriers to Recognition and Management of Anaphylaxis
Ashley Ciliberti, MD

1:30 pm A003 – Direct Amoxicillin Challenge Without Preliminary Skin Testing for Pediatric Patients With Low-risk Penicillin Allergy Symptoms
Laura A. Wang, MD, MPH

1:45 pm A004 – Trends in Anaphylaxis in Young Children in the United States from 2006-2015
Lacey B. Robinson, MD

2:00 pm A005 – Erythema Multiforme-like Rashes: Are They Truly Antibiotic-associated?
Katharine M. Guarnieri, MD

2:15 pm A006 – Adverse Drug Reactions in Cystic Fibrosis Patients: Using Data to Develop an Antibiotic Evaluation Program
Karen M. Anstey, MD

2:30 pm Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to:
• Discuss the risk of penicillin allergy relabeling after negative inpatient penicillin allergy testing as it pertains to the use of multiple electronic medical records.
• Recognize that there is a lack of physician comfort with anaphylaxis, epinephrine use and patient education which may be improved through an educational lecture series.
• Identify low-risk pediatric patients who would be able to receive a direct oral amoxicillin challenge without the need for preliminary skin testing.
• Discuss trends of anaphylaxis in young children (< 3 years of age) presenting to the emergency department in the United States from 2006-2015.
• Compare and contrast the clinical presentation of antibiotic-associated and non-antibiotic-associated erythema multiforme-like rashes.
• Discuss the discrete types and rates of documented antibiotic adverse drug reactions in cystic fibrosis patients, and describe how this data can be applied to develop a clinical program that provides targeted evaluation of these antibiotics to allow cystic fibrosis patients to receive first-line antibiotic therapy.

2:30 – 3:00 pm Refreshment Break
Level 3 • George R. Brown Convention Center

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Session 1B

Allergy Diagnostics and Immunotherapy and Clinical Immunology, Immunodeficiency, Food Allergy

Moderators: Mitchell Grayson, MD, FACAAI, and Michelle Maciag, MD

1:00 pm Welcome and Introductions
Mitchell Grayson, MD, FACAAI, and Michelle Maciag, MD

1:00 pm Clemens von Pirquet Award – Third Place
A100 – Long-term Adherence to Imported Fire Ant Subcutaneous Immunotherapy
Brittanie I. Neaves, MD

1:15 pm A101 – Analysis of Allergen-specific IgE Cut Points to Cat, Dog, and Grass in Children
Bradley M. Boelkins, MD

1:30 pm A102 – Imported Fire Ant Immunotherapy Prescribing Patterns in a Large Health Care System
Robert H. Wauters, MD

1:45 pm A250 – Humoral Immunodeficiency in Patients With Chronic Lymphocytic Leukemia
S. Shahzad Mustafa, MD, FACAAI

2:00 pm A251 – Reconstitution of IgG Subclasses Following Immunoglobulin Administration in Adults With Common Variable Immune Deficiency
David J. Reeder, MD

2:15 pm A300 – Elevated Allergic Comorbidity in Patients With Food Protein-induced Enterocolitis
Melanie Ruffner, MD, PhD

2:30 pm Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to:
• Discuss long-term adherence rates of immunotherapy to imported fire ants.
• Identify patient characteristics that may affect optimal single serum allergen-specific IgE cut points.
• Describe the prescribing trend towards maintenance dose of 0.5 ml of 1:100 w/v for IFA immunotherapy in a large nationwide cohort.
• Appropriately evaluate patients with chronic lymphocytic leukemia for humoral immunodeficiency.
• Discuss the merits of assessing for IgG subclass reconstitution among their patients with CVID, particularly those who continue to get bacterial infections despite administration of exogenous immunoglobulin.
• Discuss data that suggests FPIES patients are at a higher risk of IgE-mediated allergies.

2:30 – 3:00 pm
Refreshment Break
Level 3 • George R. Brown Convention Center

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Session 1C
Adverse Drug Reactions, Insect Reactions, Anaphylaxis, Asthma, Other Lower Airway Disorders, Other

Moderators: Peck Ong, MD, FACAAI, and Peter Capucilli, MD

1:00 pm Welcome and Introductions
Peck Ong, MD, FACAAI, and Peter Capucilli, MD

1:00 pm A107 – Impact of Penicillin Allergy Label in Liver Transplant Recipients During Transplant Hospitalization
Gabriel Motoa, MD

1:15 pm A200 – Asthma Population Management in the Children’s Hospital Emergency Department
Claire Atkinson, MD

1:30 pm A201 – Influence of Natural Lung Surfactant Inhalation on Symptoms and Lung Function in Severe Bronchial Asthma
Oleg Rosenberg

1:45 pm A202 – Lack of Concordance Between FeNO and Spirometry in Patients With Chronic Cough
Talal M. Nsouli, MD, FACAAI

2:00 pm A350 – Telemedicine and Patient Satisfaction in Allergy and Immunology
Jay M. Portnoy, MD, FACAAI

2:15 pm Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to:
• Describe outcomes of liver transplant recipients when a penicillin allergy label exists.
• Identify strategies for improving delivery of asthma action plans and asthma education to pediatric patients.
• Identify the influence of natural lung surfactant inhalation on clinical symptoms and pulmonary function parameters in patients with severe bronchial asthma.
• Identify and discuss the value of fractional exhaled nitric oxide (FeNO) in diagnosing cough variant asthma in patients with chronic cough.
• Recognize the importance of telemedicine.

2:30 – 3:00 pm Refreshment Break
Level 3 • George R. Brown Convention Center
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

3:00 – 4:30 pm Oral Abstracts Session 2
(See page 77-79 for details.)
**Problem-based Learning**

**PBL – A Child With Asthma and Food Allergy That Needs Proper Coding: Codeman and Doctor Document Strike Again**

*Moderator: Don A. Bukstein, MD, FACAAI*

Following a real-time assessment of the audience discussion of the PBL case, Dr. Meadows, Dr. Gross and the audience will interactively discuss proper coding and documentation for the patient.

**Track:** Practice Management/Professional Issues

3:00 pm  
**Welcome and Introductions**  
Don A. Bukstein, MD, FACAAI

**Post-PBL Interactive Discussion**  
Gary N. Gross, MD, FACAAI, and J. Allen Meadows, MD, FACAAI

4:30 pm  
**Adjourn**

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Interactively discuss a real case of an asthmatic patient that is being considered and then placed on SLIT versus SCIT-AIT.
- Discuss how to offer and use coding options in context of what is important to document in order to justify reimbursements.
- Interactively investigate different coding and documentation strategies.

---

**Telemedicine for the Allergist**

*Moderators: Jay M. Portnoy, MD, FACAAI, and Justin C. Greiwe, MD, FACAAI*

The technology involved in telemedicine, direct-to-consumer platforms and case examples of actual technology will be discussed and reviewed. This expert presentation will spark your interest in exploring the future of telemedicine.

**Track:** Practice Management/Professional Issues

3:00 pm  
**Welcome and Introductions**  
Jay M. Portnoy, MD, FACAAI, and Justin C. Greiwe, MD, FACAAI

3:05 pm  
**How to Get Started in Telemedicine**  
Jay M. Portnoy, MD, FACAAI

3:25 pm  
**Direct-to-consumer Telemedicine**  
Tania Elliott, MD, FACAAI

3:45 pm  
**Facilitated Telemedicine as Virtual Visits**  
Jennifer Shih, MD

4:05 pm  
**The Future of Telemedicine for Allergy**  
David M. Lang, MD, FACAAI

4:20 pm  
**Questions and Discussion**

4:30 pm  
**Adjourn**

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Set up a telemedicine service in an allergy practice.
- Use a direct-to-consumer platform to see allergy patients.
- See allergy patients using telemedicine.
- Change the way patients are seen using telemedicine.
Sunday General Sessions

Sunday General Sessions

3:00 – 4:30 pm • Room 360 • George R. Brown Convention Center

Symposium

How to Implement a Penicillin Allergy Program in Your Community

Moderators: David R. Stukus, MD, FACAAI, and Allison Ramsey, MD, FACAAI

It has been well established that 10% of the general population reports having a penicillin allergy, but 90% of those individuals are not truly allergic. Allergists can be exceptionally useful in the education surrounding penicillin allergy and assessment through skin testing and oral challenges. This symposium will discuss how allergists can serve as experts and advocates in their community, regardless of their practice setting, in the communication and development of a penicillin allergy reconciliation program.

Track: Population Health and Infectious Diseases / International Travel

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 pm</td>
<td>Welcome and Introductions</td>
<td>David R. Stukus, MD, FACAAI, and Allison Ramsey, MD, FACAAI</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>How to Effectively Educate Patients, the General Public, and Our Colleagues About Penicillin Allergy</td>
<td>David R. Stukus, MD, FACAAI</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Utilization of Algorithms to Assess Patients Across the Spectrum, From Inpatient Hospitalization to the Outpatient Setting</td>
<td>Kimberly G. Blumenthal, MD, MSc</td>
</tr>
<tr>
<td>3:55 pm</td>
<td>We Need to Own This: The Role of the Allergist</td>
<td>David A. Khan, MD, FACAAI</td>
</tr>
<tr>
<td>4:20 pm</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

Learning Objectives

Upon completion of this session, participants should be able to:
- Develop talking points to help primary care physicians and patients better understand penicillin allergy.
- Utilize established resources to work with local hospitals in the development of penicillin allergy reconciliation programs.
- Utilize non-allergist health care professionals in the assessment of patient-reported penicillin allergy.
3:00 pm Welcome and Introductions
Michael Pistiner, MD, MMSc, FACAAI

3:00 pm Clemens von Pirquet Award – First Place
A301 – Understanding the Psychosocial Impact of Food Protein-induced Enterocolitis Syndrome (FPIES)
Michelle C. Maciag, MD

3:15 pm A302 – Utilization of Quality Improvement Methodology to Facilitate Early Peanut Introduction for At-risk Infants
Monica T. Kraft, MD

3:30 pm A303 – Review of 122 Consecutive Oral Food Challenges to Walnut
Mary G. Baker, MD

3:45 pm A304 – Food Allergy Resolution and Subsequent Introduction Among Black and White Children in the FORWARD Study
Adam Robinson, BS

4:00 pm A305 – Differences in Food Allergy Knowledge Between Black and White Parents in the FORWARD Study
Jialing Jiang, BA

4:15 pm A306 – Maternal Diet Diversity During Pregnancy and Eczema and Food Allergy in Offspring: Healthy Start Study
Carina Venter, PhD, RD

4:30 pm Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to:
• Discuss the degree of stress and worry and reduced quality of life among families affected by FPIES and identify sources of significant burden to better advocate for affected patients and their families.
• Apply QI methodology to assist implementation of early peanut introduction guidelines in the clinic setting.
• Identify variables associated with walnut oral food challenge outcome.
• Discuss prevalence of food allergy resolution, subsequent food introduction and potential barriers.
• Describe differences in food allergy knowledge between black and white parents of children with food allergy and identify topics of future educational efforts.
• Describe the role of the maternal diet in the development of infant eczema and/or food allergy.
3:00 pm Welcome and Introductions
Myron Zitt, MD, FACAAI, and Jared Darveaux, MD

3:00 pm A203 – Visual Recognition of Asthma Medications in Inner City Asthma Children and Caregivers
Mansi Kothari, MD, MBBS

3:15 pm A204 – Stay On Therapy! Monoclonal Antibody Treatment Does Not Impact Methacholine Challenge Test Results
Maritza Rivera-Valenzuela

3:30 pm A205 – Sex Dimorphism in the Gene Expression of Airway Epithelial Cells From Asthmatics
Sergio E. Chiarella, MD

3:45 pm A206 – BMI Trajectory In Childhood Is Associated With Asthma at Young Adulthood Mediated by DNA Methylation
Rutu Patel, MPH, MBBS

4:00 pm A207 – Assessing Knowledge of Asthma Management Among Internal Medicine Residents
Abigail Finley, MD, MPH

4:15 pm A208 – Association Between Patients’ Perception of Their Asthma Control and the Symptomatic Burden of Asthma
Mark P. Small, BSc

4:30 pm Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to:
• Identify that the standard written asthma action plan may not be an adequate tool to sustain adherence to asthma medications and improve asthma outcome in inner-city populations.
• Discuss the impact of biologic therapy on metacholine challenge test in patients with severe asthma and identify clinical improvement despite having a positive methacholine challenge test in follow-up visits.
• Discuss the sex dimorphism present in asthma airway epithelial cell biology.
• Identify the CpGs (and its gene) that mediate the association of BMI trajectories in childhood with asthma at young adulthood and hence direct preventive efforts accordingly.
• Have a greater understanding of the level of knowledge among internal medicine residents regarding the diagnosis and management of asthma and understand how improved education in these areas in an internal medicine residency could translate into improved level of care provided to patients in resident primary care clinics.
• Ask their asthma patients about multiple components of their patients’ symptoms and impact to make better informed decisions in the management of their patient’s disease.
Sunday Oral Abstracts: Session 2

3:00 – 4:30 pm • Room 361ABC • George R. Brown Convention Center

Session 2C
Other, Rhinitis, Other Upper Airway Disorders, Skin Disorders

Moderators: Mark Davis-Lorton, MD, FACAAI, and Brittanie Neaves, MD

3:00 pm
Welcome and Introductions
Mark Davis-Lorton, MD, FACAAI, and Brittanie Neaves, MD

3:00 pm
Clemens von Pirquet Award – Second Place
A352 – Is It Time to Rethink the Allergy Training Requirements for Pediatric Residents?
Peter Capucilli, MD

3:15 pm
A353 – Geographical Distribution of Allergy/Immunology Providers in the United States Is Influenced by Median Income
Di Sun, MD, MPH

3:30 pm
A354 – Healthcare Utilization in Relation to Sensitization Against HDM Pre/post a Housing Intervention in Malmö, Sweden
Jens C. Richter

3:45 pm
A355 – Impact of the Penicillin Allergy Label on Time to First Antibiotic Dose in Septic Patients
David Frankel, MD

4:00 pm
A450 – Increased Platelet and Eosinophil Numbers Are Associated With Alcohol Hypersensitivity in Chronic Rhinosinusitis
Margaret Kim, MD

4:15 pm
A500 – Association Between Maternal Diet Diversity and Infant Microbial Abundance: IOW 3rd Generation Cohort
Syed H. Arshad, MBBS, DM

4:30 pm
Adjourn

Learning Objectives:
Upon completion of this session, participants should be able to:
• Discuss the potential feasibility of establishing required allergy/immunology training for pediatric residents.
• Understand the unequal geographical distribution of allergy/immunology providers in the United States and the influence of median income on distribution.
• Reflect on the social determinants of health that may be of relevance in their daily practice, such as paying attention to their patients’ housing conditions.
• Identify the differences in outcomes between septic patients with a penicillin allergy versus those without a penicillin allergy.
• Identify the innate immune cells associated with alcohol hypersensitivity in patients with chronic rhinosinusitis.
• Understand how maternal diet diversity may affect infant microbial diversity.
Sunday General Sessions

4:45 – 5:30 pm • Grand Ballroom (Level 3) • George R. Brown Convention Center

Town Hall Meeting Hosted by ACAAI House of Delegates

Beer, wine and cheese reception. All meeting attendees welcome!

4:45 pm Welcome and Introductions
Travis Miller, MD, FACAAI
Speaker of the ACAAI House of Delegates

4:50 pm Medicare for All
Susan Rudd Bailey, MD, FACAAI
Speaker of the AMA House of Delegates

5:05 pm Health Care Disparities
Bill Finerfrock, President
Capitol Associates, Inc.

5:20 pm Questions and Discussion

5:30 pm ACAAI Annual Business Meeting Commences

ACAAI Annual Business Meeting

5:30 – 6:30 pm • Grand Ballroom (Level 3) • George R. Brown Convention Center

The College invites all members to attend the annual business meeting.

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Call to Order and Approval of 2018 Minutes & Standing Rules, State of the College
Todd A. Mahr, MD, FACAAI, President

Historian’s Report
Joseph A. Bellanti, MD, FACAAI, Historian

Presentation of New Fellows, Distinguished and International Distinguished Fellows, Distinguished Service, Woman in Allergy, Special Recognition and EMD Awards
Todd A. Mahr, MD, FACAAI

Foundation Report and Young Faculty Support Awards
Richard W. Weber, MD, FACAAI, Foundation President

Alliance Report and Clemens von Pirquet Awards
Mrs. Patricia Wedner, Alliance President

Bylaws Committee Report
Gregory W. Bensch, MD, FACAAI, Bylaws Committee Chair

Recognition of Outgoing Regents
Todd A. Mahr, MD, FACAAI

Nominating Council Report and Election of Officers
Bryan L. Martin, DO, FACAAI, Nominating Council Chair

Installation of New President and President’s Acceptance
Todd A. Mahr, MD, FACAAI and J. Allen Meadows, MD, FACAAI, President 2019-2020

Presentation to Outgoing President and New Business
J. Allen Meadows, MD, FACAAI

7:00 – 9:00 pm
Non-CME Corporate Forum
(See page 96 for details.)
Allergists Can Offer More Than Just Skin Testing

Moderator: Luz S. Fonacier, MD, FACAAI

Allergists are well trained in the diagnosis and medical management of various allergic conditions. However, allergists can also play a central role in addressing other important aspects of these conditions that patients face in their daily lives. Allergists can lead the charge in educating other medical professionals and promoting quality care while also generating interest in our specialty among the next generation of physicians.

**Track:** Practice Management/Professional Issues

**8:00 am** Welcome and Introductions
Luz S. Fonacier, MD, FACAAI

**8:05 am** Bernard Berman Memorial Lecture
Hot Topics: FDA
Bryan L. Martin, DO, FACAAI

**8:25 am** Psychosocial Issues of Allergy
Hermant Sharma, MD

**8:45 am** Bela Schick Lecture
Something Special, Is It the Specialty or the Practitioner?
Michael R. Nelson, MD, PhD, FACAAI

**9:05 am** Delivering Quality Care Is Not Cost-prohibitive
J. Allen Meadows, MD, FACAAI

**9:30 am** Adjourn

**Learning Objectives**
Upon completion of this session, participants should be able to:
- Understand how the FDA approval process determines availability of treatment options.
- Address psychosocial aspects of living with allergic conditions with patients during clinical encounters.
- Maintain relevance within our specialty through proactive approaches to patient care and education.
- Focus on quality measures to help guide optimal patient care.

**9:30 – 9:45 am**
Refreshment Break
Grand Ballroom Foyer (Level 3)
George R. Brown Convention Center

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
**Monday General Sessions**

**9:45 am – 12:30 pm • Grand Ballroom (Level 3) • George R. Brown Convention Center**

**CAP (Continuous Assessment Program) Review**

*Moderator: Lisa J. Kobynski, MD, MPH, FACAAI*

The CAP Review is a literature-style review covering most of the articles chosen by the ABAI for the current six-month cycle of the Continuous Assessment Program (CAP). Each presenter will focus on key aspects of the study design, results and implications for practice. The goal of this session is to help prepare attendees for the second cycle of ABAI CAP program.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 am</td>
<td>Welcome and Introductions</td>
<td>Lisa J. Kobynski, MD, MPH, FACAAI</td>
</tr>
<tr>
<td>9:50 am</td>
<td>Anaphylaxis</td>
<td>Anne K. Ellis, MD, MSc, FACAAI</td>
</tr>
<tr>
<td>10:15 am</td>
<td>Immune Hypersensitivity / Immunodeficiencies</td>
<td>Nikita Raje, MD</td>
</tr>
<tr>
<td>10:40 am</td>
<td>Immunodeficiencies</td>
<td>Lisa J. Kobynski, MD, MPH, FACAAI</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Refreshment Break</td>
<td></td>
</tr>
<tr>
<td>11:15 am</td>
<td>Lung Disorders / Food and Drug Allergy / Hypersensitivity Reactions</td>
<td>Brian T. Kelly, MD</td>
</tr>
<tr>
<td>11:40 am</td>
<td>Food and Drug Allergy / Eosinophilic Disorders / EOE</td>
<td>Gerald Lee, MD, MPH, FACAAI</td>
</tr>
<tr>
<td>12:05 pm</td>
<td>Dermatology / Head and Neck</td>
<td>Kelly M. Maples, MD, FACAAI</td>
</tr>
<tr>
<td>12:25 pm</td>
<td>Head and Neck</td>
<td>Lisa J. Kobynski, MD, MPH, FACAAI</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:
- Identify key concepts from recently published research pertaining to allergic conditions.
- Utilize the ABAI continuous assessment program in the maintenance of certification process.

---

**9:45 – 11:00 am • Room 370 • George R. Brown Convention Center**

**Symposium**

**MOC/CME**

**Climate Change and Natural Disasters: The Central Role of Allergists**

*Moderators: William K. Dolen, MD, FACAAI, and Meagan W. Shepherd, MD, FACAAI*

Our changing climate has impacted not only our temperatures, but the onset and duration of pollen season as well. It is important for allergists to understand the impact that climate change is having on our patients and to anticipate changes to how we provide care. Natural disasters create many challenges and are extremely disruptive to people’s lives. An often-neglected aspect of natural disasters includes the impact that flooding, fires and severe weather can have on the health of people with asthma and allergic conditions. Allergists who care for patients in natural disaster-prone areas can help them prepare for when those disasters strike.

**Track: Population Health and Infectious Diseases/International Travel**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 am</td>
<td>Welcome and Introductions</td>
<td>William K. Dolen, MD, FACAAI, and Meagan W. Shepherd, MD, FACAAI</td>
</tr>
<tr>
<td>9:50 am</td>
<td>Climate Change and the Impact on Allergic Conditions</td>
<td>David B. Peden, MD, FACAAI</td>
</tr>
<tr>
<td>10:10 am</td>
<td>When Disaster Strikes: The Health Impacts of Hurricanes, Floods and Fires</td>
<td>Nicholas Rider, DO</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Be Aware and Prepare: How Allergists Can Help Patients Before Their Time of Need</td>
<td>Maya Gharfeh, MD, MPH</td>
</tr>
<tr>
<td>10:50 am</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00 am</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:
- Discuss possible roles for allergists in addressing air quality disasters.
- Anticipate medication challenges facing patients during poor air quality.
- Be able to work with public health to develop health care plans for at-risk populations.
Monday General Sessions

**Interdisciplinary Panel Session**

**Urticaria: Are You Itching to Learn More?**

*Moderators: Sandra M. Gawchik, DO, FACAAI, and Jonathan S. Tam, MD, FACAAI*

This session will update the participant on the current state-of-the-art regarding spontaneous urticaria and physical or inducible urticarias. A comprehensive overview of the pathophysiology, differential diagnosis and treatment strategies will be discussed. The participant will gain an understanding of the various treatment guidelines referred to in the U.S. and Europe. At the end of this session, the participant will have an understanding of the approach to diagnosis and treatment of patients with spontaneous and inducible urticarias.

**Track:** Dermatology

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 am</td>
<td>Welcome and Introductions</td>
<td>Sandra M. Gawchik, DO, FACAAI, and Jonathan S. Tam, MD, FACAAI</td>
</tr>
<tr>
<td>9:50 am</td>
<td>What's New with Spontaneous Urticaria</td>
<td>David R. Weldon, MD, FACAAI</td>
</tr>
<tr>
<td>10:10 am</td>
<td>Chronic Inducible Urticaria</td>
<td>Marcus Maurer, MD</td>
</tr>
<tr>
<td>10:30 am</td>
<td>When Antihistamines/Omalizumab Are Not Enough</td>
<td>Allen Kaplan, MD, FACAAI</td>
</tr>
<tr>
<td>10:50 am</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00 am</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

**Learning Objectives**

Upon completion of this session, participants should be able to:
- Define the criteria for chronic and inducible urticaria. Formulate an appropriate diagnostic workup for symptoms suggestive of CIU and inducible urticaria.
- Recognize the various patterns of urticaria and their therapeutic implications, taking into account the potential differential diagnosis.
- Identify components of step-wise management of urticaria following national and international guidelines. Be able to discuss various treatment options, including approved biologic therapy, along with risks versus benefits and taking into account patient quality-of-life issues.

**11:00 – 11:15 am**

**Refreshment Break**

Level 3 • George R. Brown Convention Center

*Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.*
Monday General Sessions

11:15 am – 12:30 pm • Room 360 • George R. Brown Convention Center
Clinical Conundrum
Managing the Patient With Recurrent Infections
Moderators: Mary Beth Fasano, MD, MSPH, FACAAI, and S. Shahzad Mustafa, MD, FACAAI

Track: Clinical Immunology and Autoimmune and Biologicals

11:15 am Welcome and Introductions
Mary Beth Fasano, MD, MSPH, FACAAI, and S. Shahzad Mustafa, MD, FACAAI

11:20 am Considerations in Long-term Management of Children With PIDD
Mark M. Ballow, MD, FACAAI

11:40 am Considerations in Management of Adult-onset PIDD
Nicholas Rider, DO

Noon Adults With Hypogammaglobulinemia: Cytopenias and Malignancy
Thomas A. Fleischer, MD, FACAAI

12:20 pm Questions and Discussion
12:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Identify factors that affect long-term outcomes in children with PIDD.
• Identify factors that affect long-term outcomes in adults with PIDD.
• Identify and manage two frequent comorbidities: autoimmune cytopenias and malignancies.

11:15 am – 12:30 pm • Room 370 • George R. Brown Convention Center
Symposium MOC/CME
New Horizons in Chronic Rhinosinusitis
Moderators: Alan B. Goldsobel, MD, FACAAI, and Puneet Shroff, MD, FACAAI

This session will provide a foundation for exploring newer medical, surgical and biologic therapies for chronic rhinosinusitis (CRS) with and without nasal polyps. Etiology, diagnosis and management will be reviewed.

Track: Rhinitis/Sinusitis/Ocular and Anaphylaxis

11:15 am Welcome and Introductions
Alan B. Goldsobel, MD, FACAAI, and Puneet Shroff, MD, FACAAI

11:20 am New Understanding in the Etiology and Pathogenesis of Chronic Rhinosinusitis
Jonathan A. Bernstein, MD, FACAAI

11:40 am What’s New in Medical and Surgical Management of CRS
Joseph Han, MD

Noon The Coming Revolution of Biologics in CRS
Anju T. Peters, MD

12:20 pm Questions and Discussion
12:30 pm Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:
• Recognize CRS as a clinical issue and develop an improved knowledge of the etiology and pathogenesis.
• Be able to develop a management plan for a patient with CRS based on new medical and surgical management options.
• Appreciate the involvement of Type 2 inflammation in CRS and the role biologics may play in management.

12:30 pm 2019 Annual Scientific Meeting Adjourns
Fellows-in-Training Program

All Fellows-in-Training are encouraged to participate in the following special activities designed to meet their unique needs and interests. Friday’s FIT Business Meeting includes the presentations and election of the 2019 – 2020 Junior Fellow-in-Training representative to the Board of Regents. All the activities shown on this page, as well as all general sessions, are complimentary.

### Friday

**FIT Integrated Educational Program & Business Meeting**  
ARS  
4:30 – 6:00 pm  
Room 350DEF • George R. Brown Convention Center  
Moderators: Christin L. Deal, MD, and Miriam Samstein, MD, PhD  
*Business meeting supported by Circassia*

During the educational program, speakers will discuss anaphylaxis and primary immune deficiency. Knowledge about these diseases is ever-expanding and fellows are infrequently lectured on these subjects. Allergist/immunologists-in-training will benefit from understanding these disorders, both for their board exams and for their future practices.

**Learning Objectives**

Upon completion of this session, participants should be able to:

- Interpret the data behind anaphylaxis management.
- Understand importance of epinephrine use in anaphylaxis.
- Understand the impact of A/I deep learning on detection and decision-making in primary immunodeficiency.

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 4:30 pm | Welcome and Introductions  
Christin L. Deal, MD, and Miriam Samstein, MD, PhD |
| 4:35 pm | Junior FIT Representative Candidate Speeches |
| 4:50 pm | Early Administration of Epinephrine in Anaphylaxis - What’s the Data?  
Jay A. Lieberman, MD, FACAAAI |
| 5:15 pm | Questions and Discussion |
| 5:20 pm | AI/Deep Learning for Disease Detection and Decision-making in Primary Immunodeficiency  
Nicholas Rider, DO |
| 5:45 pm | Questions and Discussion |
| 5:50 pm | Announcement of 2019 – 2020 Junior FIT Representative |
| 5:55 pm | Closing Remarks |
| 6:00 pm | Adjourn |

**Friday (continued)**

**President’s Welcome Reception**  
6:00 – 7:30 pm  
Minute Maid Park  
*Supported by Aimmune Therapeutics*  
See page 47 for more details.

**Saturday**

**Fellows-in-Training and Allergy/Immunology Program Directors’ Breakfast**  
6:15 – 7:15 am  
Ballroom of the Americas Salons AB (Level 2)  
Hilton Americas-Houston Hotel  
*Supported by ALK Inc.*

**Doctors’ Job Fair**  
11:30 am – 3:00 pm  
Halls A3 & B3 (Level 3)  
George R. Brown Convention Center

**28th Annual FIT Bowl Competition**  
5:30 – 7:30 pm  
Houston Ballroom (Level 2)  
Marriott Marquis Houston Hotel  
*Supported by DBV Technologies*

**Sunday**

**Fellows-in-Training and Allergy/Immunology Program Directors’ Luncheon**  
11:30 am – 1:00 pm  
Ballroom of the Americas Salon E (Level 2)  
Hilton Americas-Houston Hotel  
*Supported by Stallergenes Greer*
Fellows-in-Training Awards and Scholarships

Clemens von Pirquet Awards

First Place – Alliance Memorial Award
Michelle Maciag, MD
Boston Children’s Hospital, Boston, MA

Second Place
Peter Capucilli, MD
The Children’s Hospital of Philadelphia, Philadelphia, PA

Third Place
Brittanie Neaves, MD
Wilford Hall Ambulatory Surgical Center, San Antonio, TX

Travel Scholarships

The College awarded travel scholarships to 225 Fellows-in-Training to attend the 2019 Annual Scientific Meeting.

ACAAI Thanks Its Travel Scholarship Sponsors

The Fellows-in-Training section of the College expresses its appreciation to the following companies that sponsored Fellows-in-Training Travel Scholarships this year:

Genentech
HollisterStier Allergy
Pharming Group NV
Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Friday Office Administrators Practice Management Course

8:00 am – 4:30 pm • Room 371ABDE • George R. Brown Convention Center

Separate Registration Fee • Admission by Ticket Only

Moderator: Kay Tyler, MBA

Target Audience: Office practice administrators/managers, nurse managers and other clinical staff responsible for practice management activities, new and established allergist-immunologists in private practice, employed allergists and FITs.

Track: Practice Management/Professional Issues

8:00 am Welcome and Introductions
Kay Tyler, MBA

8:05 am Everything You Want to Know About Coding for Allergy but Are Afraid to Ask
Gary N. Gross, MD, FACAAI
This session will address how to code for allergy-specific visits and services. Topics will include 95165, rush/cluster/rapid desensitization, coding for biologics (does buy and bill work?), food challenges, SLIT, venom immunotherapy, telehealth and more.

9:10 am College Practice Management Resources to Help Your Practice Thrive
Jennifer Pfeifer, MBA, CMPE
This session will review the practice management resources available through the College, including toolkits, online educational modules, archived webinars. This session will showcase new and updated College resources related to biologics, telehealth, coding, prior authorizations, shared decision-making, collections, practice profitability and more.

9:30 am Refreshment Break

Breakout Sessions: 10:00 – 11:30 am

10:00 – 10:45 am
Biologics: A Look at the Risks, Rewards and Service
Room 371C • George R. Brown Convention Center
Jennifer Kuehn, CPC
A look at how biologics can work in small, medium and large practice settings.

Use of Technology in Revenue Cycle Management
Room 371F • George R. Brown Convention Center
Charlie Furr
Attendees will learn how current technologies and workflow techniques can be used to streamline the practice revenue cycle. Hear how a thriving Asthma & Allergy Center used these applications to increase revenue and decrease days in accounts receivable.

USP 797: What the New Rule Means for Your Practice
Room 371ABDE • George R. Brown Convention Center
Kay Tyler, MBA
The new USP Chapter 797 standards on sterile compounding were released in June. Find out what your practice needs to do to be compliant with regards to allergen extract mixing. We’ll review the specific requirements for personnel qualifications, facilities and documentation. You’ll leave with all the information you need to ensure your practice is compliant with the new rules.

10:45 – 11:30 am
Biologics: A Look at the Risks, Rewards and Service
Room 371C • George R. Brown Convention Center
Jennifer Kuehn, CPC
A look at how biologics can work in small, medium and large practice settings.

Use of Technology in Revenue Cycle Management
Room 371F • George R. Brown Convention Center
Charlie Furr
Attendees will learn how current technologies and workflow techniques can be used to streamline the practice revenue cycle. Hear how a thriving Asthma & Allergy Center used these applications to increase revenue and decrease days in accounts receivable.

USP 797: What the New Rule Means for Your Practice
Room 371ABDE • George R. Brown Convention Center
Kay Tyler, MBA
The new USP Chapter 797 standards on sterile compounding were released in June. Find out what your practice needs to do to be compliant with regards to allergen extract mixing. We’ll review the specific requirements for personnel qualifications, facilities and documentation. You’ll leave with all the information you need to ensure your practice is compliant with the new rules.

Continues next page
11:30 am  Lunch Break (on own)
1:00 pm  Government and Regulatory Update
Bill Finerfrock
This session will provide an update on regulatory changes as they apply to allergy and immunology practices and discuss the new USP 797 regulations and requirements, as well as upcoming changes to the physician fee schedule, MIPS, etc.

Breakout Sessions: 1:45 – 3:45 pm

1:45 – 2:30 pm  But This Is How We’ve Always Done It!
Room 371ABDE • George R. Brown Convention Center
Scott Dennis, MHA
Attendees will learn how to tackle culturally-entrenched processes that need updating and will be introduced to demonstrated tools that help with new process implementation such as Lean Methodology. We will provide examples for communicating why the process changes are being made to your clinic coworkers, who do not always welcome changes to their daily routines.

HR: Investing in the Happy Factor
Room 371C • George R. Brown Convention Center
Lauren Sloan, MHA, RN
Employee satisfaction and happiness assumes a larger role in retaining excellent staff than ever before. The practice of hiring and keeping key employees has drastically changed. This session will offer insights into new recruitment strategies and employee benefits that will keep your staff from moving on.

Why Patient Experience and Patient Engagement Is Crucial to the Success of Your Practice
Room 371F • George R. Brown Convention Center
Brittany Slowey, MHA, and Robert Jehling, MBA
This presentation will focus on what patient experience is and what it is not. This will identify important objectives and why they are so important for any health care organization to succeed in an ever-changing market. The role patient experience plays in increasing reimbursement rates will also be discussed. Patient engagement should not be frowned upon. Instead, patient engagement offers a practice the opportunity to test what they hope to discover, verify what they already know and reveal new insights to help them improve. We will also discuss cost-effective opportunities for process improvements that will create a positive patient experience, thus creating increased revenue for the practice.

2:30 – 3:00 pm  Refreshment Break / Visit Exhibits and E-posters
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

3:00 – 3:45 pm  But This Is How We’ve Always Done It!
Room 371ABDE • George R. Brown Convention Center
Scott Dennis, MHA
Attendees will learn how to tackle culturally-entrenched processes that need updating and will be introduced to demonstrated tools that help with new process implementation such as Lean Methodology. We will provide examples for communicating why the process changes are being made to your clinic coworkers, who do not always welcome changes to their daily routines.

HR: Investing in the Happy Factor
Room 371C • George R. Brown Convention Center
Lauren Sloan, MHA, RN
Employee satisfaction and happiness assumes a larger role in retaining excellent staff than ever before. The practice of hiring and keeping key employees has drastically changed. This session will offer insights into new recruitment strategies and employee benefits that will keep your staff from moving on.

Why Patient Experience and Patient Engagement Is Crucial to the Success of Your Practice
Room 371F • George R. Brown Convention Center
Brittany Slowey, MHA, and Robert Jehling, MBA
This presentation will focus on what patient experience is and what it is not. This will identify important objectives and why they are so important for any health care organization to succeed in an ever-changing market. The role patient experience plays in increasing reimbursement rates will also be discussed. Patient engagement should not be frowned upon. Instead, patient engagement offers a practice the opportunity to test what they hope to discover, verify what they already know and reveal new insights to help them improve. We will also discuss cost-effective opportunities for process improvements that will create a positive patient experience, thus creating increased revenue for the practice.

Continues next page
Leadership: The Essential Nuts and Bolts to Survive Practice Management
John Milewski
This presentation will review the basic foundation of key leadership qualities in today’s business world. It will provide key concepts from leaders in today’s marketplace (such as John Maxwell, Richard Ryerson, Zig Ziglar, Jim Collins and others). It will provide participants an understanding of these key concepts, and through integration, it will improve the operational strategies of their medical practice. In addition, it will provide participants the opportunity to understand their leadership style and explore how this understanding will allow them to improve their practice management careers.

4:30 pm  Adjourn

Learning Objectives
Upon completion of this session, participants should be able to:

- Maximize collections and reduce claim errors with the most up-to-date rules for billing and coding.
- Decide if biologics buy and bill can work in a small practice setting. Move forward with a plan to make buy and bill biologics work in a medium-to-large practice. Identify the risks of buy and bill and the rewards associated.
- Identify their customer. Be introduced to a different paradigm in customer service thinking. Articulate the difference in managing and leading a team.
- Identify strategies that use technology to improve insurance and patient collections.
- Explain how to implement the new USP 797 regulations in allergy practice. Summarize government regulations required by allergy practices.
- Identify process improvement opportunities and how to communicate the benefits of implementing new processes to the clinic.
- Identify what patient experience is. Explain why patient engagement is important to your revenue cycle. Describe cost-effective changes that can be made to help your practice succeed.
- Recognize factors that influence employee satisfaction and retention. Identify and assess candidates to make sure they are the best fit for your practice. Describe recruiting resources and strategies.
- Identify the foundation of leadership in order to build a good leadership team. Discuss the importance of the practice’s strategies and how culture can be lost if not in alignment. Discuss how leaders in practice management succeed in working with various physicians and multiple bosses.
Friday Advanced Practice Health Care Providers Course

8:00 am – 4:30 pm • Room 362ABDE • George R. Brown Convention Center
Separate Registration • Admission by Ticket Only
(You must be registered for the Annual Scientific Meeting to enroll in the Advanced Practice Health Care Providers Course.)
Moderator: Jodi Shroba, MSN, APRN, CPNP

Target Audience: Nurse practitioners, physician assistants, allergy/immunology nurses, other health care providers with extensive experience and physicians.
This education activity will be submitted to the California Board of Registered Nursing (CBRN) for approval of up to 6.0 contact hours of accredited education.

Track: Practice Management/Professional Issues

8:00 am – 4:30 pm
Moderator: Jodi Shroba, MSN, APRN, CPNP

8:00 am   Vocal Cord Dysfunction, the Great Asthma Imitator
Michelle Dickens, MSN, FNP-C, AE-C
Dyspnea on exertion is often diagnosed as asthma, especially in adolescents. However, vocal cord dysfunction can often mimic asthma. This session will explore the presentation, diagnosis and management of vocal cord dysfunction.

8:45 am   Personalized Medicine and Biologics for Severe Asthma
Bradley E. Chipps, MD, FACAAI
The field of biologics has greatly expanded over the past year. This session will review currently-approved biologics for asthma and atopic dermatitis, along with the ideal patient profiles for each therapy. We will also discuss new therapeutics in the pipeline.

9:05 am   When Your Patient Is a Vaccine-refuser
John M. Kelso, MD, FACAAI
There is a growing belief that vaccines are harmful and cause more harm than good. As more patients believe this false information, we have a generation of children who are unvaccinated. This presentation will discuss how vaccine refusal can affect your practice and how to have a conversation about vaccines with your patients.

9:25 am   Questions and Answers
9:30 am   Refreshment Break

10:00 am – 11:30 am
Moderator: Amanda L. Michaud, PA-C

10:00 am   Approaching Rashes
Sandy Skotnicki, MD
Rashes can be a challenging and time-consuming portion of practice. This session will utilize evidence-based guidelines and sequentially review history pearls, signs and symptoms, rash identification and tips for management. Individual cases will be presented and evaluated as a group, highlighting best practices.

10:45 am   When Your Patient Is a Green Consumer
Maureen George, PhD, RN, AE-C
A green consumer is a patient who is environmentally conscious, wanting to buy and use products that present the least harm to the natural environment. Although ozone-depleting substances such as chlorofluorocarbon propellants have been removed from metered dose inhalers (MDIs), new hydrofluoroalkane (HPAs) propellants still have a carbon footprint. In addition, disposable units are not recycled, contributing to landfill waste.

11:30 am   Lunch (on own)
(Continues next page)
Friday Advanced Practice Health Care Providers Course (continued)

8:00 am – 4:30 pm • George R. Brown Convention Center
Separate Registration • Admission by Ticket Only

Breakout Sessions: 1:00 – 4:30 pm

1:00 – 2:30 pm
**Shared Decision-making and Improved Adherence and Compliance**
Room 362ABDE • George R. Brown Convention Center
Cheryl K. Bernstein, RN, CCRC, and Maureen George, PhD, RN, AE-C
This program will focus on tools and educational methods that can be used to help promote shared decision-making for asthma and allergic diseases between health care professionals and patients. The College’s online shared decision-making tools will be used as examples.

**A Tough Nut to Crack: The Complexity of Tree Nut Allergy Management**
Room 362CF • George R. Brown Convention Center
Jodi Shroba, MSN, APRN, CPNP, and Maria Crain, CPNP, AE-C
This session will discuss diagnosis, testing and management of rhinitis. It will be presented as interactive problem-based learning cases.

2:30 – 3:00 pm
**Refreshment Break / Visit Exhibits and E-posters**
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

3:00 – 4:30 pm
**Management of the Coughing and Wheezing Infant and Toddler**
Room 362CF • George R. Brown Convention Center
Lila Kertz, MSN, RN, CPNP, AE-C, and Marciorose Winston, MSN, CPNP, AE-C
Managing intermittent coughing and wheezing is part of any pediatric practice. Maintaining knowledge of the current treatment recommendations is essential, including when to start daily medications. This session will review guidelines and current thoughts regarding management.

**PBL – Review of Common Immunodeficiency Diagnosis**
Room 362ABDE • George R. Brown Convention Center
Brenda L. Snyder, APRN, CPNP, and Nikita Raje, MD, FACAAI
This presentation will present case studies of common immunological disorders, from presentation to diagnosis and management.

4:30 pm
**Adjourn**

**Learning Objectives – Morning Session and Afternoon Breakout Sessions**
Upon completion of this session, participants should be able to:

- Explore common presentations of vocal cord dysfunction.
- Contextualize green choices as part of prescribing decisions to better align medical needs with patient preferences.
- Describe the function, utility and safety of current and emerging biologic therapies.
- Explain the use of testing, including component testing. Explain how oral challenges can be performed. Discuss home management of tree nut allergy.
- Design treatment compliance/adherence strategies to enhance shared patient/provider goals.
- Discuss current asthma guidelines for children under 5 years of age. Explain the use of non-asthma medications for treatment of children under 5 years of age.
- Formulate a plan for testing and diagnosis of immunological disorders. Explain management of immunological disorders.

4:45 – 6:00 pm
**Advanced Practice, Allied Health and Office Administrators Networking Reception**
Room 335AB • Hilton Americas-Houston Hotel
Supported by Aimmune Therapeutics
Saturday Allied Health Professionals Course

10:00 am – 4:30 pm • Room 371 • George R. Brown Convention Center
Separate Registration • Admission by Ticket Only
(You must be registered for the Annual Scientific Meeting to enroll in the Allied Health Professionals Course)
Moderator: Maureen George, PhD, RN, AE-C

Supported by an independent educational grant from Aimmune Therapeutics

Target Audience: Health professionals including, but not limited to, RNs, LPNs, MAs, PAs, NPs, MDs/DOs.

This education activity will be submitted to the California Board of Registered Nursing (CBRN) for approval of up to 9.0 contact hours of accredited education.

Track: Practice Management/Professional Issues

10:00 am  Angioedema: What to Do When It’s Not HAE
Kimberly Clay, RN, MSN, APRN, FNP-BC
Angioedema is a very challenging and complex condition that is seen in allergy offices. There are several possible causes for acute swelling, and it is not always easy to determine the etiology. This session will review the pathophysiology of angioedema, important history-taking questions, diagnostic work-up and management plan for those patients who have normal HAE lab studies.

10:05 am  How to Help Our Patients Get Their Medications and Other Tips to Improve Patient Access
This presentation will discuss the challenges that our patients may face when trying to obtain care, including transportation, finances, literacy and access to medication. This session will focus on how to assess these barriers and offer tools that may help to improve patient’s access to care and treatment.

10:45 am  Tips to Help Patients Obtain Medications
Tara Doran, RN, MHA

11:05 am  Tips to Assess and Help Patients with Psychosocial Challenges
Theresa Aldape

11:30 am – 1:00 pm
Allied Health Professionals Luncheon
Ballroom of the Americas Salon B (Level 2)
Hilton Americas-Houston Hotel
Supported by Aimmune Therapeutics
Managing the Whole Person, Not Just the Food Allergy
Room 371 • George R. Brown Convention Center
Food allergies have a significant impact on quality of life. It is important, as allied health providers, that we consider a holistic approach to patient care. Participants will be given practical, useful tips to help families manage daily activities including school, holiday parties and family events.

1:00 pm  Bullied for Having a Food Allergy and Coping Strategies to Help
Hermant Sharma, MD, MHS

1:45 pm  Engaging Schools in Best Practice to Keep Everyone Safe
Jodi Shroba, MSN, APRN, CPNP

Myth-busting in the Allergy Practice:
Separating Fact From Fiction
Room 362ABDE • George R. Brown Convention Center
Amanda L. Michaud, PA-C, and Abby L. Allen, RN, NP
This session will discuss common questions, misconceptions and urban myths encountered in the allergy practice. Topics include foods, medications, vaccines and other frequently-found myths regarding allergies.

The Use of Case Simulation for the Education of Allergy Emergencies – Spotlight on Anaphylaxis
Room 350DEF • George R. Brown Convention Center
(Limited to 25 attendees. Separate registration fee.)
Anne K. Ellis, MD, MSc, FACAAI; Marcella Aquino, MD, FACAAI; Aleena Banerji, MD, and Kimberly Blumenthal, MD, MSc
Studies have demonstrated that hands-on practice, offered by case simulations, is more effective than standard classroom instruction for emergency situational training. Simulations allow health care professionals to practice crisis management and teamwork skills to increase confidence in life-threatening emergencies, such as anaphylaxis.

In-office Challenges: The Good, The Bad and Anaphylaxis: Is Your Office Ready?
Room 371 • George R. Brown Convention Center
Anaphylaxis is a life-threatening reaction that can occur from ingestion of allergenic food or injection of immunotherapy. This medical emergency can occur in the office, and it is important that all office staff are prepared to treat. This session will provide case studies and review treatment.

3:00 pm  Anaphylaxis Case Studies
Jay A. Lieberman, MD, FACAAI

3:45 pm  Conducting Oral Food Challenges – Preparing Your Office and Staff
Maria Crain, CPNP, AE-C

Strategies for Getting the Most From Spirometry
Room 362ABDE • George R. Brown Convention Center
This activity is supported by Micro Direct, Inc. through an independent educational grant consisting of disposable supplies.
This session will combine the popular spirometry workshop with this year’s focus on advancing your skills to improve patient’s performance of spirometry. There will be a hands-on opportunity to practice with spirometry machines. The second portion of this presentation will discuss other types of tests that may be performed to answer the clinical question.

3:00 pm  Challenge Accepted! Choosing the Right Bronchoprovocation Testing
Michelle Dickens, MSN, FNP-C, AE-C

3:45 pm  Three Critical Skills for Better Spirometry
Helen Murphy, RRT, AE-C

2:30 - 3:00 pm
Refreshment Break / Visit Exhibits and E-posters
Halls A3 & B3 (Level 3)
George R. Brown Convention Center
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Sunday Allied Health Professionals Course

10:00 am – 4:30 pm • Room 371 • George R. Brown Convention Center
Separate Registration • Admission by Ticket Only
(You must be registered for the Annual Scientific Meeting to enroll in the Allied Health Professionals Course)
Moderator: Helen M. Murphy, RRT, AE-C
Supported by an independent educational grant from Aimmune Therapeutics

Target Audience: Health professionals including, but not limited to, RNs, LPNs, MAs, PAs, NPs, MDs/DOs.
This education activity will be submitted to the California Board of Registered Nursing (CBRN) for approval of up to 9.0 contact hours of accredited education.

10:00 am A New Horizon in the Management of Atopic Dermatitis
Mark Boguniewicz, MD, FACAAI
Atopic dermatitis is a chronic skin condition that has been difficult to treat. New targeted therapies have been released in the last few years and more products are in the pipeline. This session will discuss management of atopic dermatitis with new therapies available and will discuss what is currently in research.

10:45 am Accelerated Immunotherapy and an Update on USP 797 Compounding
Cheryl Bernstein, BSN, RN, CCRC
This program will provide an update to the FDA and USP 797 compounding requirements and the implications for extract preparation in the allergy office. Problem solving and a practical approach will be included to assist the participants to organize, plan and document office USP 797 compounding compliance. This program will review administration of standard allergen immunotherapy and provide information and guidelines for cluster/rush IT.

11:30 am Lunch Break (on own)

1:00 pm When IgE Is Not to Blame: Non-IgE-mediated Food Reactions and Nutritional Management
Raquel Durban, MS, RD, CSP, LDN, and Abby L. Allen, RN, NP
This presentation will focus on the new guidelines regarding the diagnosis and management of EoE. It will also discuss other non-IgE-mediated food disorders.

2:30 pm Refreshment Break

3:00 pm Up in Smoke: The Use of Marijuana and E-cigs in Patients With Allergic Disease and Asthma
David R. Naimi, DO, and Rohit K. Katial, MD, FACAAI
This presentation will discuss the ever-growing use of e-cigarettes and marijuana and the possible effects it can have on our patients with atopic disease. It will also discuss the potential for development of allergic reactions to these products.

The Use of Marijuana and Its Potential Effects
David R. Naimi, DO

The Use of E-cigarettes and Its Potential Effects
Rohit K. Katial, MD, FACAAI

4:30 pm Adjourn
Non-CME Corporate Forums

Following the close of Thursday, Friday, Saturday and Sunday’s scientific session, all registrants are invited to attend the special Corporate Forums at the Hilton Americas-Houston and the Marriott Marquis Houston Hotels. Corporate Forums are non-CME promotional symposia organized by industry and designed to enhance your learning experience.

Thursday, Nov. 7

6:30 – 8:30 pm
Ballroom of the Americas Salons DE
Hilton Americas-Houston Hotel
Using Shared Decision Making to Discuss Treatment Options and Identify Appropriate Patients for Oral Immunotherapy, and a Review on Practical Implementation Experience
Supported by Aimmune Therapeutics

Presented by:
Jiho Kim, MD
Jennifer Jobrack, Principal, The Food Allergy Pros, LLC
Douglas T. Johnston, DO
Bruce Joshua Lanser, MD

Increasing awareness of the challenges of living with food allergies by walking through a patient journey is key in understanding the patient and caregiver’s perspective. Shared decision making is a discussion tool that can be leveraged to help identify appropriate patients for peanut oral immunotherapy and to make treatment decisions that best align with what is most important to patients/caregivers; including the patient’s/caregiver’s willingness, support-system, goals, values, and perspective. In addition, our faculty will close with sharing practical experiences in implementing oral immunotherapy.

Also, visit Aimmune Therapeutics at Booth #619.

Friday, Nov. 8

8:00 – 10:00 pm
Ballroom of the Americas Salons DE
Hilton Americas-Houston Hotel
A VR View: Severe Uncontrolled Asthma: Phenotypes, Endotypes, and Treatment Response Decisions
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Presented by:
Michael Wechsler, MD

Please join us on November 8 at 8:15pm as Michael Wechsler, MD of National Jewish Health in Denver presents a Non-CME program titled, A VR View: Severe Uncontrolled Asthma: Phenotypes, Endotypes, and Treatment Response Decisions. This program will include VR animations and will be of interest to any clinician who manages moderate-to-severe asthma.

Also, visit Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. at Booth #313.

6:30 – 8:30 pm
Houston Ballroom Salons I-II
Marriott Marquis Houston Hotel
A Presentation Sponsored by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Presented by:
Don Bukstein, MD
Moises Calderon-Zapata, MD
Brian Stone, MD
Tonya Winters

ALK-Abelló, Inc. will host a dessert reception, which includes 4 mini-presentations that illustrate today’s AIT candidate, monotherapy for polysensitized patients, real-world experience of SLIT-tablets, and expanding AIT in your practice to more patients.

$25 donations will be made to the “Fellows-in-Training Travel Scholarship Fund through the American College of Allergy, Asthma & Immunology’s Foundation” and “Allergy & Asthma Network” for each participant attending all 4 mini-presentations.

Also, visit ALK Inc. at Booth #513.
Non-CME Corporate Forums

Following the close of Thursday, Friday, Saturday and Sunday’s scientific session, all registrants are invited to attend the special Corporate Forums at the Hilton Americas-Houston and the Marriott Marquis Houston Hotels. Corporate Forums are non-CME promotional symposia organized by industry and designed to enhance your learning experience.

Saturday, Nov. 9

8:00 – 10:00 pm
Ballroom of the Americas Salon A
Hilton Americas-Houston Hotel
The Allergic Asthma Challenge
Supported by Genentech and Novartis Pharmaceuticals Corporation

Presented by:
Thomas B. Casale, MD
Jonathan Corren, MD

Test your asthma knowledge! “The Allergic Asthma Challenge” gives you an opportunity to compete against your colleagues in a trivia format. Questions and educational content will focus on asthma phenotypes and endotypes, asthma biomarkers, and the role of IgE in allergic asthma. We look forward to seeing you there!

Also, visit Genentech and Novartis Pharmaceuticals Corporation at Booth #713.

8:00 – 10:00 pm
Ballroom of the Americas Salon F
Hilton Americas-Houston Hotel
The Role of Eosinophils and Their Potential Heterogeneity in Airways Disease
Supported by GlaxoSmithKline

Presented by:
Nicola Hanania, MD
Nestor Molfino, MD

Eosinophils play an important role in airways inflammation and proposed phenotypes in asthma and COPD. This program will review the biology of eosinophils and cellular-mediated mechanisms of airway inflammation. Use of eosinophils to identify subpopulations as well as guideline recommendations for incorporation of phenotyping into clinical practice will be highlighted.

Also, visit GlaxoSmithKline at Booth #1012.

Sunday, Nov. 10

7:00 – 9:00 pm
Ballroom of the Americas Salon D
Hilton Americas-Houston Hotel
Marching Forward in Atopic Dermatitis:
Digging Deep on Shared Decision Making
Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Presented by:
Peter A. Lio, MD
Anne Marie Singh, MD

In this Interactive Exchange™ dinner program, faculty will review the pathophysiology of atopic dermatitis, and discuss clinical characteristics, and comorbid conditions. Experts will describe appropriate use of systemic treatment options, including biologic therapy. Attendees of this program will gain a fresh perspective on management strategies for patients with moderate-to-severe disease.

Also, visit Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.at Booth #313.
E-posters – Meet the Authors

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Electronic posters are a vital part of your meeting experience. The posters and presentation schedule are searchable and accessible 24/7 from your meeting app, dedicated stations near the e-posters in the exhibit hall or online at college.acaai.org/eposters.

Two categories of e-posters are included. Scientific Research e-posters feature new studies and research in the field of allergy/immunology. Medically Challenging Case e-posters highlight the management of novel or very uncommon diseases, the unusual presentation of a disease or something unusual masquerading as common.

Each e-poster has been assigned a specific presentation time in which the author will present their research from a dedicated presentation monitor and answer questions.

Presentations will take place in Halls A3 & B3 (Level 3) of the George R. Brown Convention Center:

<table>
<thead>
<tr>
<th>Day</th>
<th>Monitors 1-6: Medically Challenging Cases</th>
<th>Monitors 7-11: Scientific Research</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday</td>
<td>3:00 – 6:00 pm</td>
<td>2:30 – 3:00 pm</td>
</tr>
<tr>
<td>Saturday</td>
<td>11:30 am – 1:00 pm</td>
<td>9:30 – 10:00 am</td>
</tr>
<tr>
<td>Sunday</td>
<td>9:30 – 10:00 am</td>
<td>11:30 am – 1:00 pm</td>
</tr>
</tbody>
</table>

Monitors 1-6: Medically Challenging Cases – hear about unusual cases.
Monitors 7-11: Scientific Research – learn about the latest studies.
<table>
<thead>
<tr>
<th>Faculty Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aldape, T. .......................... 92</td>
</tr>
<tr>
<td>Alexis, A. .......................... 59</td>
</tr>
<tr>
<td>Allen, A. ......................... 6, 93, 94</td>
</tr>
<tr>
<td>Anagnostou, A. ............... 38, 43</td>
</tr>
<tr>
<td>Anderson, W. ................. 42, 51, 64, 68</td>
</tr>
<tr>
<td>Ansotegui, I. .................. 71</td>
</tr>
<tr>
<td>Anstey, K. ................. 30, 31, 93</td>
</tr>
<tr>
<td>Aquino, M. ................. 30, 31, 93</td>
</tr>
<tr>
<td>Arshad, S. ...................... 35, 65, 79</td>
</tr>
<tr>
<td>Atkinson, C. .................. 74</td>
</tr>
<tr>
<td>Bacharier, L. ............... 64</td>
</tr>
<tr>
<td>Bahna, S. ..................... 70</td>
</tr>
<tr>
<td>Bailey, S. ................... 48, 58, 80</td>
</tr>
<tr>
<td>Baker, M. ..................... 77</td>
</tr>
<tr>
<td>Ballow, M. ................... 66, 68</td>
</tr>
<tr>
<td>Banerji, A. ................... 30, 31, 39, 52, 93</td>
</tr>
<tr>
<td>Barmettler, S. ............... 30, 31</td>
</tr>
<tr>
<td>Bellanti, J. .................. 52, 80</td>
</tr>
<tr>
<td>Bender, B. .................... 51</td>
</tr>
<tr>
<td>Berger, W. .................... 41</td>
</tr>
<tr>
<td>Bernstein, C. ............... 6, 91, 94</td>
</tr>
<tr>
<td>Bernstein, J. ................ 84</td>
</tr>
<tr>
<td>Bielory, L. .................. 52</td>
</tr>
<tr>
<td>Bird, J. ..................... 55, 66</td>
</tr>
<tr>
<td>Blumenthal, K. .............. 30, 31, 76, 93</td>
</tr>
<tr>
<td>Boelkis, B. .................... 73</td>
</tr>
<tr>
<td>Boguniewicz, M. ........... 59, 94</td>
</tr>
<tr>
<td>Brown-Whitehorn, T ........ 61</td>
</tr>
<tr>
<td>Brucker, H. .................. 58</td>
</tr>
<tr>
<td>Bukstein, D. .................. 75</td>
</tr>
<tr>
<td>Calderon-Zapata, M ......... 40, 42</td>
</tr>
<tr>
<td>Calhoun, W. ................... 56</td>
</tr>
<tr>
<td>Capucilli, P. ................. 8, 74, 79, 86</td>
</tr>
<tr>
<td>Carmody, J. ................... 55</td>
</tr>
<tr>
<td>Carr, W. ..................... 35, 40, 43, 57, 63</td>
</tr>
<tr>
<td>Casale, T. ..................... 42</td>
</tr>
<tr>
<td>Castells, M. .................. 52</td>
</tr>
<tr>
<td>Castro, M. ..................... 56</td>
</tr>
<tr>
<td>Chan, E. ...................... 52, 60</td>
</tr>
<tr>
<td>Chase, N. ..................... 41</td>
</tr>
<tr>
<td>Chiarella, S. .................. 78</td>
</tr>
<tr>
<td>Chinn, I. ..................... 70</td>
</tr>
<tr>
<td>Chinthrajah, S. ............. 61</td>
</tr>
<tr>
<td>Chipps, B. ................... 1, 90</td>
</tr>
<tr>
<td>Cho, S. ....................... 31, 32, 33</td>
</tr>
<tr>
<td>Ciliberti, A. ................. 72</td>
</tr>
<tr>
<td>Clay, K. ...................... 6, 92</td>
</tr>
<tr>
<td>Corbett, M. .................. 65</td>
</tr>
<tr>
<td>Corren, J. ................... 42, 61, 64</td>
</tr>
<tr>
<td>Crain, M. ..................... 91, 93</td>
</tr>
<tr>
<td>Darveaux, J................... 51, 78</td>
</tr>
<tr>
<td>Davis, C. ..................... 42, 66</td>
</tr>
<tr>
<td>Davis, R. ..................... 69</td>
</tr>
<tr>
<td>Davis-Lorton, M. ............. 79</td>
</tr>
<tr>
<td>Deal, C. ...................... 1, 6, 85</td>
</tr>
<tr>
<td>Dennis, S. .................. 88</td>
</tr>
<tr>
<td>Dickens, M. .................. 90, 93</td>
</tr>
<tr>
<td>Dolen, W. ..................... 82</td>
</tr>
<tr>
<td>Doran, T. ..................... 6, 63, 92</td>
</tr>
<tr>
<td>Dubuske, L. .................. 40</td>
</tr>
<tr>
<td>Dunn Galvin, A. ............. 61</td>
</tr>
<tr>
<td>Ebinawan, M. ................ 71</td>
</tr>
<tr>
<td>Elkayam, D. .................. 32, 33</td>
</tr>
<tr>
<td>Elliott, T. ................... 75</td>
</tr>
<tr>
<td>Ellis, A. ..................... 6, 30, 31, 39, 41, 49, 82, 93</td>
</tr>
<tr>
<td>Farooqui, N. .................. 51</td>
</tr>
<tr>
<td>Fasano, M. .................. 66, 84</td>
</tr>
<tr>
<td>Finegold, I. .................. 42</td>
</tr>
<tr>
<td>Fineman, S. .................. 41, 44, 57</td>
</tr>
<tr>
<td>Finerfrock, B. .............. 58, 80, 88</td>
</tr>
<tr>
<td>Finley, A. .................... 78</td>
</tr>
<tr>
<td>Fleischer, D. .................. 38, 52</td>
</tr>
<tr>
<td>Fleisher, T. .................. 84</td>
</tr>
<tr>
<td>Foggs, M. .................... 56</td>
</tr>
<tr>
<td>Fonacier, L. .................. 1, 6, 32, 81</td>
</tr>
<tr>
<td>Forbes, L. .................... 30, 54, 70</td>
</tr>
<tr>
<td>Forester, J. .................. 42</td>
</tr>
<tr>
<td>Frankel, D. ................... 79</td>
</tr>
<tr>
<td>Freeman, A. .................. 66</td>
</tr>
<tr>
<td>Furr, C. ...................... 87</td>
</tr>
<tr>
<td>Gardner, E. .................. 70</td>
</tr>
<tr>
<td>Gawchik, S. .................. 6, 32, 44, 83</td>
</tr>
<tr>
<td>George, M. ................... 6, 90, 91, 92</td>
</tr>
<tr>
<td>Gedrich, R. .................. 61</td>
</tr>
<tr>
<td>Gevaert, P. .................. 61</td>
</tr>
<tr>
<td>Gharfeh, M. .................. 82</td>
</tr>
<tr>
<td>Golden, D. ................... 45</td>
</tr>
<tr>
<td>Goldsobel, A. ............. 6, 59, 64, 84</td>
</tr>
<tr>
<td>Gonzalez-Reyes, E. ........... 67</td>
</tr>
<tr>
<td>Gower, R. ..................... 67</td>
</tr>
<tr>
<td>Grayson, M. ................... 39, 73</td>
</tr>
<tr>
<td>Greenberger, P. .......... 41</td>
</tr>
<tr>
<td>Greenhawt, M. ............ 6, 34, 35, 36, 37, 38, 39, 45, 49, 60, 61</td>
</tr>
<tr>
<td>Greiwe, J. ................... 49, 75</td>
</tr>
<tr>
<td>Gross, G. ..................... 44, 58, 75, 87</td>
</tr>
<tr>
<td>Guarneri, K. ................... 72</td>
</tr>
<tr>
<td>Gupta, R. ..................... 56, 66, 68</td>
</tr>
<tr>
<td>Han, J. ....................... 84</td>
</tr>
<tr>
<td>Hanania, N. .................. 56</td>
</tr>
<tr>
<td>High, W. ..................... 44</td>
</tr>
<tr>
<td>Hogan, A. ..................... 52, 66</td>
</tr>
<tr>
<td>Holgate, S. .................. 7, 48</td>
</tr>
<tr>
<td>Horwitz, R. ................. 55</td>
</tr>
<tr>
<td>Hourihane, J. .............. 29, 34, 43</td>
</tr>
<tr>
<td>Imbeau, S. .................. 58</td>
</tr>
<tr>
<td>Jacob, S. ..................... 32, 44</td>
</tr>
<tr>
<td>Jehling, R. ................... 88</td>
</tr>
<tr>
<td>Jiang, J. ..................... 77</td>
</tr>
<tr>
<td>Jones, D. ..................... 43</td>
</tr>
<tr>
<td>Kaplan, A. ................... 83</td>
</tr>
<tr>
<td>Katcher, J. ......... 59</td>
</tr>
<tr>
<td>Katial, R. ................... 58, 94</td>
</tr>
<tr>
<td>Kelly, B. ..................... 6, 61, 82</td>
</tr>
<tr>
<td>Kelly, K. ..................... 50, 72</td>
</tr>
<tr>
<td>Kelso, J. ..................... 39, 90</td>
</tr>
<tr>
<td>Kertz, L. ..................... 91</td>
</tr>
<tr>
<td>Khan, D. ...................... 6, 39, 52, 76</td>
</tr>
<tr>
<td>Kim, E. ....................... 36, 43</td>
</tr>
<tr>
<td>Kim, M. ...................... 79</td>
</tr>
<tr>
<td>Kobrynksi, L. ............ 6, 30, 61, 82</td>
</tr>
<tr>
<td>Koepke, J. .................... 31, 32, 33</td>
</tr>
<tr>
<td>Kothari, M. .................. 78</td>
</tr>
<tr>
<td>Kraft, M. ..................... 77</td>
</tr>
</tbody>
</table>
Faculty Index

Kreindler, J. ................... 61  
Kuehn, J. ..................... 87  
Lang, D. ...................... 75  
Lanser, B. ..................... 52  
Lee, G. ....................... 82  
Lesiak, L. ..................... 63  
Leung, D. ..................... 59  
Levin, M. ..................... 35, 48, 56  
Levine, T. ..................... 61  
Li, J. ...................... 39, 50  
Lieberman, J. ................ 41, 42, 49, 85, 93  
Lieberman, P. .................. 41  
Long, A. ...................... 50  
Luccioli, S. .................... 35  
Luskin, A. ..................... 69  
Maciag, M. .................. 8, 73, 77, 86  
Mack, D. ..................... 38, 43  
Maples, K. .................... 1, 32, 68, 82  
Marshall, G. ................ 1, 6, 46  
Martin, B. ................... 1, 29, 50, 63, 80, 81  
Maurer, M. .................... 83  
Mawhirt, S. ................... 44, 72  
May, K. ....................... 1, 41  
McCutchcheon, S. ............ 44  
McGrath, K. ................ 6, 41, 57  
Meadows, J. ................ 1, 6, 67, 75, 80, 81  
Michaud, A. ................ 6, 90, 93  
Milewski, J. .................. 89  
Miller, T. ..................... 1, 46, 80  
Motoa, G. ..................... 74  
Murphy, H. .................... 6, 93, 94  
Murphy, K. ................... 32, 33, 59  
Mustafa, S. ................... 73, 84  
Mustillo, P. ................... 63  
Naimi, D. ..................... 58, 94  
Nanda, A. .................... 32, 46, 56  
Nassef, M. .................... 68  
Neaves, B. ................... 8, 73, 79, 86  
Nelson, H. .................... 39  
Nelson, M. ................... 29, 63, 81  
Nickels, A. ................... 46  
Norris, M. .................... 72  
Nowak-Wegrzyn, A. .... 7, 38  
Nsouli, T. ..................... 74  
O’Byrne, P. .................. 65  
O’Connor, M. ................ 46, 55  
Ogbogu, P. .................... 56  
Olsen, G. .................... 32, 33  
Ong, P. ....................... 74  
Oppenheimer, J. ........... 6, 7, 42, 55, 60  
Owen, J. ...................... 44  
Pacheco, K. .................. 32  
Parikh, P. ..................... 66  
Paris, K. ..................... 30, 66  
Patel, R. ...................... 78  
Peden, D. ..................... 82  
Perez, E. ..................... 54, 70  
Peters, A. ..................... 39, 84  
Peters, R. ..................... 35, 56  
Petersen, M. .................. 63  
Pfeifer, J. ..................... 87  
Pleasants, R. ................ 61  
Portnoy, J. ................. 42, 45, 74, 75  
Prescott, S. ................. 29, 34, 65  
Prince, B. ..................... 49, 54  
Pulver, D. .................... 32, 33  
Rachid, R. ................... 36  
Raje, N. ...................... 30, 54, 82, 91  
Ramsey, A. .................. 59, 76  
Rank, M. ..................... 29, 48, 60, 64  
Rathkopf, M. ............... 1, 41, 57  
Raveendran, R. ............ 63  
Reeder, D. ................... 73  
Richter, J. ................... 79  
Rider, N. ..................... 30, 82, 84, 85  
Riedl, M. .................... 39  
Rivera-Velazquez, M. .... 78  
Robinson, A. ................ 77  
Robinson, L. ................ 72  
Rodriguez, A. .............. 63  
Rosenberg, O. ............. 74  
Routes, J. ................... 39, 54  
Ruffner, M. ................ 73  
Rupp, M. ...................... 1, 58  
Samstein, M. ............... 1, 85  
Sánchez-Borges, M. ....... 71  
Settipane, R. ................ 40  
Shaker, M. ................... 37, 45, 55  
Sharma, H. .................. 81, 93  
Shepherd, M. ............... 55, 82  
Sher, M. ...................... 59  
Shih, J. ....................... 75  
Shreffler, W. ................ 37  
Shroba, J. ................... 6, 90, 91, 93  
Shroff, P. ..................... 84  
Silvers, W. ................... 58  
Skotnicki, S. ............... 44, 90  
Sloan, L. ..................... 88  
Slowey, B. ................... 88  
Small, M. .................... 78  
Snyder, B. ................... 91  
Stahl, M. ..................... 51  
Stukus, D. .................. 5, 6, 34, 35, 36, 37, 38, 48, 61, 76  
Sublett, J.L. ............... 41, 57, 67  
Sublett, J.W. ................ 44, 59, 66  
Sun, D. ....................... 79  
Tam, J. ....................... 83  
Tankersley, M. ............. 42  
Tanno, L. ..................... 71  
Tracy, J. ..................... 6, 7, 44, 57, 58, 63, 67  
Tuck, J. ...................... 6, 55, 61  
Tyler, K. ..................... 87  
Venter, C. ................... 34, 52, 65, 77  
Vickery, B. .................. 38, 55  
Wallace, D. ................ 7, 41, 48, 60, 68  
Wang, J. ..................... 45, 55, 66  
Wang, L. ..................... 72  
Wasserman, R. ............. 30, 38, 66  
Wauters, R. ................ 73  
Weinstein, A. ............... 69  
Weldon, D. .................. 32, 83  
Winston, M. .................. 91  
Zachary, C. ................... 56  
Zitt, M. ...................... 59, 78
Alliance of the ACAAI Program

The Alliance of the American College of Allergy, Asthma & Immunology hosts a variety of social events and programs throughout the annual meeting.

Alliance Hospitality Suite
8:00 – 10:30 am • Friday through Sunday
Lanier Grand Ballroom Salons J-K (Level 4)
Hilton Americas-Houston Hotel

Registered spouses and guests are invited to start the day with a visit to the hospitality suite. It’s a perfect way to connect with old friends and meet new ones.

Enjoy the following complimentary programs in the hospitality suite:

American Ninja Warrior: Artis Thompson III
8:30 – 9:30 am • Friday
Artis Thompson III grew up in a single-parent home where he watched his mom work two jobs to support him and his three siblings. He applies the work ethic and lessons he learned from her in his daily and professional life as a personal trainer, semi-pro football player and participant on American Ninja Warrior. As an extreme athlete and an amputee, he strives to be an inspiration to his community and to show everyone that they can do the things they love, no matter their personal situation.

Fine Jewelry with Vincent Peach
8:30 – 9:30 am • Saturday
Coming from a long line of prominent US jewelers and “pearl men,” Vincent Peach has honed his ancestral expertise into unique, truly organic fine jewelry creations. Vincent handcrafts truly one-of-a-kind fine jewelry pieces featuring rare pearls, brilliant diamonds, precious metals and exotic leathers. Join us for a trunk show and talk that highlights the Vincent Peach jewelry collection, combining the casual elegance of leather and the extraordinary beauty of diamonds and pearls.

Gentle Morning Workout
8:30 – 9:30 am • Sunday
Greet the day with a gentle work out to stretch your muscles and calm your mind with Houston’s very own Cathy Wertheimer, MEd, ACSM! Cathy will be leading a custom-tailored workout created specifically for Alliance members in the Hospitality Suite.

Alliance Brunch
Noon – 3:00 pm • Sunday
The Grove Houston • 1611 Lamar St.
Registration Required • Fee $30 • Limit 50
Spouses and alliance members are invited to attend the Alliance Brunch and business meeting.
These are commercial presentations conducted by exhibiting companies in specially-constructed theaters on the exhibit floor. This year we will have three Product Theaters located in the George R Brown Convention Center Exhibit Halls A3 & B3, where a limited number of 25-minute and 85-minute sessions will be presented each day during the refreshment and lunch breaks. Product Theaters are non-CME forums organized by industry and designed to enhance your learning experience.

**Saturday, 9:35 – 10:00 am**

**Product Theater 1**

**Thinking Differently About Asthma Management: Revisiting a Window of Opportunity**

*Supported by AstraZeneca*

*Presented by: Reynold A Panettieri, MD*

This program will examine the relationship between short-acting 2-agonist (SABA) reliance, patient behavior, and asthma morbidity. An understanding of SABA reliance and its consequences highlights an unmet need and an opportunity to optimize control.

*Also visit AstraZeneca at Booth #301.*

---

**Product Theater 2**

**A Path to Asthma Control**

*Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.*

*Presented by: Neal Jain, MD*

Listen to an expert clinician discussion an add-on maintenance treatment for patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or oral corticosteroid-dependent asthma. Our presenter will highlight key roles for Type 2 Inflammation in the pathobiology of asthma and the efficacy and safety data across three clinical trials in nearly 3,000 patients with asthma. Additionally, our presenter will lead an interactive discussion of different patient types who might be eligible for treatment.

*Also visit Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. at Booth #313.*

---

**Product Theater 3**

**Advancing the Treatment of Eosinophilic Disease**

*Supported by GlaxoSmithKline*

*Presented by: Dennis K. Ledford, MD*

Join us for an engaging program exploring the role of eosinophils in disease management. We will examine key efficacy and safety data for a treatment that reduces eosinophils, including long-term data in patients with severe asthma. We will also discuss clinical approaches for identifying appropriate patient types that may benefit from a targeted treatment to reduce eosinophils.

*Also visit GlaxoSmithKline at Booth #1012.*

---

**Saturday, 11:35 am – 1:00 pm**

**Product Theater 1**

**Severe Eosinophilic Asthma: Case Studies with a Targeted Treatment Approach**

*Supported by AstraZeneca*

*Presented by: Warner Carr, MD*

Please join us to learn more about ways to help identify eosinophilic asthma through a combination of clinical features, patient history and measurements of eosinophils told through three compelling patient case studies. Hosted by a national expert, explore a targeted treatment approach for patients with both efficacy and safety profile data.

*Also visit AstraZeneca at Booth #301.*
Product Theaters

These are commercial presentations conducted by exhibiting companies in specially-constructed theaters on the exhibit floor. This year we will have three Product Theaters located in the George R Brown Convention Center Exhibit Halls A3 & B3, where a limited number of 25-minute and 85-minute sessions will be presented each day during the refreshment and lunch breaks. Product Theaters are non-CME forums organized by industry and designed to enhance your learning experience.

Saturday, 11:35 am – 1:00 pm

Experience That Matters: Learn About the Possibility of Hereditary Angioedema (HAE) Patients Reducing Their Attack Rate to One a Year

Supported by CSL Behring
Presented by: Raffi Tachdjian, MD, MPH
Zahra Khan (HAE Patient Advocate)

Join us as we present NEWLY PUBLISHED data from the Open Label Extension Study following patients’ long term. Hear from an HAE Opinion Leader, and an HAE Patient, as they talk about the impact of HAE and successfully managing the disease.

Also visit CSL Behring at Booth #123.

Saturday, 2:35 – 3:00 pm

XHANCE®: A Case-based Approach to Treatment

Supported by Optinose
Presented by: Shahnaz Fatteh, MD

Explore a unique patient case to understand how XHANCE is a different treatment approach.

Also visit Optinose at Booth #1021.

Immune Response Pathways: Characteristics of Asthma and Comorbidities

Supported by Novartis Pharmaceuticals Corporation

Allergic asthma is a specific phenotype of a common disease with wide heterogeneity. Associated comorbidities often go hand-in-hand with the condition. Such comorbidities may share common immunopathological mechanisms with asthma that can influence its control. Immune Response Pathways: Characteristics of Asthma and Comorbidities will focus on the immune response of allergic asthma, accurate recognition of these characteristics and proper management of comorbidities.

Also visit Novartis Pharmaceuticals Corporation at Booth #1213.

Sunday, 9:35 – 10:00 am

Steroid-Free EUCRISA: A Treatment Option for Mild-to-Moderate Atopic Dermatitis in Patients 2 Years and Older

Supported by Pfizer, Inc.
Presented by: Ankmalika Gupta, MD

Join us for an interactive presentation on a steroid-free topical therapy for the treatment of mild-to-moderate atopic dermatitis. Expert faculty will guide the audience through an in-depth look into the product and answer questions to help attendees gain a better understanding of this treatment option.

Also visit Pfizer, Inc. at Booth #1013.
Product Theaters

These are commercial presentations conducted by exhibiting companies in specially-constructed theaters on the exhibit floor. This year we will have **three Product Theaters located in the George R Brown Convention Center Exhibit Halls A3 & B3**, where a limited number of 25-minute and 85-minute sessions will be presented each day during the refreshment and lunch breaks. Product Theaters are non-CME forums organized by industry and designed to enhance your learning experience.

### Sunday, 11:35 am – 1:00 pm

**1. Principles of Severe Eosinophilic Asthma**  
*Supported by AstraZeneca*  
Presented by: Reynold A Panettieri, MD

Join us for an educational program exploring the mechanistic role of eosinophils in severe asthma. This interactive presentation will review updated guidance in assessing severe asthma, examine the role of eosinophils in severe asthma, and highlight the impact of oral corticosteroid (OCS) use in severe uncontrolled asthma.  
*Also visit AstraZeneca at Booth #301.*

**2. DUPIXENT® (dupilumab): Product Theater**  
*Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.*

Presented by:  
Jonathan A. Bernstein, MD  
Lawrence D. Sher, MD

*Also visit Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. at Booth #313.*

**3. Evolving Understanding of Inflammatory Mediators in Asthma**  
*Supported by Novartis Pharmaceuticals Corporation*  
Presented by: Bradley E. Chipps, MD

In this presentation, Dr. Bradley Chipps will discuss the multiple pro-inflammatory pathways involved in asthma pathophysiology, reviewing established mediators such as IgE, IL-4/IL-13 and IL-5, as well as covering new science surrounding DP2 as a major regulator of the inflammatory cascade. The presentation will also explore the impact of persistent inflammation on downstream structural effects and, ultimately, clinical manifestations of asthma that remain poorly controlled in many patients.  
*Also visit Novartis Pharmaceuticals Corporation at Booth #1003.*
Exhibit Hall Passport Contest

Participate for a chance to win some great prizes including: Apple iPads, $500 Amazon gift cards or complimentary 2020 ACAAI Annual Meeting registrations.

Here’s how to play:

1. Find the ACAAI Passport Contest Game Card in your registration bag.
2. Enter your contact information (first and last name, ID number from your badge, and your email address) on the game card. Email addresses will be given to the participating companies and only completed game cards will be eligible for the raffle.
3. Visit each company that is participating in the Passport Contest for an engaging conversation or product demonstration.
4. Have the company representative place a stamp next to their company name on the game card.
5. Drop off your completed game card (with all 12 stamps) at the College Resource Center, booth #613, in the exhibit hall to be entered into a drawing for an Apple iPad (1 of 2), $500 Amazon gift card (1 of 2) or complimentary 2020 ACAAI Annual Meeting registration (1 of 2).

Entries must be received by 11:00 am, Sunday, Nov. 10. Drawings will be held in the Exhibit Hall at approximately 1:00 pm on Sunday, Nov. 10. PARTICIPANTS NEED NOT BE PRESENT TO WIN. The ACAAI Exhibit Hall Passport Contest is open to all Annual Meeting registrants and excludes guests and exhibitors. Only one Passport Contest Game Card per registered attendee. All contact information must be completed on the passport form to be eligible for the prize drawing.

(Email address will be shared with the 12 participating companies.)

Exhibit Hall Hours:

- Friday, Nov. 8 . . . . . . . . . . . . . . . . 2:00 – 6:00 pm
- Saturday, Nov. 9 . . . . . . . . . . . . . . . . 9:00 am – 4:30 pm
- Sunday, Nov. 10 . . . . . . . . . . . . . . . . 9:00 am – 1:30 pm

ACAAI Future Meeting Dates

<table>
<thead>
<tr>
<th>November 12-16, 2020</th>
<th>November 9-13, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phoenix, Arizona</td>
<td>Anaheim, California</td>
</tr>
<tr>
<td>November 4-8, 2021</td>
<td>October 24-28, 2024</td>
</tr>
<tr>
<td>New Orleans, Louisiana</td>
<td>Boston, Massachusetts</td>
</tr>
<tr>
<td>November 10-14, 2022</td>
<td>November 6-10, 2025</td>
</tr>
<tr>
<td>Louisville, Kentucky</td>
<td>Orlando, Florida</td>
</tr>
</tbody>
</table>
Halls A3 and B3 (Level 3) • George R. Brown Convention Center

Exhibit Hours:
2:00 – 6:00 pm, Friday
9:00 am – 4:30 pm, Saturday
9:00 am – 1:30 pm, Sunday

ACAAI Resource Center
Booth 613
85 W. Algonquin Rd., Suite 550
Arlington Heights, IL 60005
Phone: (847) 725-2266
Website: acaai.org
Contact Name: Amy Romanelli
Contact Email: amyromanelli@acaai.org

Visit the College Resource Center to find out how the College provides the support you need. Get connected and learn more about ongoing College programs, Vision 2020 and more.

ADAKO USA
Booth 338
1921 Carnegie Ave., Suite C
Santa Ana, CA 92705
Phone: (714) 360-7943
Website: adakousa.com
Contact Name: Akin Cakar
Contact Email: adakousa@gmail.com

Leading distributor of 3D massage chairs.

Advocacy & Awareness for Immune Disorders Association (AAIDA)
Booth 436
P.O Box 34326
Charlotte, NC 28234
Phone: (704) 993-8389
Website: godoaaida.org
Contact Name: Lauren Dunlap
Contact Email: myaaida01@gmail.com

AAIDA is a 501(c)(3), whose purpose is to educate patients and providers alike to advocate for patients living with immune disorders, create awareness about immune disorders and to make strides in research to find cures and novel treatment options for these diseases.

Aimmune Therapeutics
Booth 619
8000 Marina Blvd., Suite 300
Brisbane, CA 94005
Phone: (319) 350-9376
Website: aimmune.com
Contact Name: Amber Stark
Contact Email: astark@aimmune.com

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for potentially life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to reduce the risk of severe allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first, investigational, complex biologic product candidate, AR101 [Peanut (Arachis hypogaea) Allergen Powder], is being developed as a treatment to reduce the frequency and severity of allergic reactions following accidental exposure to peanut. The BLA for AR101 (proposed trade name, PALFORZIA™) is under review by the FDA, which granted AR101 Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The European Medicines Agency (EMA) is reviewing Aimmune’s Marketing Authorization Application (MAA) for AR101, which Aimmune submitted in June 2019. Aimmune initiated a randomized phase 2 clinical trial of its second investigational, complex biologic product, AR201, for the treatment of egg allergy in August 2019. For more information, please see www.aimmune.com.
### ALK, Inc.

**Booth 513**

1700 Royston Ln.  
Round Rock, TX 78664  
Phone: (908) 842-8359  
Website: alk.net/us  
Contact Name: Paul Ulrich  
Contact Email: paul.ulrich@alk.net

As the world leader in allergy immunotherapy (AIT), ALK is devoted to improving the quality of life for people with allergies by offering more convenient methods of administration, and thereby expanding the overall use of AIT to more patients. We are committed to broadening our presence in allergy care and will continue to innovate, develop and market new solutions beyond AIT that bring us closer to allergic patients. Our goal is to build an effective future growth platform to engage with allergic patients and connect them with allergy specialists earlier in the disease progression.

### Allergy & Asthma Network

**Booth 426**

8229 Boone Blvd., Suite 260  
Vienna, VA 22182  
Phone: (703) 641-9595  
Website: allergyasthmamanetwork.org  
Contact Name: Sue Lockwood  
Contact Email: slockwood@allergyasthmamanetwork.org

Allergy & Asthma Network is the nation’s leading patient advocacy organization that works to connect the collaborative care team for people who suffer with allergies, asthma and related conditions. The Network’s mission is to end needless death due allergies, asthma, food allergies and related conditions through outreach, education, advocacy and research.
**AllergyEHR, a division of Meditab Software Inc.**
Booth 1313
2233 Watt Ave., Suite 360
Sacramento, CA 95825
Phone: (510) 459-6284
Website: allergyehr.com
Contact Name: Shameer Nalli
Contact Email: shameern@meditab.com

AllergyEHR is an all-inclusive system for allergists that integrates powerful immunotherapy features into a customizable EMR and practice management solution. Created by medical professionals with allergists in mind, the mobile-friendly solution offers several notable features, such as a skin test module, a shot module, shot schedule templates and automated immunotherapy billing. With the help of AllergyEHR, allergy practices across the nation have been able to improve their efficiency and bottom line by automating processes, improving workflows, creating custom treatment plans, enhancing patient engagement, plus more.

**Altus Infusion**
Booth 824
11233 Shadow Creek Pkwy., Suite 303
Pearland, TX 77584
Phone: (954) 895-7887
Website: altusinfusion.com
Contact Name: Gregory Tutko, RN, MBA
Contact Email: gtutko@altushealthsystem.com

Altus Infusion is an infusion and injection therapy management company. We partner with physicians to provide comprehensive infusion and injection therapies in their office. At Altus Infusion, we are committed to improving access, quality and affordability of care for all patients. We believe in the motto: “Treat each patient like family.”

**American Board of Allergy & Immunology (ABAI)**
Booth 530
1835 Market St., Suite 1210
Philadelphia, PA 19103
Website: abai.org
Contact Name: Gina Capozzoli
Contact Email: gcapozzoli@abai.org

The ABAI was established in 1971 as a conjoint board of the ABIM and ABP. The internal medicine subspecialty existed from 1936-1971, and the pediatric subspecialty existed from 1944-1971. The ABAI is committed to working closely with its parent boards to maintain the highest educational and clinical standards in the specialty of allergy/immunology.

**American Partnership for Eosinophilic Disorders (APFED)**
Booth 533
P.O. Box 29545
Atlanta, GA 30359
Phone: (713) 493-7749
Website: apfed.org
Contact Name: Lisa Brunet
Contact Email: lisa@apfed.org

The American Partnership for Eosinophilic Disorders (APFED) is a 501(c)(3) nonprofit organization founded in December 2001 by a group of mothers of young children living with eosinophil-associated diseases. We are a patient advocacy group dedicated to improving the lives of those living with eosinophilic disorders. Our mission is to passionately embrace, support and improve the lives of patients and families affected by eosinophil-associated diseases through education and awareness, research and advocacy. APFED’s vision is the development of a cure while improving the quality of life for those suffering with eosinophil-associated diseases.

**Amerimmune**
Booth 636
11212 Waples Mill Rd., Suite 100
Fairfax, VA 22030
Phone: (571) 214-3372
Website: amerimmune.com
Contact Name: Ivan Santos
Contact Email: isantos@amerimmunellc.com

Amerimmune was started by Dr. Oral Alpan and Margaret Brown, in Fairfax, Virginia, bringing their collective expertise of 40+ years from the National Institutes of Health. The mission of Amerimmune is to bring clinically driven flow cytometry-based laboratory test development to all private medical practices. Amerimmune was established to provide high quality and cost effective immune-work up. After almost a decade, Amerimmune is now taking the initial model to apply into all private clinical practices across the country. The vision is to make an impact on the practice of medicine…and make it more cost-effective.
Our association was formed to promote the growth and development of PAs and NPs who have an active interest in the field of allergy, asthma and immunology. We provide the general membership with a forum for informal assembly regarding the issues that relate to physician assistants in allergy and immunology. We facilitate mutual assistance and support of physician assistants, health professionals and health services by organizing and disseminating health care information through forums, panels and other similar programs concerning the delivery and quality of health care services.

Asthma and Allergy Foundation of America

1235 South Clark St., Suite 305
Arlington, VA 22202
Phone: (301) 832-3478
Website: aafa.org
Contact Name: Kimm Rafferty

The Asthma and Allergy Foundation of America (AAFA), founded in 1953, is dedicated to improving the quality of life for people with asthma, food allergy and other allergic diseases through education, advocacy, support and research. Our patient services include free online courses for a new diagnosis of asthma or food allergy; web-based patient education and community outreach through online patient communities; an 800 line; and an “Ask the Allergist” service. We can also connect patients with local AAFA chapters and support groups. AAFA is actively engaged in patient-centered outcomes research and other research studies. Visit us at aafa.org or kidswithfoodallergies.org.

AstraZeneca

1800 Concord Pike
Wilmington, DE 19850-5437
Phone: (800) 236-9933
Website: astrazeneca-us.com
Contact Name: Christie Wilhelm
Contact Email: christie.wilhelm@astrazeneca.com

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – oncology, cardiovascular and metabolic diseases and respiratory. The company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

AstraZeneca Medical Affairs

1800 Concord Pike
Wilmington, DE 19850
Website: astrazeneca.com
Contact Name: Kristel Johnson
Contact Email: kristel.johnson@etglobal.com

Bedfont Scientific Ltd

Station Rd.
Harrietsham, Maidstone, Kent ME17 1JA
United Kingdom
Phone: 01622 851122
Website: bedfont.com
Contact Name: Amber Kirk
Contact Email: amber@bedfont.com

See Bedfont’s innovative range of breath analysis monitors built on over 40 years of experience. The Gastrolzyer range of hydrogen and methane breath monitors offers a quick, easy and non-invasive method of detecting gastrointestinal disorders such lactose intolerance and IBS. The NOBreath fractional exhaled nitric oxide monitor aids in the diagnosis and control of asthma. Through regular FeNO monitoring, health care professionals can differentiate between allergic (eosinophilic) and non-allergic subtypes of asthma. This, in turn, enables them to identify the correct inhaled corticosteroids, but also to adjust the level of medication, if needed, safely and accurately, for improved asthma management.
BioCryst Pharmaceuticals, Inc.

4505 Emperor Blvd., Suite 200
Durham, NC 27703
Phone: (919) 815-7054
Website: biocryst.com
Contact Name: Carol Rockett
Contact Email: crockett@biocryst.com

BioCryst is a biotech company headquartered in Durham, North Carolina with a Discovery Center of Excellence in Birmingham, Alabama. We discover novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. At BioCryst, we are committed to delivering extraordinary medicines that empower patients to live ordinary lives. We are passionate about developing and advancing novel medicines, with a focus on oral therapies, for people with rare and serious diseases to help them take part in the everyday activities they enjoy.

Covis Pharma

Grafenauweg 12
CH-6300 Zug
Switzerland
Phone: (502) 640-5682
Website: covispharma.com
Contact Name: Glenn Esgro
Contact Email: gesgro@covispharma.com

Covis Pharma, headquartered in Zug, Switzerland, is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Covis offers a portfolio of pharmaceutical products providing patients with affordable and therapeutic equivalent medications of select brands in respiratory/allergy, cardiovascular, gastroenterology, CNS and authorized generics.

Circassia Pharmaceuticals, Inc

5151 McRimmon Pkwy., Suite 260
Morrisville, NC 27560
Phone: (866) 275-6469
Website: circassia.com
Contact Name: Robert Yanez
Contact Email: robert.yanez@circassia.com

Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. Circassia sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners. In 2017, the company established a commercial collaboration with AstraZeneca in the United States, in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza®, and has the commercial rights to NDA-stage COPD product Duaklir®. For more information please visit www.circassia.com.

CSL Behring

1020 First Ave.
King of Prussia, PA 19406
Website: cslbehring.com
Contact Name: Molly Hess Knodel
Contact Email: molly.hessknodel@cslbehring.com

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease and neurological disorders. CSL Behring’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. For more information visit www.cslbehring.com and follow us on www.twitter.com/cslbehring.
CVS Specialty  
Booth 1412  
1 CVS Dr.  
Woonsocket, RI 02895  
Phone: (800) 237-2767  
Website: cvsspecialty.com  
Contact Name: Jennifer Huntley  
Contact Email: jennifer.huntley@cvshealth.com  
CVS Specialty and Coram provide compassionate, high-quality infusion care to patients where they live, work or travel. Local teams from more than 90 locations throughout the country offer the highest level of personalized care, education and support. With nearly 1,200 skilled clinicians and more than 30 years of experience, Coram CVS Specialty Infusion Services leads the industry with commitment from the heart. The company has achieved a 96 percent patient satisfaction rating for seven years.

Diplomat Specialty Infusion Group  
Booth 735  
7167 E. Kemper Rd.  
Cincinnati, OH 45249  
Phone: (346) 208-2634  
Website: diplomatpharmacy.com  
Contact Name: Sheri Kempf  
Contact Email: skempf@diplomat.is  
Diplomat Specialty Infusion Group is a nationwide provider of personalized support for patients with primary immunodeficiency disease (PIDD). This includes the provision of immune globulin (IG) treatment at home.

eClinicalWorks  
Booth 1219  
2 Technology Dr.  
Westborough, MA 01581  
Phone: (508) 836-2700  
Website: eclinicalworks.com  
Contact Name: Michael Webber  
Contact Email: tradeshows@eclinicalworks.com  
The eClinicalWorks EHR/PM is a complete solution for your health care IT needs, including everything providers need for the testing and treatment of allergies. Allergy module contains configurable worksheets for the antigen tests needed to document wheal/flare or impression. Once skin tests are complete, providers can write formulations for the vials to be prepared.

DBV Technologies  
Booth 507  
25 Deforest Ave., Suite 203  
Summit, NJ 07901  
Phone: (908) 679-5200  
Website: dbv-technologies.com  
Contact Name: Jeff Germani  
Contact Email: jeff.germani@dbv-technologies.com  
DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy. We are committed to developing safe and effective therapies for food allergic patients for whom there are no currently-approved treatments. DBV is developing epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. Our development program includes peanut and milk allergy, as well as potential applications in the field of food allergies.

Edge Pharma / Xtract Solutions  
Booth 343  
6443 Ridings Rd., Suite 116  
Syracuse, NY 13206  
Phone: (802) 992-1179  
Website: xtractsolutions.com  
Contact Name: Randy Kahn  
Contact Email: rkahn@edgepharma.com  
Edge Pharma and Xtract Solutions are leaders in advancing software technology and outsourcing services for the practice of allergen immunotherapy. We work with allergy clinics who are frustrated that their immunotherapy workflows are not as optimized as they should be and are often still using paper despite having an EMR. Others fear the risks to patient safety associated with mixing and delivering allergy shots and want to make the process safer, and some practices are growing and need process improvements to keep up their quality and productivity standards. Stop by or call to learn how we can help your practice.
Edge Pharmaceuticals
Booth 339
7264 NW 63rd Ter.
Parkland, FL 33067
Phone: (877) 580-EDGE
Website: edgepharmaceuticals.com
Contact Name: Richard Aloi
Contact Email: sales@edgepharmaceuticals.com

We specialize in:
• Sublingual immunotherapy (SLIT) – metered dose delivery bottles
• Allergy testing and treatment supplies – extracts, diluent, etc
• Specialty pharmacy compounding services and products

We look forward to meeting with you. Please stop by our booth to see us.

EHRC Technologies
Booth 730
1835 E Hallandale Beach Blvd., Suite 201
Hallandale Beach, FL 33009
Phone: (786) 766-0828
Website: ehrctech.com
Contact Name: Ran Cohen
Contact Email: ehrctgroup@gmail.com

We specialize in promoting solutions supporting the healing process of damaged cells, tissues and nerves using LLLT and electro-therapy technologies, which are known to help manage pain, increase blood flow, decrease muscle spasms and reduce inflammation. The treatment is completely safe, FDA-approved and has no reported side effects. The benefits extend to a wide range of fields including, but not limited to: dermatology, neurology, orthopedics, surgery, gynecology, dentistry and more.

Elsevier, Inc.
Booth 807
1600 JFK Blvd., Suite 1800
Philadelphia, PA 19103
Phone: (817) 734-4998
Website: elsevierhealth.com
Contact Name: Allen Wright
Contact Email: al.wright@elsevier.com

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health and technology professionals, empowering them to make better decisions and deliver better care.

Food Allergy & Anaphylaxis Connection Team (FAACT)
Booth 726
P.O. Box 511
West Chester, OH 45071
Phone: (815) 276-3015
Website: foodallergyawareness.org
Contact Name: Eleanor Garrow-Holding, CEO
Contact Email: eleanor.garrow@foodallergyawareness.org

FAACT’s mission is to educate, advocate and raise awareness for all individuals and families affected by food allergies and life-threatening anaphylaxis. FAACT is also your voice for food allergy awareness. Whether it’s keeping children safe at school, parents knowing their rights, responding to food allergy bullying, reading labels, dealing with workplace issues, traveling or dining out with the family, this website has the facts you need to manage food allergies and stay healthy. FAACT is here to support you in managing your food allergies – today, tomorrow, and into the future.

Food Allergy Research & Education (FARE)
Booth 440
7901 Jones Branch Dr., Suite 240
McLean, VA 22102
Phone: (800) 929-4040
Website: foodallergy.org
Contact Name: Roberta Slivensky
Contact Email: rslivensky@foodallergy.org

Food Allergy Research & Education (FARE) is the world’s leading food allergy advocacy organization and the largest private funder of food allergy research. Our mission is to improve the quality of life and the health of individuals with food allergies and to provide them hope through the promise of new treatments. FARE is transforming the future of food allergy through innovative initiatives that will lead to increased awareness, new and improved treatments and prevention strategies, effective policies and legislation and novel approaches to managing the disease. For more information, please visit www.foodallergy.org.
Exhibits

Gold Partner

Genentech/Novartis (Booth 713)
1 DNA Way
South San Francisco, CA 94080
Phone: (201) 452-2476
Website: genentech.com
Contact Name: Ellen Armijo
Contact Email: iarmijo.ellen@gene.com

For more than 40 years, we've been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California.

Platinum Partner

GlaxoSmithKline (Booth 1012)
5 Moore Dr.
Research Triangle Park, NC 27709
Phone: (888) 825-5249
Website: gsk.com
Contact Name: Sudha Karthigeyan
Contact Email: sudharshanaa.x.karthigeyan@gsk.com

GSK is a science-led global health care company with a mission to help people do more, feel better, live longer. We research, manufacture and make available a broad range of medicines, vaccines and consumer health care products. Visit our exhibit for information about our products and resources.

Hackensack Meridian Health (Booth 637)
1967 Rte. 34
Building C, Suite 104
Wall, NJ 07719
Phone: (732) 751-3561
Website: hackensackmeridianhealth.org
Contact Name: Jodi Fendrick
Contact Email: jodi.fendrick@hackensackmeridian.org

Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care, aiming to serve as a national model for changing and simplifying health care delivery through partnerships with innovative companies and focusing on quality and safety. Four of our hospitals – Hackensack University, Jersey Shore University, Ocean and Riverview Medical Centers – are among the top hospitals in New Jersey for 2019 – 2020, according to U.S. News & World Report.

Healix Infusion Therapy (Booth 532)
14140 SW Fwy., Suite 400
Sugar Land, TX 77478
Phone: (281) 295-4118
Website: healix.net
Contact Name: Momotaz Rahman
Contact Email: mrahman@healix.net

Healix is the nation’s leader in providing physician office-based infusion services. We focus on patient and physician peace of mind. For 30 years, we have offered unparalleled capabilities for optimal patient care, comfort, compliance and clinical outcomes in an outpatient setting.

HollisterStier Allergy (Booth 1129)
3525 North Regal St.
Spokane, WA 99207-5796
Phone: (800) 495-7437
Website: hsallergy.com
Contact Name: Mary Miller
Contact Email: karndt@jhs.jubl.com

Strength. Balance. Consistency. With nearly 100 years of leadership in research, extract production and immunotherapy products, doctors around the world choose HollisterStier Allergy. Our promise has always been to provide quality products, services and resources to physicians and allergy patients, and we remain committed to those ideals today. Our complete line of high quality products – including phenol-free extracts – and testing supplies, allows physicians to provide patients with the best possible care. Allergy experts since 1921. Commitment since day one.
Horizon Therapeutics
Booth 631
150 S. Saunders Rd.
Lake Forest, IL 60045
Phone: (215) 345-1515
Website: horizontherapeutics.com
Contact Name: Corrine Salsburg
Contact Email: salsburgc@porettaorr.com

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com, follow us @HorizonNews on Twitter, like us on Facebook or explore career opportunities on LinkedIn.

Immune Deficiency Foundation
Booth 732
110 West Rd., Suite 300
Towson, MD 21204-4803
Phone: (443) 377-7449
Website: primaryimmune.org
Contact Name: Elizabeth Ferguson
Contact Email: eferguson@primaryimmune.org

The Immune Deficiency Foundation is the national patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education and research.

Infinity Massage Chairs
Booth 327
72 Stad Rd., Unit 2
Seabrook, NH 03874
Phone: (603) 347-6006
Website: infinitymassagechairs.com
Contact Name: Miranda Lynch
Contact Email: mlynch@infinitymassagechairs.com

Infinity Massage Chairs is the fastest-growing massage chair brand in North America, with an A+ rating with the Better Business Bureau. Our mission is to improve the health and wellness of our customers to live more comfortably and make the most of every day. Experience relaxation!

International Food Allergen Management Academy
Booth 139
245 N. Highland Ave., 230-491
Atlanta, GA 30307
Phone: (310) 728-0629
Website: ifamacademy.org
Contact Name: Lara Holland
Contact Email: lara@centeredtable.com

The International Food Allergen Management Academy provides individual counseling and customized day-to-day life management plans to help 250 million people with life-threatening food allergies, worldwide. We are in 5 countries, with 30 professionals who speak 7 languages. IFAMA provides:
- Health & body care
- Patient & public education
- Physician recruitment

KabaFusion
Booth 134
160 Raritan Center Pkwy.
Edison, NJ 08837
Phone: (800) 383-8393
Website: kabafusion.com
Contact Name: Cheryl Anesh
Contact Email: canesh@kabafusion.com

KabaFusion is a pharmacist-owned, patient-focused team of professionals with extensive experience in home infusion and specialty infusion therapy. Our pharmacists, nurses and reimbursement specialists work as a team to provide your patient with compassionate, efficient and reliable care. As a result, patients experience seamless coordination of care, reduced adverse events, reduced costs and optimization of their medical treatment. KabaFusion and its affiliate companies are contracted with most major health plans and medical groups.
kaléo
111 Virginia St., Suite 300
Richmond, VA 23219
Website: kaleopharma.com
Contact Name: Holly Hutchens
Contact Email: info@kaleopharma.com
Kaléo is a pharmaceutical company dedicated to building innovative solutions that can help empower patients with certain serious and life-threatening medical conditions. We believe patients and caregivers are the experts on how medical conditions impact their lives, and so we include them as an integral part of our development process and consider their needs foremost. Kaléo products combine established drugs with innovative delivery platforms. Kaléo is a privately-held company headquartered in Richmond, Virginia. For more information, visit www.kaleopharma.com.

Kaz USA, Inc., a Helen of Troy Company
400 Donald Lynch Blvd.
Marlborough, MA 01752
Phone: (508) 490-7322
Website: honeywellpluggedin.com
Contact Name: Sonia LeBlanc
Contact Email: sleblanc@helenoftroy.com
Offering affordable, reliable, high quality HEPA filtration products for over 25 years, Honeywell Air Purifiers are frequently recommended by allergists as part of a patient’s overall treatment plan.

Leadiant Biosciences, Inc.
9841 Washingtonian Blvd., Suite 500
Gaithersburg, MD 20878
Phone: (301) 670-2481
Website: leadiant.com
Contact Name: Nancy Parsons
Contact Email: nancy.parsons@leadiant.com
Leadiant Biosciences, Inc. is a rare corporation dedicated to creating novel medicines for the unmet needs of patients with rare diseases. Truly unique in its field, Leadiant Biosciences places its considerable scientific resources behind the discovery of compounds that benefit the few. Simply because it’s the right thing to do. By maintaining an environment based on integrity, commitment and placing the patient first, Leadiant Biosciences is able to consider what may be a small commercial success nothing less than a human triumph.

Lincoln Diagnostics, Inc.
P.O. Box 1128
Decatur, IL 62525
Phone: (217) 877-2531
Website: lincolndiagnostics.com
Contact Name: John Lenski Jr
Contact Email: jlenski@lincolndiagnostics.com
Lincoln Diagnostics is displaying state-of-the-art, safety-engineered skin testing devices that meet all current OSHA requirements – Multi-Test® PC (Pain Control), UniTest® PC (Pain Control), Multi-Test® II, Multi-Test®, Duotip-Test® II, and Duotip-Test®. Please visit our exhibit to learn about the economic value of using Lincoln’s devices and why they are the most widely used and most extensively published on devices available.

Medpro
1550 Katy Gap Rd.
Katy, TX 77494
Phone: (702) 626-2307
Website: medproequipment.com
Contact Name: Bryan Cymbalista
Contact Email: bryansams40@yahoo.com
Medpro specializes in a variety of solutions at the medical field with a non-invasive treatment for clinics and corporate.

Methapharm Inc.
81 Sinclair Blvd.
Brantford, ON N3S 7X6
Canada
Phone: (833) 887-7686
Website: methapharm.com
Contact Name: Rob Boomsma
Contact Email: rboomsma@methapharm.com
Methapharm specializes in respiratory diagnostics for bronchial challenge testing. We currently offer Provocholine for the methacholine challenge test and Aridol for the mannitol challenge test.
Micro Direct, Inc.  Booth 1117
803 Webster St.
Lewiston, ME 04240
Phone: (800) 588-3381
Website: mdspiromo.com
Contact Name: Ann Therriault
Contact Email: ann.therriault@mdspiromo.com

Micro Direct is pleased to offer total spirometry solutions with five models priced from $695 to $2,495, all designed to meet your needs, and each with your choice of inexpensive cardboard mouthpieces, one-way mouthpieces or full protection pulmonary filters. Micro Direct also offers an inexpensive peak flow meter for home and office use and home spirometers for patient use. Stop by our booth to see the complete Micro Direct product line and ask about our show specials!

Mission: Allergy, Inc.  Booth 707
28 Hawleyville Rd.
Hawleyville, CT 06440
Phone: (203) 364-1570
Website: missionallergy.com
Contact Name: Jeffrey Miller
Contact Email: jmiller@missionallergy.com

Leading allergists and allergy divisions recommend Mission: Allergy for its scientific accuracy and its highest quality microfiber pillow and mattress encasings and other products for allergen avoidance. Please stop by our booth to request your free supply of our informative Allergy Self-Help Guide for patients and to view an unusual display of live dust mites in high definition.

ModuleMD, LLC  Booth 325
8359 Office Park Dr.
Grand Blanc, MI 48439
Phone: (877) 347-7978
Website: modulemd.com
Contact Name: Miranda Moore
Contact Email: info@modulemd.com

ModuleMD enhances the clinical, operational and financial performance of allergy practices. The ModuleMD WISE™ software suite streamlines practice processes with an integrated 2015 Edition ONC-Certified EHR, Skin Testing, Immunotherapy, Practice Management, Revenue Management, ePrescribe, Telemedicine, Appointment Reminder, and Patient Engagement software. When you select ModuleMD WISE™ for your practice, you receive more than just a product or a service, you have a dedicated partner with an interest in the success of your practice. In addition to technology, ModuleMD offers comprehensive billing and revenue management services. Providing solutions...not just software. Contact us for a demo today: info@modulemd.com

Molekule  Booth 632
1184 Harrison St.
San Francisco, CA 94103
Phone: (407) 490-2758
Website: molekule.com
Contact Name: Jenny Wong
Contact Email: jwong@molekule.com

Molekule is on a mission to solve the global air pollution crisis by reimagining the future of clean air. Its groundbreaking technology, Photo Electrochemical Oxidation (PECO), lets the Molekule Air Purifier destroy pollutants, allergens, mold, bacteria, viruses and airborne chemicals. That’s why it’s the only air purifier on the market that safely destroys indoor air pollutants.

More Relief  Booth 1115
9733 Russian Hill St.
Las Vegas, NV 89141
Phone: (702) 283-6401
Website: emp10.com
Contact Name: Josh Greenman
Contact Email: alliedpowersllc@gmail.com

Morgan Scientific, Inc  Booth 630
151 Essex St., Suite 8
Haverhill, MA 01832
Phone: (978) 521-4440
Website: morgansci.com
Contact Name: Gareth Morgan
Contact Email: gmorgan@morgansci.com

Morgan Scientific has a legacy of three generations of providing PFT diagnostic equipment and software in a class all its own. Come and get a demo or our new ComPAS2 software and Compact PFT device, and see how we are revolutionizing PFT labs across the country. Learn why 7 of the top 10 pediatric hospitals and the #1 teaching hospital in the US use our equipment and software. Enterprise IT solutions, EMR interfacing, workflow optimizations and customizations are what we do best, so stop by, meet our dragon and find out how we are improving pulmonary function testing!
MotherToBaby
9500 Gilman Dr., Mail Code 0828
La Jolla, CA 92039
Phone: (877) 311-8972
Website: mothertobaby.org
Contact Name: Vanessa Gonzalez
Contact Email: vibarra@ucsd.edu
MotherToBaby is the nation’s leading authority and most trusted source of evidence-based information on the safety of medications and other exposures during pregnancy and while breastfeeding. Our free teratogen information service is available to health care professionals and the general public. MotherToBaby also conducts observational research on the safety of medications and vaccines in pregnancy, which allows us to help moms and health care providers make informed treatment decisions.

National Allergy / Allergy Control Products
Booth 731
1620-D Satellite Blvd.
Duluth, GA 30097
Phone: (800) 522-1448
Website: nationalallergy.com or allergycontrol.com
Contact Name: Carlton Hardee
Contact Email: chardee@allergypreventionteam.com
Welcome to National Allergy and Allergy Control Products. We are one of the nation’s largest asthma, sinus and allergy products suppliers. Our goal is to help make your environment allergen free. The allergy products we carry are for personal and home use and are offered at a competitive price! For more information contact us at www.nationalallergy.com, www.allergycontrol.com, or call (800) 522-1448.

ndd Medical Technologies
Booth 1113
300 Brickstone Square, Suite 604
Andover, MA 01810
Phone: (978) 470-0923
Website: nddmed.com
Contact Name: Ashley Flanagan
Contact Email: aflanagan@nddmed.com
A leader in lung function testing based in Switzerland and the U.S., ndd is helping to improve the quality of life for millions of people living with lung disease. Built around the company’s patented TrueFlow™ technology, ndd’s innovative, easy-to-use products such as the EasyOne® Air, Easy on-PC and EasyOne Pro® help clinicians diagnose and treat COPD, asthma and other chronic lung diseases earlier and with greater precision by providing accurate information at the point of care. For more information on ndd, please visit www.nddmed.com or follow us on Twitter @nddmedical.

NeilMed Pharmaceuticals, Inc.
Booth 820
601 Aviation Blvd.
Santa Rosa, CA 95404
Phone: (707) 525-3784
Website: neilmed.com
Contact Name: Ashly Guntz
Contact Email: tradeshows@neilmed.com
The mission of the company is to create and maintain safe, affordable and effective products to sustain long-term growth and create drug-free and effective nasal/sinus, ear and wound care devices for millions of consumers worldwide. Please visit the website www.neilmed.com for more details.

Novartis Pharmaceuticals Corporation
Booth 734, 1003, 1213
One Health Plz.
East Hanover, NJ 07936
Website: novartis.com
Contact Name: Nicole Vernisi
Contact Email: nicole.vernisi@novartis.com
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally, and we are finding innovative ways to expand access to our latest treatments. About 105,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
Novartis Pharmaceuticals Corporation
One Health Plz.
East Hanover, NJ 07936-1080
Phone: (862) 778-9203
Website: novartis.com
Contact Name: Rose Ford
Contact Email: rose.ford@novartis.com

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Octapharma USA, Inc.
121 River St., Suite 1201
Hoboken, NJ 07030
Phone: (201) 216-6635
Website: octapharmausa.com
Contact Name: Katy Calicchia
Contact Email: katy.calicchia@octapharma.com

Our company’s mission is to enhance the safe and optical use of human proteins. Since the 1980s, we have introduced life-saving or life-enhancing treatments that have helped people lead normal lives. We are proud to introduce Cutaquig, a subcutaneous immune globulin therapy that delivers innovative service and support. Cutaquig is indicated for the treatment of primary immunodeficiency in adults.

Optinose
1020 Stony Hill Rd., Suite 300
Yardley, PA 19067
Phone: (302) 383-9664
Website: optinose.com
Contact Name: Kristen Miller
Contact Email: kristen.miller@optinose.com

Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Pfizer
235 East 42nd St.
New York, NY 10017
Phone: (610) 506-5496
Website: pfizer.com
Contact Name: Gail Griffith
Contact Email: gail.griffith@pfizer.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.

Pharmaceutical Specialties, Inc.
1620 Industrial Dr. NW
Rochester, MN 55901
Phone: (800) 325-8232
Website: psico.com
Contact Name: Mariah Ranney
Contact Email: mariahr@psico.com
Pharming Healthcare, Inc.  
685 Route 202/206, Suite 202  
Bridgewater, NJ 08807  
Phone: (201) 799-4898  
Website: pharming.com  
Contact Name: Caitlin Marsh  
Contact Email: c.marsh@pharming.com  
Pharming Healthcare, Inc. is dedicated to providing life-changing solutions to patients. Pharming is currently involved in the marketing and development of drugs for the treatment of hereditary angioedema.

Propeller Health  
634 West Main St., Suite 102  
Madison, WI 53703  
Phone: (415) 786-4665  
Website: propellerhealth.com  
Contact Name: Anastasia Alvarez  
Contact Email: anastasia.alvarez@propellerhealth.com  
Propeller Health is a digital health company that’s leading a revolution in respiratory care. Propeller is dedicated to helping people with asthma or COPD breathe easier and to helping clinicians provide better care for their patients with asthma or COPD. Propeller sensors attach to inhalers and automatically track where, when and how often users take their medication. The sensors send information to an app on the user’s smartphone, where analytics and machine learning deliver personalized insight and support. Propeller has 9 FDA clearances, has been offered through 70+ commercial programs and has been validated in 19+ peer-reviewed publications.

PulmOne USA  
270 Madison Ave., 9th Floor  
New York, NY 10016  
Phone: (844) 785-6663  
Website: pulm-one.com  
Contact Name: Scott Yokobosky  
Contact Email: usinfo@pulm-one.com  
PulmOne’s MiniBox+ is the world’s first Complete Pulmonary Function Testing (PFT) system with desktop, cabinless and gasless plethysmography, as well as Spirometry and DLCO testing.  
• Easily operated by your medical staff, with no interruption of work flow.  
• Patient-friendly with lung volumes in under 2 minutes of tidal breathing.  
• Clinically proven and fully reimbursable.  
• ROI within months – by testing only 2-5 patients per day.  
• The MiniBox+ is used by physicians in over 30 states.  
• Live demos during exhibition hours.

Rabbit Air  
125 N. Raymond Ave., Suite 308  
Pasadena, CA 91103  
Phone: (888) 866-8862  
Website: rabbitair.com  
Contact Name: Tamina Park  
Contact Email: taminap@rabbitair.com  
Our Los Angeles-based company is dedicated to improving quality of life through clean air. Rabbit Air purifiers use a HEPA filter and charcoal-based activated carbon filter to trap and reduce indoor air pollution and buildup of common allergens for optimum efficiency and performance.  
Certified Asthma & Allergy Friendly™ by the Asthma and Allergy Foundation of America, our MinusA2 air purifier offers a choice of filters to target specific contaminants – pet dander, germs, chemical toxins, and odors – and defends even the most sensitive respiratory systems. Our products are portable, and customized filters are interchangeable to grow with families and their environments.
Regeneron Pharmaceuticals/Sanofi Genzyme
777 Old Saw Mill River Rd.
Tarrytown, NY 10591
Phone: (914) 847-7689
Website: regeneron.com and sanofi.com
Contact Email: medical.information@regeneron.com

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. Since 2007, Sanofi & Regeneron have collaborated to develop

Retractable Technologies, Inc.
511 Lobo Ln.
Little Elm, TX 75068
Phone: (888) 703-1010
Website: retractable.com
Contact Name: Cherita Green
Contact Email: rtisales@vanishpoint.com

Innovative products to address your safety needs. UNIQUELY DESIGNED INJECTION DEVICES
RTI’s automated retraction technology found in VanishPoint® and EasyPoint® devices effectively reduces the risk of a contaminated sharps injury and reuse.

Rosch Visionary Systems, Inc.
1601 11th Ave., Suite 102
Altoona, PA 16601
Phone: (800) 307-3320
Website: roschvisionary.com
Contact Name: Lee Johnson
Contact Email: rvssales@roschvisionary.com

Rosch Visionary Systems is the leading provider of allergy software. Rosch Immunotherapy is designed to manage allergy extract mixing, injections and reactions. Our system is lined with multiple safety features and complies with regulations involving the USP Chapter 797, numerous auditing reports, charging, ability to interface with vendors and much more. Rosch Skin Testing electronically records all prick and intradermal, using the results to build the patient’s immunotherapy prescription. Visionary Allergy Tracker will remind patients when they are due for their injection(s) via text, email and push notifications, as well as tracking their immunotherapy history via our state-of-the-art phone app.

Stallergenes Greer
639 Nuway Circle NE
P.O. Box 800
Lenoir, NC 28645
Website: greerlabs.com
Contact Name: Courtney Fraser
Contact Email: sfraser@greerlabs.com

Headquartered in London (UK), Stallergenes Greer plc is a global company specializing in the development and commercialization of allergy immunotherapy products and services for use in the diagnosis and treatment of allergies. Stallergenes Greer plc is the parent company of Greer Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes SAS (whose registered office is in France).

Additional information is available at www.greerlabs.com. MPN 050216H1871
Headquartered in London (UK), Stallergenes Greer plc is a global health care company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of Greer Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes SAS (whose registered office is in France). Additional information is available at www.stallergenesgreer.com.

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing better health and a brighter future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: oncology, gastroenterology (GI), neuroscience and rare diseases. We also make targeted R&D investments in plasma-derived therapies and vaccines. www.takeda.com

Food protein-induced enterocolitis syndrome (FPIES) is a food allergy affecting the gastrointestinal tract. Acute symptoms of FPIES include profound vomiting, diarrhea and dehydration, which can lead to shock. Chronic symptoms of FPIES may manifest in increasingly severe vomiting and poor growth and progress to sepsis-like illness. Please note that each child is unique and may experience their own range and intensity of these symptoms and benefit from individualized care. The FPIES Foundation is a 501(c)(3) non-profit organization dedicated to overcoming the challenges of FPIES by offering tools for education, support, and advocacy to empower families and the medical community.

Specialized racks to store vials of vaccines. Great addition to allergist clinic for the serum storage. Very sturdy and neat design for well organized refrigerators.
Tivic Health Systems Inc. Booth 634
750 Menlo Ave., Suite 200
Menlo Park, CA 94025
Phone: (773) 230-7026
Website: tivichealth.com
Contact Name: Maureen Perou
Contact Email: maureen.perou@tivichealth.com

Tivic Health Systems Inc., a neuromodulation medical device company, is dedicated to developing microcurrent therapy solutions for chronic diseases and conditions. First on the market, Tivic Health just launched ClearUP Sinus Pain Relief, an over-the-counter medical device for the temporary relief of sinus pain for those suffering from allergic rhinitis. ClearUP is already FDA-cleared and clinically proven where 3 out of 4 experienced sinus pain reduction. Visit booth #634 to see this handheld, non-invasive, drug-free, state-of-the-art microcurrent technology.

Tourette Association of America Booth 635
42-40 Bell Blvd., Suite 205
Bayside, NY 11361
Phone: (718) 224-2999
Website: tourette.org
Contact Name: Angela Sullivan
Contact Email: angela.sullivan@tourette.org

Founded in 1972, the Tourette Association of America is dedicated to making life better for all individuals affected by Tourette and Tic Disorders. The only nationwide organization serving this community, the Association works to raise awareness, fund research and provide on-going support. The Tourette Association directs a network of 32 chapters and over 80 support groups across the country. For more information on Tourette and Tic Disorders, call 1-888-4-TOURET, visit www.tourette.org, and on Facebook, Twitter, Instagram and YouTube.

Vitalograph Booth 431
13310 West 99th St.
Lenexa, KS 66215
Phone: (913) 732-3228
Website: vitalograph.com
Contact Name: Mark Russell
Contact Email: mark.russell@vitalograph.com

Vitalograph offers a full range of pulmonary, cardiac and audiological diagnostic devices and clinical trial professional services. Our range includes a variety of world class spirometers, asthma monitors, COPD screeners, peak flow meters, e-diaries and inhaler trainers. With headquarters in Lenexa, Kansas; Buckingham, England; Ennis, Ireland; Hamburg, Germany; Tokyo and Hong Kong, Vitalograph truly offers global coverage for all your spirometry needs.

World Allergy Organization (WAO) Booth 337
555 E Wells St., Suite 1100
Milwaukee, WI 53202
Phone: (414) 276-1791
Website: worldallergy.org
Contact Name: Justin Dodge
Contact Email: jdodge@worldallergy.org

The World Allergy Organization (WAO) is an international umbrella organization whose members consist of 99 regional and national allergology and clinical immunology societies from around the world. By collaborating with member societies, WAO provides direct educational outreach programs, symposia and lectureships to members in over 100 countries around the globe.

Xtract Solutions Booth 341
9954 SW Arctic Dr.
Beaverton, OR 97005
Phone: (503) 379-0110
Website: xtractsolutions.com
Contact Name: Scott Tracy
Contact Email: scott@xtractsolutions.com

Xtract Solutions is the leader in advancing software technology for the practice of allergen immunotherapy. We work with allergy clinics who are frustrated that their immunotherapy workflows are not as optimized as they should be and are often still using paper despite having an EMR. Others fear the risks to patient safety associated with mixing and delivering allergy shots and want to make the process safer, and some practices are growing and need process improvements to keep up their quality and productivity standards. Whatever the issues may be, Xtract Solutions has the experience and know-how necessary to solve most problems.
## Index of Exhibits

### Exhibits – Listed by Category

#### Allergy Extracts
- ALK, Inc. ..................................... 513
- HollisterStier Allergy .......................... 1129
- Stallergenes Greer ............................. 721
- Stallergenes Greer—Medical Affairs ............... 607

#### Clinical Research Organizations
- Vitalograph................................... 431

#### Computer Hardware/Software
- AllergyEHR, a division of Meditab Software Inc. ...... 1313
- ModuleMD, LLC ............................... 325
- Rosch Visionary Systems, Inc. .................... 1128
- Xtract Solutions ............................... 341

#### Diagnostic Equipment
- Amerimmune .................................... 636
- Bedfont Scientific Ltd. .......................... 238
- Lincoln Diagnostics, Inc. ........................ 1212
- Micro Direct, Inc. ................................ 1117
- PulmOne USA ................................... 706
- Vitalograph. .................................... 431

#### Diagnostic Testing
- Amerimmune .................................... 636
- Bedfont Scientific Ltd. .......................... 238
- Circassia Pharmaceuticals, Inc. ................ 427
- Edge Pharmaceuticals ............................ 339
- HollisterStier Allergy ............................. 1129
- Lincoln Diagnostics, Inc. ........................ 1212
- Medpro ......................................... 1029
- Methapharm Inc. ................................ 130
- Morgan Scientific, Inc. ........................... 630
- ndd Medical Technologies....................... 1113

#### Environmental Products
- Kaz USA, Inc, a Helen of Troy Company ............. 433
- Mission: Allergy, Inc. ............................ 707
- Molekule ......................................... 632
- National Allergy/Allergy Control Products ............ 731
- Rabbit Air ........................................ 727

#### Equipment/Supplies
- Mission: Allergy, Inc. ............................ 707
- Retractable Technologies, Inc....................... 535
- The Rack Sys, LLC. ................................ 534

#### Health/Body Care
- ADAKO USA ..................................... 338
- EHRC Technologies .............................. 730
- Infinity Massage Chairs ........................... 327
- Medpro .......................................... 1029
- More Relief ..................................... 1115
- NeilMed Pharmaceuticals, Inc. .................... 820
- Pharmaceutical Specialties, Inc. ................... 531
- Tivic Health Systems Inc. ........................ 634

#### Immunotherapy
- ALK, Inc. ........................................ 513
- Aimmune Therapeutics ............................ 619
- DBV Technologies ................................. 507
- Edge Pharmaceuticals .............................. 339
- Healex Pharmaceuticals ............................ 532
- KabaFusion ...................................... 134
- Octapharma USA, Inc. ............................ 737
- Rosch Visionary Systems, Inc. .................... 1128
- Stallergenes Greer ................................. 721
- Stallergenes Greer– Medical Affairs ............... 607
- Xtract Solutions ................................. 341

#### Office Management
- Allergy Partners ................................. 424
- Altus Infusion .................................... 824
- Healex Infusion Therapy ........................... 532

#### Other
- Association of PAs in Allergy, Asthma & Immunology ........................................ 136
- AstraZeneca Medical Affairs ......................... 503
- CVS Specialty ..................................... 1412
- Diplomat Specialty Infusion Group .................. 735
- Infinity Massage Chairs .............................. 327
Index of Exhibits

Exhibits – Listed by Category

**Other (continued)**
- International Food Allergen Management Academy .................................. 139
- ModuleMD, LLC .................................. 325
- Rabbit Air ........................................ 727
- World Allergy Organization (WAO) .................................................. 337
- eClinicalWorks ................................... 1219

**Patient/Public Education**
- Advocacy & Awareness for Immune Disorders Association (AAIDA) .................. 436
- Allergy & Asthma Network .................................................. 426
- American Partnership for Eosinophilic Disorders (APFED) ......................... 533
- Asthma and Allergy Foundation of America ............................................. 442
- Food Allergy & Anaphylaxis Connection Team (FAACT) ......................... 726
- Food Allergy Research & Education (FARE) ........................................ 440
- Immune Deficiency Foundation .................................................... 732
- MotherToBaby ........................................ 1227
- The FPIES Foundation .................................................. 438
- Tourette Association of America ................................................ 635

**Pharmaceuticals (continued)**
- Pharmaceutical Specialties, Inc. ................................................. 531
- Pharming Healthcare, Inc. ................................................ 131
- Regeneron Pharmaceuticals/Sanofi Genzyme ...................................... 313, 441
- Takeda .................................................. 100
- Teva Respiratory ............................................... 113
- kaléo ..................................................... 331

**Physician Education**
- ACAAI Resource Center .......................................................... 613
- American Board of Allergy & Immunology (ABAI) .................................. 530
- American Partnership for Eosinophilic Disorders (APFED) ......................... 533
- Immune Deficiency Foundation .................................................... 732
- Kaz USA, Inc, a Helen of Troy Company .......................................... 433
- World Allergy Organization (WAO) .................................................. 337

**Physician Recruitment**
- Allergy Partners .................................................. 424
- Hackensack Meridian Health ...................................................... 637

**Publications**
- Advocacy & Awareness for Immune Disorders Association (AAIDA) ............... 436
- Allergy & Asthma Network .................................................. 426
- Allergy and Asthma Proceedings .................................................. 627
- Elsevier, Inc. .................................................. 807

**Spirometry**
- Micro Direct, Inc. .................................................. 1117
- Morgan Scientific, Inc. .................................................. 630
- PulmOne USA .................................................. 706
- ndd Medical Technologies .................................................. 1113

**Technology**
- AllergyEHR, a division of Meditab Software Inc. .................................. 1313
- Optinose .................................................. 1021
- Propeller Health .................................................. 501
- eClinicalWorks .................................................. 1219
# Index of Exhibitors

## Exhibits – Listed by Booth

<table>
<thead>
<tr>
<th>Booth</th>
<th>Company/Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>Takeda</td>
</tr>
<tr>
<td>113</td>
<td>Teva Respiratory</td>
</tr>
<tr>
<td>123, 128</td>
<td>CSL Behring</td>
</tr>
<tr>
<td>130</td>
<td>Methapharm Inc.</td>
</tr>
<tr>
<td>131</td>
<td>Pharming Healthcare, Inc.</td>
</tr>
<tr>
<td>132</td>
<td>BioCryst Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>134</td>
<td>KabaFusion</td>
</tr>
<tr>
<td>136</td>
<td>Association of PAs in Allergy, Asthma &amp; Immunology</td>
</tr>
<tr>
<td>139</td>
<td>International Food Allergen Management Academy</td>
</tr>
<tr>
<td>238</td>
<td>Bedfont Scientific Ltd</td>
</tr>
<tr>
<td>239</td>
<td>Leadiant Biosciences, Inc.</td>
</tr>
<tr>
<td>301</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>313, 441</td>
<td>Regeneron Pharmaceuticals/Sanofi Genzyme</td>
</tr>
<tr>
<td>325</td>
<td>ModuleMD, LLC</td>
</tr>
<tr>
<td>327</td>
<td>Infinity Massage Chairs</td>
</tr>
<tr>
<td>331</td>
<td>kaléo</td>
</tr>
<tr>
<td>337</td>
<td>World Allergy Organization (WAO)</td>
</tr>
<tr>
<td>338</td>
<td>ADAKO USA</td>
</tr>
<tr>
<td>339</td>
<td>Edge Pharmaceuticals</td>
</tr>
<tr>
<td>341</td>
<td>Xtract Solutions</td>
</tr>
<tr>
<td>343</td>
<td>Edge Pharma / Xtract Solutions</td>
</tr>
<tr>
<td>424</td>
<td>Allergy Partners</td>
</tr>
<tr>
<td>426</td>
<td>Allergy &amp; Asthma Network</td>
</tr>
<tr>
<td>427</td>
<td>Circassia Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>431</td>
<td>Vitalograph</td>
</tr>
<tr>
<td>433</td>
<td>Kaz USA, Inc, a Helen of Troy Company</td>
</tr>
<tr>
<td>436</td>
<td>Advocacy &amp; Awareness for Immune Disorders Association (AAIDA)</td>
</tr>
<tr>
<td>438</td>
<td>The FPIES Foundation</td>
</tr>
<tr>
<td>440</td>
<td>Food Allergy Research &amp; Education (FARE)</td>
</tr>
<tr>
<td>442</td>
<td>Asthma and Allergy Foundation of America</td>
</tr>
<tr>
<td>501</td>
<td>Propeller Health</td>
</tr>
<tr>
<td>503</td>
<td>AstraZeneca Medical Affairs</td>
</tr>
<tr>
<td>507</td>
<td>DBV Technologies</td>
</tr>
<tr>
<td>513</td>
<td>ALK, Inc.</td>
</tr>
<tr>
<td>530</td>
<td>American Board of Allergy &amp; Immunology (ABAI)</td>
</tr>
<tr>
<td>531</td>
<td>Pharmaceutical Specialties, Inc.</td>
</tr>
<tr>
<td>532</td>
<td>Healix Infusion Therapy</td>
</tr>
<tr>
<td>533</td>
<td>American Partnership for Eosinophilic Disorders (APFED)</td>
</tr>
<tr>
<td>534</td>
<td>The Rack Sys, LLC.</td>
</tr>
<tr>
<td>535</td>
<td>Retractable Technologies, Inc.</td>
</tr>
<tr>
<td>607</td>
<td>Stallergenes Greer—Medical Affairs</td>
</tr>
<tr>
<td>613</td>
<td>ACAAI Resource Center</td>
</tr>
<tr>
<td>619</td>
<td>Aimmune Therapeutics</td>
</tr>
<tr>
<td>627</td>
<td>Allergy and Asthma Proceedings</td>
</tr>
<tr>
<td>630</td>
<td>Morgan Scientific, Inc</td>
</tr>
<tr>
<td>631</td>
<td>Horizon Therapeutics</td>
</tr>
<tr>
<td>632</td>
<td>Molekule</td>
</tr>
<tr>
<td>634</td>
<td>Tivic Health Systems Inc</td>
</tr>
<tr>
<td>635</td>
<td>Tourette Association of America</td>
</tr>
<tr>
<td>636</td>
<td>Amerimmune</td>
</tr>
<tr>
<td>637</td>
<td>Hackensack Meridian Health</td>
</tr>
<tr>
<td>706</td>
<td>PulmOne USA</td>
</tr>
<tr>
<td>707</td>
<td>Mission: Allergy, Inc.</td>
</tr>
<tr>
<td>713</td>
<td>Genentech/Novartis</td>
</tr>
<tr>
<td>721</td>
<td>Stallergenes Greer</td>
</tr>
<tr>
<td>726</td>
<td>Food Allergy &amp; Anaphylaxis Connection Team (FAACT)</td>
</tr>
<tr>
<td>727</td>
<td>Rabbit Air</td>
</tr>
<tr>
<td>730</td>
<td>EHRC Technologies</td>
</tr>
<tr>
<td>731</td>
<td>National Allergy/Allergy Control Products</td>
</tr>
<tr>
<td>732</td>
<td>Immune Deficiency Foundation</td>
</tr>
<tr>
<td>734, 1003, 1213, 1318</td>
<td>Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>735</td>
<td>Diplomat Specialty Infusion Group</td>
</tr>
<tr>
<td>737</td>
<td>Octapharma USA, Inc.</td>
</tr>
<tr>
<td>807</td>
<td>Elsevier, Inc.</td>
</tr>
<tr>
<td>820</td>
<td>NeilMed Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>824</td>
<td>Altus Infusion</td>
</tr>
<tr>
<td>826, 1013</td>
<td>Pfizer</td>
</tr>
<tr>
<td>1012</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>1021</td>
<td>Optinose</td>
</tr>
<tr>
<td>1029</td>
<td>Medpro</td>
</tr>
<tr>
<td>1113</td>
<td>ndd Medical Technologies</td>
</tr>
<tr>
<td>1115</td>
<td>More Relief</td>
</tr>
<tr>
<td>1117</td>
<td>Micro Direct, Inc.</td>
</tr>
<tr>
<td>1128</td>
<td>Rosch Visionary Systems, Inc.</td>
</tr>
<tr>
<td>1129</td>
<td>HollisterStier Allergy</td>
</tr>
<tr>
<td>1212</td>
<td>Lincoln Diagnostics, Inc.</td>
</tr>
<tr>
<td>1219</td>
<td>eClinicalWorks</td>
</tr>
<tr>
<td>1223</td>
<td>Covis Pharma</td>
</tr>
<tr>
<td>1227</td>
<td>MotherToBaby</td>
</tr>
<tr>
<td>1313</td>
<td>AllergyEHR, a division of Meditab Software Inc.</td>
</tr>
<tr>
<td>1412</td>
<td>CVS Specialty</td>
</tr>
</tbody>
</table>
### Exhibits – Listed by Company Name

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACAAI Resource Center</td>
<td>613</td>
</tr>
<tr>
<td>ADAKO USA</td>
<td>338</td>
</tr>
<tr>
<td>Advocacy &amp; Awareness for Immune Disorders Association (AAIDA)</td>
<td>436</td>
</tr>
<tr>
<td>Aimmune Therapeutics</td>
<td>619</td>
</tr>
<tr>
<td>ALK, Inc.</td>
<td>513</td>
</tr>
<tr>
<td>Allergy &amp; Asthma Network</td>
<td>426</td>
</tr>
<tr>
<td>Allergy and Asthma Proceedings</td>
<td>627</td>
</tr>
<tr>
<td>Allergy Partners</td>
<td>424</td>
</tr>
<tr>
<td>AllergyEHR a division of Meditab Software Inc.</td>
<td>1313</td>
</tr>
<tr>
<td>Altus Infusion</td>
<td>824</td>
</tr>
<tr>
<td>American Board of Allergy &amp; Immunology (ABAI)</td>
<td>530</td>
</tr>
<tr>
<td>American Partnership for Eosinophilic Disorders (APFED)</td>
<td>533</td>
</tr>
<tr>
<td>Amerimmune</td>
<td>636</td>
</tr>
<tr>
<td>Association of PAs in Allergy, Asthma &amp; Immunology</td>
<td>136</td>
</tr>
<tr>
<td>Asthma and Allergy Foundation of America</td>
<td>442</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>301</td>
</tr>
<tr>
<td>AstraZeneca Medical Affairs</td>
<td>503</td>
</tr>
<tr>
<td>Bedfont Scientific Ltd</td>
<td>238</td>
</tr>
<tr>
<td>BioCryst Pharmaceuticals, Inc.</td>
<td>132</td>
</tr>
<tr>
<td>Circassia Pharmaceuticals, Inc.</td>
<td>427</td>
</tr>
<tr>
<td>Covis Pharma</td>
<td>1223</td>
</tr>
<tr>
<td>CSL Behring</td>
<td>123, 128</td>
</tr>
<tr>
<td>CVS Specialty</td>
<td>1412</td>
</tr>
<tr>
<td>DBV Technologies</td>
<td>507</td>
</tr>
<tr>
<td>Diplomat Specialty Infusion Group</td>
<td>735</td>
</tr>
<tr>
<td>eClinicalWorks</td>
<td>1219</td>
</tr>
<tr>
<td>Edge Pharma / Xtract Solutions</td>
<td>343</td>
</tr>
<tr>
<td>Edge Pharmaceuticals</td>
<td>339</td>
</tr>
<tr>
<td>EHRC Technologies</td>
<td>730</td>
</tr>
<tr>
<td>Elsevier, Inc.</td>
<td>807</td>
</tr>
<tr>
<td>Food Allergy &amp; Anaphylaxis Connection Team (FAACT)</td>
<td>726</td>
</tr>
<tr>
<td>Food Allergy Research &amp; Education (FARE)</td>
<td>440</td>
</tr>
<tr>
<td>Genentech/Novartis</td>
<td>713</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>1012</td>
</tr>
<tr>
<td>Hackensack Meridian Health</td>
<td>637</td>
</tr>
<tr>
<td>Healix Infusion Therapy</td>
<td>532</td>
</tr>
<tr>
<td>HollisterStier Allergy</td>
<td>1129</td>
</tr>
<tr>
<td>Horizon Therapeutics</td>
<td>631</td>
</tr>
<tr>
<td>Immune Deficiency Foundation</td>
<td>732</td>
</tr>
<tr>
<td>Infinity Massage Chairs</td>
<td>327</td>
</tr>
<tr>
<td>International Food Allergen Management Academy</td>
<td>139</td>
</tr>
<tr>
<td>KabaFusion</td>
<td>134</td>
</tr>
<tr>
<td>kaléo</td>
<td>331</td>
</tr>
<tr>
<td>Kaz USA, Inc, A Helen of Troy Company</td>
<td>433</td>
</tr>
<tr>
<td>Leadiant Biosciences, Inc.</td>
<td>239</td>
</tr>
<tr>
<td>Lincoln Diagnostics, Inc.</td>
<td>1212</td>
</tr>
<tr>
<td>Medpro</td>
<td>1029</td>
</tr>
<tr>
<td>Methapharm Inc.</td>
<td>130</td>
</tr>
<tr>
<td>Micro Direct, Inc.</td>
<td>1117</td>
</tr>
<tr>
<td>Mission: Allergy, Inc.</td>
<td>707</td>
</tr>
<tr>
<td>ModuleMD, LLC</td>
<td>325</td>
</tr>
<tr>
<td>Molekule</td>
<td>632</td>
</tr>
<tr>
<td>More Relief</td>
<td>1115</td>
</tr>
<tr>
<td>Morgan Scientific, Inc.</td>
<td>630</td>
</tr>
<tr>
<td>MotherToBaby</td>
<td>1227</td>
</tr>
<tr>
<td>National Allergy/Allergy Control Products</td>
<td>731</td>
</tr>
<tr>
<td>ndd Medical Technologies</td>
<td>1113</td>
</tr>
<tr>
<td>NeilMed Pharmaceuticals Corporation</td>
<td>820</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals Corporation</td>
<td>734, 1003, 1213, 1318</td>
</tr>
<tr>
<td>Octapharma USA</td>
<td>737</td>
</tr>
<tr>
<td>Optinose</td>
<td>1021</td>
</tr>
<tr>
<td>Pfizer</td>
<td>826, 1013</td>
</tr>
<tr>
<td>Pharmaceutical Specialties, Inc.</td>
<td>531</td>
</tr>
<tr>
<td>Pharming Healthcare, Inc.</td>
<td>131</td>
</tr>
<tr>
<td>Propeller Health</td>
<td>501</td>
</tr>
<tr>
<td>PulmOne USA</td>
<td>706</td>
</tr>
<tr>
<td>Rabbit Air</td>
<td>727</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals/Sanofi Genzyme</td>
<td>313, 441</td>
</tr>
<tr>
<td>Retractable Technologies, Inc.</td>
<td>535</td>
</tr>
<tr>
<td>Rosch Visionary Systems, Inc.</td>
<td>1128</td>
</tr>
<tr>
<td>Stallergenes Greer</td>
<td>721</td>
</tr>
<tr>
<td>Stallergenes Greer—Medical Affairs</td>
<td>607</td>
</tr>
<tr>
<td>Takeda</td>
<td>100</td>
</tr>
<tr>
<td>Teva Respiratory</td>
<td>.113</td>
</tr>
<tr>
<td>The FPIES Foundation</td>
<td>438</td>
</tr>
<tr>
<td>The Rack Sys, LLC.</td>
<td>534</td>
</tr>
<tr>
<td>Tivic Health Systems Inc.</td>
<td>634</td>
</tr>
<tr>
<td>Tourette Association of America</td>
<td>635</td>
</tr>
<tr>
<td>Vitalograph</td>
<td>431</td>
</tr>
<tr>
<td>World Allergy Organization (WAO)</td>
<td>337</td>
</tr>
<tr>
<td>Xtract Solutions</td>
<td>341</td>
</tr>
</tbody>
</table>
Exhibit Hall Map – Exhibitors
The Rustic features farm-to-table food and nightly musical performances from local and national acts.
Take Everett and Evelyn. Healthy. Moving forward together. And still as much in love as they were when they met in 1944—back when he was a paratrooper and she was a nurse.

For more than a century, Merck has been inventing medicines and vaccines for many of the world’s most challenging diseases. Today, we’re inventing new ways to treat cancer, with more than 450 clinical studies underway. All in an effort to help keep people healthy, hopeful, and allow their relationships to endure for years to come.

Learn more at Merck.com/InventingForLife
This activity is provided by Integritas Communications.
This activity is supported by a grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies, or position of the American College of Allergy, Asthma & Immunology.